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Abstract  
 
E-cadherin is a cell surface glycoprotein involved in calcium-dependent cell adhesion.  E-
cadherin expression is essential during embryo development as E-cadherin null (Ecad-/-) 
embryos fail to develop beyond the blastocyst stage.  Furthermore, E-cadherin is down-
regulated during epithelial to mesenchymal transition (EMT), a cellular remodelling 
event which is essential during embryo development and is associated with metastatic 
tumour progression.  Expression of E-cadherin in wild type (WT) embryonic stem (ES) 
cells is involved in the establishment of cell-cell adhesions, regulation of motility and 
proliferation and the response of the cells to external growth factors.  Accordingly, Ecad-
/- ES cells do not form cell-cell adhesions, exhibit increased proliferation and motility, 
and utilise the Activin/Nodal signalling pathway instead of Lif for the maintenance of 
pluripotency.  The results of microarray analysis comparing WT and Ecad-/- ES cell 
transcript expression undertaken to investigate the mechanisms underlying these cellular 
alterations, revealed a 235-fold down-regulation of Junctional adhesion molecule 2 
(Jam2), a cell surface protein belonging to the Immunoglobulin superfamily.  In this 
study, we investigate the E-cadherin/Jam2 relationship and demonstrate that Jam2 
transcript expression is positively regulated by E-cadherin.  We show that although the 
full length E-cadherin protein encoding the terminal 71 amino acids of the cytoplasmic 
domain is required for expression of Jam2 in ES cells, β-catenin signalling is unlikely to 
be involved in the regulation of Jam2 by E-cadherin as β-cat-/- ES cells also do not 
express Jam2.  Through use of promoter/luciferase constructs we show that the Jam2 
promoter is subject to altered regulatory events in Ecad-/- ES cells compared to WT ES 
cells.  Analysis of the Jam2 promoter region using ECR Browser software leads us to 
hypothesise the involvement of E-boxes, Sp1, Ahr/Arnt, and Zeb1 transcription factors in 
the regulation of Jam2 in ES cells.  Finally, we show that despite the regulation of Jam2 
by E-cadherin, and the high level of expression of Jam2 in WT ES cells, that absence of 
Jam2 from ES cells does not affect the EMT undergone by the cells during spontaneous 
differentiation.  Jam2-/- ES cells undergoing spontaneous differentiation down-regulate 
E-cadherin cell-surface expression, up-regulate N-cadherin cell-surface expression, show 
increased transcripts for EMT-associated transcription factors and protease activity, all 
comparable to that seen in WT ES cells.  Furthermore, we confirm that Jam2-/- ES cells 
up-regulate transcripts representative of the three primary germ layers during 
spontaneous differentiation, as seen in WT ES cells.  Overall, our results show that 
although Jam2 appears to be dispensable in ES cell biology, further investigation into the 
regulation of Jam2 by E-cadherin could provide novel insights into the events that take 
place following loss of E-cadherin in epithelial cells, thereby advancing our knowledge 
of events during embryo development and metastatic tumour progression.  
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Rationale for Submission of the Thesis in the 
Alternative Format 
The reasons for submitting this thesis in the alternative format are three-fold.  Firstly, it is 
the preference of the School of Dentistry for all theses to be submitted in this format.  
Secondly, the work within this thesis is to be submitted for publication.  And thirdly, the 
results from the investigations undertaken for this PhD naturally fell into 3 main sections; 
the E-cadherin-Jam2 relationship, the regulation of Jam2 in mouse ES cells, and the role 
of Jam2 in EMT.  Following on from this, the structure of the thesis format is as follows- 
 
Chapter 1 is an introduction in the style of the normal thesis format, encompassing a 
review of the research to date relevant to this study including subsections on E-cadherin, 
Jam2, EMT and embryonic stem cells. 
 
Chapter 2 includes details of all the materials and methods used throughout the study. 
 
Chapter 3- the first results chapter, written in a format suitable for publication, titled “The 
Relationship Between E-cadherin and Jam2 Expression in Mouse ES Cells”. 
 
Chapter 4- the second results chapter, written in a format suitable for publication, titled 
“The Transcriptional Regulation of Jam2 by E-cadherin in Mouse ES cells”. 
 
Chapter 5- the third results chapter, written in a format suitable for publication, titled 
“The Role of Jam2 During EMT in Mouse ES Cells”. 
 
Chapter 6 is a discussion in the style of the normal thesis format, covering further issues 
and ideas not covered within the individual discussions of the three results sections.  
Proposals for the direction of potential future work relating to this study are also 
considered, followed by a conclusion rounding up the discoveries made within this study.  
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1.1 E-cadherin 
1.1.1 Cadherins 
Cadherins are a large group of glycoproteins involved in calcium-dependent cell adhesion 
(Halbleib and Nelson, 2006).  The most studied of the cadherins are the classical 
cadherins, which include E-cadherin (epithelial), N-cadherin (neural), R-cadherin (retinal) 
and P-cadherin (platelet).  They all share a similar structure consisting of 5 extra-cellular 
domains, EC1-EC5, a transmembrane domain, and a small cytoplasmic domain.  They 
are classified as either type I or type II depending on whether they possess a conserved 
HAV (His-Ala-Val) tripeptide motif within their extracellular portion (type I) or not (type 
II) (Nollet et al., 2000). Cadherins are located on the surface of many different cell types 
most commonly forming homotypic interactions with molecules on adjacent cells (Huber 
et al., 1996; Takeichi, 1995). 
 
1.1.2 E-cadherin 
1.1.2.1 Gene and protein 
The human E-cadherin gene, CDH1, is located on chromosome 16q22.1, and consists of 
16 exons and 15 introns, a characteristic shared by all the classical cadherins (Berx et al., 
1995).  In mice, the E-cadherin gene is located on chromosome 8 and displays 82% 
similarity in nucleotide sequence and 83% similarity in amino acid sequence to the 
human counterpart (Mansouri et al., 1988).  The mature E-cadherin peptide is 728 amino 
acids in length and has a molecular weight of approximately 120kDa (Nagafuchi et al., 
1987).  The E-cadherin protein contains one extracellular domain, a single 
transmembrane domain, and a short cytoplasmic domain (Figure 1.1).  The extracellular 
domain contains 5 EC domains of approximately 110 amino acids (EC1-5) (Takeichi, 
1995).  EC1 has a structure similar to an Ig fold composed of 7 beta sheets and 2 alpha 
helices, and contains the HAV motif which is essential for homophilic binding.  Calcium 
pockets are located between each EC domain, and calcium binding has been shown to be 
essential for dimer formation as mutations in these areas abolish homodimerisation. The 
calcium binding pockets also provide protection of the linker sequences between EC 
domains from proteases, and give rigidity to the extracellular region, changing it from a 
globular to a rod-like structure (Overduin et al., 1995).  E-cadherin functions as a dimer, 
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 first cis-interacting with E-cadherin molecules on the same cell through the HAV 
domain, then trans-interacting with E-cadherin molecules on neighbouring cells 
(Blaschuk et al., 1990; Sato et al., 2006).   
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Figure 1.1 Structure of E-cadherin with associated intracellular interactions. E-cadherin is 
composed of an extracellular region of 5 EC domains (EC1-5), a single transmembrane domain, 
and a short cytoplasmic domain.  The cytoplasmic domain consists of: the juxtamembrane 
domain (JMD) which interacts with p120 catenin, Presenillin-1 (Ps-1) and Hakai; and a catenin 
binding domain (CBD) which interacts with β- or γ-catenin, which links E-cadherin to the actin 
cytoskeleton through α-catenin and Epithelial protein lost in neoplasm (Eplin).  The CBD also 
binds Protein tyrosine phosphatase μ (Ptpμ). 
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1.1.2.2 Expression, location and function of E-cadherin.  
E-cadherin is first expressed at the 2 cell stage of embryonic development, and is 
essential for compaction at the 8-cell stage.  E-cadherin null (Ecad-/-) embryo 
development arrests at the blastocyst stage, due to loss of epithelial integrity, and die at 
the implantation stage.  In Ecad-/- embryos the trophectodermal epithelial layer is 
malformed, with loose cell contacts provided by the maternal E-cadherin still present in 
the embryo, whereas the trophectodermal layer of wild type (WT) embryos exhibit clear 
epithelial morphology (Larue et al., 1994).  In addition, Ecad-/- embryos express lower 
levels of the cell junction molecules β- and α-catenin, and these molecules, plus the 
cytoskeletal protein Zona occludens-1 (Zo-1) are abnormally located in these embryos 
(Ohsugi et al., 1997).  During normal embryonic development, E-cadherin expression is 
down-regulated during gastrulation as the epiblast cells of the primitive streak undergo 
epithelial to mesenchymal transition (EMT).  These cells exit the primitive streak and 
migrate away to form endoderm and mesoderm, whilst the remaining epiblast cells 
become ectoderm.  E-cadherin expression is subsequently up-regulated in cells that 
undergo mesenchymal to epithelial transitions (MET) as part of normal development 
(Viebahn, 1995).  
 
In normal healthy adult tissues E-cadherin is predominantly located within the adherens 
junctions of epithelial cells.  Close contacts are maintained between epithelial cells 
through adhesions and interactions provided by the junctions present on their lateral 
surfaces, allowing the cells to function as a single tissue.  E-cadherin has been shown to 
be required for the formation of adherens junctions, and the formation of adjacent tight 
junctions is dependent on adherens junction formation (Capaldo and Macara, 2007; 
Miyoshi and Takai, 2005).  In addition, E-cadherin has been repeatedly shown to be 
essential for maintenance of the epithelial phenotype, as loss of E-cadherin function 
results in loss of cell polarity, loss of cell junctions and an increase in cellular motility 
and invasiveness, all characteristics of metastatically transformed tumour cells 
(Christofori and Semb, 1999).  
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1.1.3 E-cadherin-binding molecules 
1.1.3.1 Extracellular region 
E-cadherin forms homotypic interactions with E-cadherin molecules both on the same 
cell (cis-dimers) and on neighbouring cells (trans-dimers), through the EC1 domain of the 
extracellular region.  These interactions not only provide strong cell-cell adhesions and 
the establishment of stable adherens and tight junctions, but E-cadherin 
homodimerisation can also both positively and negatively affect the activation of 
numerous signalling pathways (Capaldo and Macara, 2007).  E-cadherin 
homodimerisation positively regulates signalling via the recruitment of kinases to the 
cadherin-catenin complex, resulting in their subsequent activation.  For example, 
Phosphatidylinositol 3 kinase (PI3k) is recruited to the cadherin-catenin complex in 
response to homophilic E-cadherin ligation, resulting in the activation of PI3k.  This has 
been found to result in the activation of Rac GTPase signalling, and the activation and 
nuclear translocation of the protein kinase Akt (Kovacs et al., 2002; Pece et al., 1999).  In 
addition, homophilic E-cadherin engagement has been found to activate Signal transducer 
and activator of transcription-3 (Stat3), through increasing the activity of Rac and Cell 
division cycle protein 42 homologue (Cdc42) proteins (Arulanandam et al., 2009).  
Homophilic binding of E-cadherin also negatively regulates signalling by retaining 
growth factor receptors at the cell surface at E-cadherin-catenin complexes, thereby 
preventing their involvement in signalling pathways.  For example, Epidermal growth 
factor receptor (Egfr) signalling is abrogated by interaction with E-cadherin homodimers, 
preventing its phosphorylation and activation (Perrais et al., 2007).   
 
In addition to E-cadherin homophilic interactions, several heterophilic interactions have 
been reported.  These include integrins αEβ7 and α2β1, Killer cell lectin-like receptor 
G1 (Klrg1), and Transforming growth factor receptor β II (TβRII).  The interaction 
between E-cadherin and αEβ7 integrin was found to take place within a different region 
of EC1 from the E-cadherin homodimerisation motif, suggesting that αEβ7 does not 
disrupt E-cadherin homodimerisation (Karecla et al., 1996).   Two functions for this 
interaction have been discovered to date including the retention of αEβ7-expressing 
lymphocytes within epithelial tissues following their extravasation from circulation, and 
the recognition and killing of E-cadherin expressing tumour cells by tumour infiltrating 
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lymphocytes (Cepek et al., 1994; Floc'h et al., 2007).  In contrast to αEβ7, Klrg1 has 
been shown to bind to same region of the EC1 domain of the E-cadherin extracellular 
domain responsible for homodimer formation, and binding of Klrg1 disrupts E-cadherin 
homodimers (Nakamura et al., 2009).  Furthermore, as opposed to targeting cells for 
death as is the case for αEβ7, binding of Klrg1 to E-cadherin prevents the lysis of the E-
cadherin-expressing cells (Ito et al., 2006).  The physical interaction of the extracellular 
domains of E-cadherin and TβRII has been identified and this interaction was found to 
affect the response of the cells to Transforming growth factor β I (Tgf-βI) (Andl et al., 
2006).  α2β1 integrin has also been shown to bind to E-cadherin, although the function of 
this interaction is not yet known (Whittard et al., 2002) 
 
1.1.3.2 Intracellular region 
The cytoplasmic domain of E-cadherin associates with several binding partners including 
those that bind to the juxtamembrane domain (JMD) (p120-catenin, Presenilin-1, Mouse 
double minute 2 and Hakai), and those that bind to the catenin binding domain (CBD) 
(β/γ-catenin and Protein tyrosine phosphatase μ), all discussed in further detail below 
(and depicted in Figure 1.1).  Additionally, the catenin binding domain of E-cadherin 
contains phosphorylation sites for kinases such as Protein kinase Cμ (Pkcμ) and Casein 
kinase 1 and 2 (Ck1 and 2), which are involved in the stabilisation of E-cadherin/β/γ-
catenin contacts (Dupre-Crochet et al., 2007; Jaggi et al., 2005; Lickert et al., 2000).   
 
1.1.3.2.1 Juxtamembrane domain binding proteins 
p120 catenin, Presenillin-1 (Ps-1), and the E3 ubiquitin ligases Hakai and Mouse double 
minute 2 (Mdm2) have all be found to bind to the JMD of the cytoplasmic region of E-
cadherin (Baki et al., 2001; Davis et al., 2003; Fujita et al., 2002; Yang et al., 2006).   The 
E-cadherin/p120-catenin interaction stabilises E-cadherin at the cell surface and studies 
using expression of exogenous cadherins (including E-cadherin) have shown that 
cadherins compete for binding to p120-catenin, therefore, the level of p120-catenin in a 
cell dictates the stability of cadherin interactions (Xiao et al., 2005).  In addition, 
knockdown of p120-catenin leads to loss of cell surface E-cadherin, loss of cell-cell 
adhesion, and alterations in β-catenin and α-catenin localisation (Davis et al., 2003).    
Furthermore, the interaction of p120-catenin with E-cadherin has been suggested to 
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prevent access of ubiquitination complexes to a target amino acid motif within JMD of E-
cadherin, preventing its entry into the cytolytic pathway (Ishiyama et al., 2010).  When 
not bound to E-cadherin, p120-catenin also has a role in cell signalling.  p120-catenin has 
been shown to bind to the transcription factor Kaiso, preventing Kaiso from inhibiting 
gene expression  (Kelly et al., 2004).  p120-catenin has also been shown to transport the 
cytoplasmic domain of E-cadherin, following its cleavage by γ-secretase, to the nucleus 
where it binds to deoxyribonucleic acid (DNA) and enhances the negative effect of p120-
catenin binding on Kaiso function (Ferber et al., 2008). 
 
Ps-1 is a transmembrane protein that competes for binding to the same area of the JMD of 
E-cadherin as p120-catenin (Baki et al., 2001).  Once bound to E-cadherin, Ps-1 promotes 
the binding of E-cadherin to β- or γ-catenin, and the subsequent binding of this complex 
to the actin cytoskeleton.  The interaction of Ps-1 with E-cadherin is not dependent on the 
E-cadherin/β-catenin interaction however, as Ps-1 was shown to bind to a truncated form 
of E-cadherin lacking the CBD (Baki et al., 2001).  Like p120-catenin, when Ps-1 is not 
bound to E-cadherin it has cell signalling roles as a subcomponent of γ-secretase.  This 
complex is responsible for cleavage of the Amyloid precursor protein, the processing of 
Notch, and also cleavage of E-cadherin (De Strooper et al., 1999; De Strooper et al., 
1998).  The cleavage of E-cadherin by the Ps-1/γ-secretase complex results in an increase 
in free cytosolic β-catenin.  Mutations within the Ps-1 binding domain of E-cadherin 
abolished cleavage of E-cadherin by the Ps-1/γ-secretase complex, therefore Ps-1 can 
either act to stabilize or disassemble E-cadherin adhesions and junctions (Marambaud et 
al., 2002).  
 
When the JMD of E-cadherin is not bound by either p120-catenin or Ps-1, the region is 
exposed to ubiquitin ligases, such as Hakai and Mdm2, which target E-cadherin for 
degradation (Yang et al., 2006).  For example, Hakai is an E3 ubiquitin ligase which, 
following Src-induced tyrosine phosphorylation of E-cadherin, will bind within the JMD 
of E-cadherin resulting in the ubiquitination of E-cadherin and its targeting for 
endocytosis (Fujita et al., 2002; Ishiyama et al., 2010).   
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1.1.3.2.2 Catenin binding domain interactions 
The CBD of E-cadherin is located in the carboxyl terminal region of the cytoplasmic 
domain, and has been shown to bind β- and γ-catenins, and receptor Protein tyrosine 
phosphatases (Ptp) (Figure 1.1). β-catenin binds to E-cadherin prior to the localisation of 
E-cadherin to the cell membrane, as β-catenin is required for the export of E-cadherin 
from the endoplasmic reticulum to the cell membrane (Chen et al., 1999).  Once located 
at the cell membrane, the E-cadherin/β-catenin interaction provides anchorage of E-
cadherin to the actin cytoskeleton, this linkage is essential for E-cadherin to form strong 
cell-cell adhesions (Nagafuchi and Takeichi, 1998).  β-catenin links E-cadherin to the 
cytoskeleton through  α-catenin, which itself binds to Epithelial protein lost in neoplasm 
(Eplin), which binds the actin cytoskeleton (Abe and Takeichi, 2008).  When not bound 
to E-cadherin at the cell surface and functioning as an adaptor protein, free β-catenin is 
either targeted for degradation by phosphorylation by a complex containing 
Glycogen synthase-3β (Gsk-3β) and Adenomatous polyposis coli, or alternatively is 
involved in signalling within the nucleus (Gottardi et al., 2001).  β-catenin is part of the 
Wnt pathway, a signalling pathway involved in cell proliferation and differentiation 
(Logan and Nusse, 2004).  Free β-catenin forms a complex with T cell factor (Tcf) and 
Lymphoid enhancer factor (Lef) which translocates to the nucleus and activates target 
Wnt genes (Nelson and Nusse, 2004).  γ-catenin, also known as Plakoglobin, shares 70% 
amino acid identity with β-catenin (McCrea et al., 1991).  Like β-catenin, it binds to E-
cadherin within the catenin binding domain, can bind to α-catenin and also function in 
Tcf/Lef signalling (Maeda et al., 2003; Ozawa et al., 1990; Ozawa et al., 1995).  Ptpμ and 
Ptp1B also bind to the carboxyl terminal of the cytoplasmic domain of E-cadherin.  This 
interaction is terminated by Src-mediated tyrosine phosphorylation of E-cadherin 
resulting in the dissociation of Ptpμ/1B from the CBD of E-cadherin (Brady-Kalnay et al., 
1998; Sheth et al., 2007).   
 
1.1.4 Regulation of E-cadherin expression 
Down-regulation of E-cadherin is both an essential step during embryonic development 
and a critical step in the metastatic progression of carcinomas, and for these reasons the 
mechanisms of down-regulation has been the focus of numerous studies (Guilford, 1999; 
Viebahn, 1995).  The processes by which E-cadherin inactivation occurs during 
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carcinoma progression are numerous, ranging from gene mutation to protein cleavage, 
and are discussed below.  
  
1.1.4.1 Epigenetic silencing and mutation 
Promoter hypermethylation of CpG islands within the 5’ promoter region of the E-
cadherin gene results in the physical obstruction of transcription factors to the DNA, 
leading to repression of gene transcription in various cancers, including breast and liver 
(Graff et al., 2000; Matsumura et al., 2001).  Furthermore, CpG methylation of E-
cadherin is associated with the recruitment of histone deacetylases, which cause 
compaction the DNA structure, further decreasing the access of transcription factors to 
the DNA (Koizume et al., 2002). 
 
Somatic mutations within the E-cadherin gene that result in gene inactivation have also 
been identified as the cause of some cancers, most commonly in diffuse gastric and 
lobular breast carcinomas (Berx et al., 1998).  Mutations can result in exon skipping 
(frequently within exon 8 or 9 which destroys the calcium binding sites) or premature 
stop codons, which result in a truncated protein (Berx et al., 1998).  In some cases, 
deletion of portions of chromosome 16 have been reported in gastric, breast and liver 
cancers, which results in loss of heterozygosity and therefore gene function of E-cadherin 
(Berx et al., 1998; Matsumura et al., 2001) 
 
1.1.4.2 Transcriptional regulation 
Several transcription factors repress E-cadherin expression by binding to E-boxes within 
the E-cadherin promoter.  These include Snail, Slug, Zeb1, Sip1, Twist, and E12/E47, 
and all have been associated with the repression of E-cadherin during cancer progression 
(Cano et al., 2000; Comijn et al., 2001; Perez-Moreno et al., 2001; Vandewalle et al., 
2005; Vesuna et al., 2008).  It has been suggested that these transcription factors may 
function in tandem with each other to fully repress E-cadherin transcription, by binding to 
different E-boxes within the E-cadherin promoter (Peinado et al., 2004).  Furthermore, 
several studies have reported an inverse correlation in expression between E-cadherin and 
one or more of these factors in various cancers, including Sip1 in breast cancer cells 
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(Comijn et al., 2001), Snail and Sip1 in diffuse and intestinal gastric carcinomas 
(Rosivatz et al., 2002) and Snail in hepatocellular carcinomas (Jiao et al., 2002). 
1.1.4.3 Protein processing 
Abrogation of E-cadherin function can also be mediated at the protein level through 
several mechanisms.  The stability of the E-cadherin/β-catenin interaction can be 
destabilised by phosphorylation, resulting in the disassembly of the cadherin/catenin 
complex and cell-cell adhesion, and the targeting of E-cadherin for endocytosis (Dupre-
Crochet et al., 2007).  Similarly, exposure of the JMD of E-cadherin to ubiquitinases can 
result in the targeting of E-cadherin for entry into the endocytic pathway (Fujita et al., 
2002; Jaggi et al., 2005; Lickert et al., 2000).  Several proteases are known to target the 
E-cadherin protein for cleavage which results in the disassembly of the E-cadherin/β-
catenin complex and associated adhesions and junctions.  For example, Ps-1 cleaves E-
cadherin at the membrane-cytoplasm interface, resulting in dissociation of β-catenin from 
the complex and eliminating the connection to the actin cytoskeleton (Marambaud et al., 
2002).  In addition, Matrix metalloproteases (Mmps) have been shown to cleave the 
extracellular domain of E-cadherin, which results not only in abrogation of the 
adhesiveness of the cells expressing the cleaved E-cadherin, but also in the surrounding 
cells as the released ectodomain functions as an inhibitor of homophilic E-cadherin 
interactions (Noe et al., 2001).  
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1.2 Junctional Adhesion Molecule Family 
1.2.1 Junctional adhesion molecules 
Junctional adhesion molecules (Jams) are a group of cell surface proteins belonging to 
the Immunoglobulin superfamily (IgSF).  The IgSF incorporates a large group of cell 
surface proteins that include adhesion molecules and antigen and cytokine receptors, all 
of which are involved in calcium-independent adhesion.  Members of the IgSF are 
categorised by the inclusion of at least one immunoglobulin (Ig) domain within their 
structure, either C-type (constant) or V-type (variable).  Within the Ig domain is an Ig-
fold of either 7 or 9 (C-type, and V-type domain respectively) anti-parallel β-sheets, 
stabilised by one or more disulfide bridges between cysteine residues (Kaas et al., 2007).  
To date five Jams have been identified, Jam1, Jam2, Jam3, Jam4 and JamL, of which 
Jam1-3 are the most closely related (Figure 1.2).  Other IgSF members related to Jams, 
are Endothelial cell-selective adhesion molecule (Esam), Coxsackievirus and adenovirus 
receptor (Car), and A33 antigen, which are most closely related to Jam4 and JamL (Ebnet 
et al., 2004).   
 
 
Esam
Car
Jam4
Jam2
Jam3
Jam1
 
Figure 1.2  Phylogenic tree of the relationship of human Jam1, 2, 3, 4, Endothelial cell-selective 
adhesion molecule (Esam) and Coxsackievirus and adenovirus receptor (Car) based on amino 
acid sequences. Figure adapted from Ebnet et al (2004). 
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Jam1, 2 and 3 share a similar structure consisting of a short cytoplasmic domain featuring 
a Post synaptic density protein/Drosophila disc large tumour suppressor/zonula 
occludens-1 protein (PDZ) domain binding motif in the terminal 5 amino acids and a 
phosphorylation site.  They also share a single transmembrane spanning domain, and an 
extracellular domain containing 2 Ig domains, linked by either 1 (Jam1) or 1 and 2 (Jam2 
and Jam3) disulfide bridges (Figure 1.3) (Ebnet et al., 2004).  JamL and Jam4 differ 
slightly in structure from Jams 1-3 possessing a larger cytoplasmic domain, a 
characteristic shared with Esam and Car.  Expression of the Jam family of molecules is 
either predominantly endothelial (Jam2 and Jam3), or epithelial and endothelial (Jam1), 
with no two members sharing identical expression patterns, indicating specific individual 
functions for each.  In this section I review each Junctional adhesion molecule 
individually, starting with an overview of the literature for the other members of the Jam 
family, followed by detailed review of all literature available for Jam2 itself. 
 
 
 
Jam1 Jam2 Jam3
Membrane distal 
V-type Ig domain
Membrane proximal 
C-type Ig domain
PDZ binding domain
Plasma membrane
Disulphide bridge
Glycosylation site
 
Figure 1.3  Diagrammatic representation of the structure of Jam 1, 2, and 3 showing two 
extracellular Ig domains, disulphide bridges, glycosylation sites and PDZ binding domain. Figure 
adapted from Ebnet et al (2004). 
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1.2.1.1 Jam1 
Although first cited in the literature in 1998, Jam1 was originally discovered as F11 
Receptor in 1990, with the two confirmed as being the same molecule in 2000 (Gupta et 
al., 2000; Kornecki et al., 1990; Martin-Padura et al., 1998).  During embryo 
development, Jam1 expression is seen in the developing vasculature, inner ear, skin, hair 
follicles, gut, lung and kidneys (Parris et al., 2005).  In the adult, Jam1 is located 
predominantly in the tight junctions between adjacent epithelial cells of numerous tissues 
including liver, kidney, placenta, and lung (Cavusoglu et al., 2007; Liu et al., 2000; 
Williams et al., 1999).  The elucidation of the structure of Jam1 by X-ray crystallography 
revealed that Jam1 forms cis-homodimers through interactions in the membrane distal Ig 
fold of the extracellular domain, which then form trans-homodimers with Jam1 
homodimers on neighbouring cells (Kostrewa et al., 2001).  Jam1 dimerisation has been 
shown to result in intracellular signalling, as Rap1A is activated upon Jam1 dimerisation, 
which results in increased cell motility (Severson and Parkos, 2009).  
 
In addition to homophilic interactions, Jam1 participates in heterophilic interactions with 
Sigma-1, a reovirus cell-surface protein, and Leukocyte function associated-1 (Lfa-1), a 
cell-surface integrin expressed on circulating lymphocytes (Barton et al., 2001; 
Ostermann et al., 2002; Severson and Parkos, 2009).  The cytoplasmic domain of Jam1 
has been shown to bind to several molecules including cell polarity protein Par3 (Ebnet et 
al., 2001; Itoh et al., 2001), Afadin (Severson et al., 2009), the scaffold protein Protein 
interacting with C-kinase-1 (Pick-1) (Reymond et al., 2005), AF-6, and Zo-1 (Ebnet et al., 
2000; Itoh et al., 2001).  The interaction of Jam1 with Afadin and Zo-1 has been shown to 
link Jam1 to the adherens junction protein Nectin  (Fukuhara, 2002).  
 
The function of Jam1 appears to be predominantly involved in cell movement, either the 
movement of Jam1-expressing cells themselves, or passage of other cells between cells 
expressing Jam1 in their cell-cell junctions.  The participation of Jam1 in cell migration 
was shown when over-expression of a Jam1 mutant protein and use of Jam1 blocking 
antibodies inhibited migration of 293T cells (Severson et al., 2008).  Jam1 was shown to 
be involved in transendothelial migration through heterophilic interactions with Lfa-1 
(Ostermann et al., 2002).  Monocyte transmigration through an endothelial cell 
monolayer was reduced in mice treated with Jam1 blocking antibodies (Martin-Padura et 
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al., 1998).  In addition, blocking of the Jam1/Lfa-1 heterophilic interaction was shown to 
reduce the recruitment of mononuclear cells to Jam1-expressing atherosclerotic lesions 
(Ostermann et al., 2005).  Furthermore, dendritic cells from Jam1-deficient mice have an 
increased general and transendothelial migratory capacity compared to dendritic cells 
from wild type mice (Cera et al., 2004).  In relation to this, Jam1 is also involved in 
epithelial barrier integrity, as gastrointestinal paracellular permeability was shown to be 
increased in Jam1-deficient mice, and transepithelial electrical resistance (TER) was 
reduced (Laukoetter et al., 2007).  In addition, use of anti-Jam1 antibodies that block 
Jam1 homodimer formation prevented barrier function restoration of epithelial cell 
monolayers (Mandell et al., 2004).  A role for Jam1 in cell proliferation has also been 
shown, as cell proliferation was increased in the colonic mucosa of Jam1-deficient mice 
(Laukoetter et al., 2007). 
 
Jam1 has been shown to be associated with various disease states, in addition to 
facilitating entry of reoviruses through its interaction with Sigma-1, including 
atherosclerosis and angiogenesis.  Elevated plasma levels of Jam1 were shown to 
correlate with increased severity in atherosclerosis patients (Cavusoglu et al., 2007).  The 
involvement of Jam1 in angiogenesis was demonstrated when treatment of endothelial 
cells with Fibroblast growth factor 2 (Fgf-2) resulted in redistribution of Jam1 from 
αVβ3 complexes in cell-cell junctions to the cell surface.  Furthermore, prevention of the 
interaction of Fgf-2 with the extracellular domain of Jam1, or mutation of the 
cytoplasmic domain of Jam1, reduced Fgf-2 induced angiogenesis (Naik et al., 2003).  In 
Jam1 deficient mice, the ability of Fgf-2 to induce angiogenesis is almost completely 
impaired (Cooke et al., 2006). In addition, the aortic rings from Jam1-deficient mice 
failed to produce microvessel sproutings when treated with Fgf-2 (Cooke et al., 2006).  
 
1.2.1.2 Jam3 
Jam3 was identified separately by two groups at a similar time to Jam2, resulting in an 
initial period of confusion regarding Jam nomenclature. One group, who had previously 
identified Jam2, identified Jam3 as the receptor for Jam2 on T lymphocytes (Arrate et al., 
2001; Cunningham et al., 2000).  The second group, unaware of the discovery and 
naming of Jam2, identified Jam3 and named it Jam2, after searching for IgSF molecules 
regulated by endothelial-tumour cell interactions (Aurrand-Lions et al., 2001a).  The 
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structure of Jam3 is typical of an IgSF member, consisting of an extracellular domain 
containing 2 Ig-domains (membrane-distal is V-type, membrane proximal is C-type), one 
transmembrane domain, and a short cytoplasmic domain (Figure 1.3) (Arrate et al., 2001).  
The expression of Jam3 is predominantly endothelial and expression has been detected in 
cells of the kidney, brain and placenta and on human blood cells (but not mouse), 
including activated T lymphocytes and platelets (Arrate et al., 2001; Santoso et al., 2002).  
Although Jam3 homodimerisation has been shown to exist, Jam3 has a higher affinity for 
Jam2, to which it binds through the membrane distal V-type Ig-domain (Lamagna et al., 
2005b; Santoso et al., 2005).  The interaction of Jam3 with Jam2 has been shown to be 
required for the distribution of a polarity complex in spermatids and for the ability of 
endothelial Jam2 to bind to α4β1 integrin on circulating lymphocytes (Cunningham et al., 
2002; Gliki et al., 2004).  In addition to binding Jam2, Jam3 also forms heterophilic 
interactions with Macrophage-1 antigen (Mac-1), an integrin expressed on leukocytes 
(Santoso et al., 2002; Zen et al., 2004).  The cytoplasmic domain of Jam3 contains a PDZ 
binding motif, a Pkc consensus sequence (Arrate et al., 2001), and a serine residue at 
amino acid position 281, shown to be a phosphorylation site involved in localisation of 
Jam3 to sites of cell-cell contact (Ebnet et al., 2003).  Interactions with the cytoplasmic 
domain of Jam3 are similar to that of Jam1, and include Par3, Zo-1 and Pick-1 (Ebnet et 
al., 2003; Ebnet et al., 2000; Reymond et al., 2005).   
 
A role for Jam3 in the immune response has been implicated and several studies have 
revealed the involvement of Jam3 in two stages of leukocyte trafficking process.  Firstly, 
studies using blocking antibodies specific to the Jam3-Mac1 interaction have shown that 
endothelial Jam3 is involved in leukocyte capture to sites of inflammation (Bradfield et 
al., 2007; Lamagna et al., 2005b).  In addition, a Jam3 blocking antibody was shown to 
reduce ear swelling in mice with induced contact dermatitis (Ludwig et al., 2005).  
Secondly, use of both over-expression and abrogation of function experiments showed 
that Jam3, through binding of Jam2, promotes leukocyte transendothelial migration, 
specifically the egression of leukocytes into circulation following transmigration 
(Aurrand-Lions et al., 2001b; Bradfield et al., 2007; Johnson-Leger et al., 2002).  In 
addition, Jam3-deficient mice are immuno-compromised, with 60% mortality due to 
opportunistic infections.  This was shown to be due to the lack of endothelial Jam3, as re-
expression of Jam3 in vascular endothelial cells restored the survival rate of Jam3-
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deficient mice, confirming the importance of Jam3 in the immune response (Imhof et al., 
2007).  A role for Jam3 in spermatogenesis has also been implicated, as Jam3 expression 
is also seen at all stages of spermatogenesis, and generation of Jam3-deficient mice has 
shown that Jam3-/- spermatids lack signs of polarisation, resulting in infertility (Gliki et 
al., 2004).   
 
The expression of Jam3 is associated with various pathologies, for example increased 
levels of Jam3 expression have been detected in atherosclerotic vessels, and in the serum 
of patients with rheumatoid arthritis (Keiper et al., 2005; Rabquer et al., 2010).  
Furthermore, exogenous expression of Jam3 in a HT1080 fibrosarcoma cell line lead to 
an increase in metastatic potential, and decrease in life span of tumour-bearing mice 
(Fuse et al., 2007).  Several studies have also reported that blocking Jam3 results in 
positive outcomes in various disease states, including a reduction in neutrophil infiltration 
to sites of ischemic reperfusion injury in inflamed tissues, blockage of new vessel 
formation in normal and tumour tissues, and prevention of Jam3-expressing tumour cells 
binding to endothelial cells (Lamagna et al., 2005a; Santoso et al., 2005; Scheiermann et 
al., 2009).  In addition, Jam3 gene and cell surface expression is negatively regulated 
following exposure of brain microvascular endothelial cells (BMVEC) to the human 
immunodeficiency virus-1 (HIV-1) protein gp120, which also resulted in an increase in 
transmigration of peripheral blood mononucleocytes (Mahajan et al., 2008).  Jam3 has 
been shown to directly induce angiogenesis as soluble Jam3, following cleavage of full-
length Jam3 by A disintegrin and metallopeptidase (Adam) 10 and 17, induces tube 
formation and angiogenesis when cultured on human microvascular endothelial cells 
(HMVEC) (Rabquer et al., 2010).  
 
1.2.1.3 Other related molecules: Jam4 and JamL 
Jam4 was first identified by Hirabayashi et al (2003) who were searching for binding 
partners of the tight junction-associated protein Membrane associated guanylate kinase 
WW and PDZ domains containing 1 (Magi-1) (Hirabayashi et al., 2003). Jam4 displays 
an amino acid homology of 14.0, 10.4, and 13.5% to mouse Jam1, Jam2, and Jam3, 
respectively, and is more closely related to Esam and Car than the other Jams (Figure 1.2) 
(Ebnet et al., 2004).  Jam4 transcript expression has been detected in kidney, small 
intestine, stomach, liver, and skeletal muscle cells (Hirabayashi et al., 2003). Like Jam2 
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and Jam3, Jam4 is also expressed at the cell membrane of male germ cells, and despite its 
expression being noted in many cell lines, generation of Jam4-deficient mice revealed no 
obvious abnormalities in any of the Jam4-expressing cell types including testis, liver, 
kidney, or haematopoietic cells (Nagamatsu et al., 2006).  
 
JamL (Jam-Like) was discovered as one of 4 genes to be up-regulated following 
induction of differentiation of the NB4 acute promyelocytic leukaemia cell line by 
treatment with all-trans retinoic acid (Moog-Lutz et al., 2003).  JamL transcripts are 
detected in peripheral blood leukocytes, and also in the foetal liver, spleen and thymus.  
Like many of the other Jams, exogenous expression of JamL leads to its localisation to 
the cell membrane at points of cell-cell contact only.  Furthermore, a role for JamL in 
transendothelial migration is probable as transfection of JamL into a leukaemic cell line 
increased the adhesion of this cell line to endothelial cells (Moog-Lutz et al., 2003).  In 
addition, Jam-L expression on monocytes has been shown to mediate migration of these 
cells across both epithelial and endothelial cell lines through interactions with Car (Guo 
et al., 2009; Zen et al., 2005). 
 
1.2.2 Jam2 
Jam2 was first identified in 2000 by 2 groups; Palmeri et al (2000) searched a cDNA 
library of human tonsillar endothelial cells for proteins that might be involved in 
transendothelial migration (Palmeri et al., 2000); and by Cunningham et al who searched 
a public expressed sequence tag database for homologues of Jam1 (Cunningham et al., 
2000).  A third group, who had just reported the cloning of a Jam protein (which was, in 
fact, Jam2), then published their discovery as “Jam3” (Aurrand-Lions et al., 2001b).  This 
led to immediate confusion in the literature regarding the nomenclature and correct 
referencing of Jam2 and Jam3, a problem which still occurs occasionally even in the most 
recent of publications e.g. the primer sequences in Mahajan et al (2008) reveal “Jam2” to 
be Jam3 (Mahajan et al., 2008).  Jam2 is also referred to as Vascular endothelial-Jam 
(Ve-Jam)(Palmeri et al., 2000), Jam2 (Cunningham et al., 2002), Jam3 (Aurrand-Lions et 
al., 2001b), and JamB (Sakaguchi et al., 2006), depending on the author, publication date, 
and the author’s awareness of the original confusion.  
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1.2.2.1 Gene and protein 
The human Jam2 gene is located on chromosome 21q21.2, and mouse Jam2 is located on 
chromosome 16, both encoding a 298 amino acid protein and showing 80% amino acid 
sequence identity (Cunningham et al., 2000; Palmeri et al., 2000).   The structure of Jam2 
is similar to that of IgSF, Jam1 and Jam3 and contains a short cytoplasmic domain, a 
single transmembrane domain, and an extracellular domain encompassing two Ig-
domains, one membrane proximal C-type, and one membrane distal V-type (Figure 1.3) 
(Palmeri et al., 2000).  Human Jam2 and Jam3 show 36% identity at the protein level, and 
53% identity at DNA level. 35% identity is observed between human and mouse Jam1 
and Jam2 (Arrate et al., 2001; Cunningham et al., 2000; Palmeri et al., 2000).  The 
protein has a predicted molecular mass of ~33kDa, with post-translational modifications 
resulting in an actual mass of ~40kDa detectable by western blot (Palmeri et al., 2000). 
 
1.2.2.2 Binding partners  
Although recombinant Jam2 ectodomain has been shown to be able to capture Jam2-
expressing Chinese hamster ovary (CHO) cells, Jam2 homodimerisation has not since 
been reported elsewhere (Cunningham et al., 2000).  Jam2 binds with a much higher 
affinity to Jam3 than other Jam2 molecules, and Jam2 has been found to bind endothelial 
and leukocyte Jam3 through the membrane distal V-type Ig domain (Arrate et al., 2001; 
Lamagna et al., 2005b; Liang et al., 2002).  Utilization of neutralising antibodies to 
specific integrins showed that Jam2 also binds to α4β1 integrin on circulating 
lymphocytes, and that the prior interaction of Jam2 with Jam3 on lymphocytes is 
essential for the Jam2-α4β1 interaction.  Binding of Jam2 to α4β1 also occurs through 
membrane distal V-type Ig domain on Jam2 (Cunningham et al., 2002).  The PDZ 
binding domain located in the cytoplasmic region of Jam2, similar to Jam1 and Jam3, has 
been shown to bind Par3, a cell polarity protein that forms a complex with Par6 and 
aPKC that is required for tight junction function (Ebnet et al., 2003).  Jam2 also binds to 
Zo-1, via the terminal 5 amino acids of the cytoplasmic domain (Ebnet et al., 2003), and 
to Pick-1, a component of adherens junctions that also interacts with Nectins (Reymond 
et al., 2005). 
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1.2.2.3 Expression and function of Jam2 during development 
The expression pattern of Jam 1, 2 and 3 in the developing mouse embryo was assessed 
using northern blot analysis of whole tissue samples and showed that Jam2 is continually 
expressed throughout the developing mouse embryo, with the highest expression level at 
embryonic day 17 (Aurrand-Lions et al., 2001b).  A similar expression pattern for Jam2 
in mouse embryonic stem (ES) cells cultured in vitro was also shown by Sakaguchi et al. 
(2006) who detected high levels of Jam2 transcripts in undifferentiated ES cells, which 
decreased as cells differentiated, rising again at day 20 of differentiation (Sakaguchi et al., 
2006).   
 
The generation of Jam2-/- mice has shown that despite the detection of Jam2 expression 
in testis and affect of Jam2 on Jam3 localisation (Jam3-deficient mice are infertile), Jam2 
mutant mice are fertile and display no obvious defects. No difference in histology of 
seminiferous tubules from testis of null mice was seen compared to those from WT mice, 
and analysis of spermatogonia showed that spermatogenesis appeared to be occurring 
normally in the absence of Jam2.  Furthermore, although Jam2 expression was detected 
in cultured primary neurospheres from WT mice, neurospheres from Jam2 mutant mice 
were unaltered in morphology, number and differentiation potential.  In addition, Jam2 
mutant mice have neural stem (NS) cell and haematopoietic (HS) cell populations 
comparable to that observed in WT mice (Sakaguchi et al., 2006). 
 
Jam2 was one of 283 genes identified by DNA microarray analysis to be expressed in 
undifferentiated mouse HS, NS and ES cells, with expression decreasing following cell 
differentiation (Ivanova et al., 2002).  Based on this finding, Jam2-/- ES cells were 
created by Sakaguchi et al (2006) to investigate the potential role of Jam2 as a 
“stemness” gene.  A puromycin resistance cassette and IRES β-geo cassette were used to 
replace exons 3-5 of both Jam2 alleles, which encode the 2 Ig folds that are required for 
dimerisation. Jam2-/- ES cells were found to express normal levels of Oct-4, Nanog and 
Sox-2, and have a normal ES cell morphology growing as densely packed adherent cells, 
with a growth rate comparable to the parental cell line.  Jam2-/- ES cells could be 
passaged long term in culture and produce teratomas of multiple differentiated cell types 
when injected into nude mice.  Despite the numerous previous studies reporting high 
levels of Jam2 expression in the heart, up-regulation of cardiac markers in embryoid 
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bodies (EBs) formed by Jam2-/- ES cells was comparable to expression in WT EBs 
(Sakaguchi et al., 2006).   
 
1.2.2.4 Expression of Jam2 in adult tissues and cells 
Whereas Jam1 expression is seen across endothelial and epithelial cell types, and Jam3 
expression is endothelial and also present on various blood cell types, Jam2 expression is 
predominantly endothelial and was in fact originally described as vascular endothelial 
junctional adhesion molecule (Ve-Jam) (Palmeri et al., 2000).  Jam2 expression has been 
detected in the endothelium of endocardium, arteries, capillaries and venules of the heart, 
on the endothelia of both large and small vessels, intermediate trophoblasts of placenta, 
lung, and foreskin, at the intercellular boundaries of tonsillar high endothelial venules 
(HEV), on BMVECs of the blood brain barrier (BBB), glomeruli of the kidneys, 
endothelium of arterioles, spermatogenic cells, and embryonic, haematopoietic and neural 
stem cells (Aurrand-Lions et al., 2001b; Gandhi et al., 2010; Ivanova et al., 2002; Liang 
et al., 2002; Palmeri et al., 2000; Sakaguchi et al., 2006).  Most recently, Zimmerli et al 
(2009) were the first group to identify Jam2 on a population of peripheral blood cells, 
specifically on conventional dendritic cells, (DCs) (Zimmerli et al., 2009) however, this 
is in conflict with a previous study and remains to be confirmed (Cera et al., 2004).   
 
Jam2 expression is regularly found to be distinct from that of Jam1 and Jam3 in both 
cellular location and cell type. In HEVs, Jam2 expression is found only within cell-cell 
junctions, whereas Jam1 and Jam3 are also located on the luminal surface of blood vessel 
endothelium.  Jam2 expression is not detected in lymphatic endothelia junctions or 
lymphatic sinuses, whereas both Jam1 and Jam3 expression is present (Aurrand-Lions et 
al., 2001b; Pfeiffer et al., 2008).  Exogenous expression of Jam1, 2 and 3 in madin darby 
canine kidney (MDCK) cells revealed a different staining pattern for Jam2 compared to 1 
and 3, with Jam2 staining described as more “diffuse” and not localised with Zo-1 in tight 
junction regions (Aurrand-Lions et al., 2001b).  When MDCK cells transfected with 
either Jam2 or Jam3 were cultured together, Jam3 expression was located at points of 
Jam2-Jam3 cell contacts and not Jam3-Jam3 cell contacts.  In contrast, Jam2 expression 
was “distributed over the surface of the cell” including between Jam2-Jam2 cell-cell 
contacts, suggesting that the trans-interaction with Jam2 is required for Jam3 cell surface 
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expression, but not vice-versa (Lamagna et al., 2005b).  The following sections review 
the role of Jam2 within specific cell types including sertoli and endothelial cells. 
 
1.2.2.4.1 Sertoli cells 
Jam2 expression is seen in sertoli-sertoli tight junctions in testicular seminiferous tubules.  
Jam1 expression is also present, however Jam3 expression is not detected (Gliki et al., 
2004; Liang et al., 2002).  Jam2 expression was also found to be located in junctional 
plaques connecting sertoli cells with round and elongated spermatids.  Jam3 is expressed 
on spermatids and was shown to be a binding partner for sertoli cell Jam2.  The 
interaction of Jam2 with Jam3 was shown to be required for recruitment of the of polarity 
proteins Par6, Cdc42, Pkcλ and protein associated to tight junction to the sertoli-
spermatid junctions within spermatid heads (Gliki et al., 2004).  However, although 
Jam3-deficient mice are infertile and spermatids from these mice lack signs of 
polarisation, Jam2-mutant mice are fertile and show normal testicular morphology 
suggesting that Jam2 function is dispensable in these cell types (Sakaguchi et al., 2006). 
 
1.2.2.4.2 Endothelial cells, inflammation and leukocyte migration 
A role for Jam2 in leukocyte trafficking was first shown by Cunningham et al (2000) who 
proposed that the homology between Jam2 and Jam1, which had previously been shown 
to be involved in leukocyte migration during inflammation, inferred that Jam2 may have 
a similar function.  The Jam2 protein was found to be able to capture numerous blood cell 
lines through interactions with α4β1 and Jam3 on the surface of the leukocytes HSB and 
HPB-ALL (Arrate et al., 2001; Cunningham et al., 2000; Liang et al., 2002).  
Confirmation of a role for Jam2 in leukocyte trafficking was provided by Ludwig et al in 
2005 who, through use of an anti-Jam2 antibody, demonstrated reduced ear swelling in 
mice with induced contact dermatitis.  This reduction was further decreased by a 
combination of anti-Jam2 and -Jam3 antibodies, suggesting distinct roles for Jam2 and 
Jam3 in this process.  Specifically, use of anti-Jam2 antibody alone was found to reduce 
epidermal CD3 staining and neutrophil infiltration, and decrease elastase and peroxidase 
activity, indicating that Jam2 may be involved in the leukocyte extravasation step of the 
leukocyte trafficking process.  Interestingly, use of an anti-Jam3 antibody that targets the 
Jam3/Jam2 interaction had no effect indicating that the anti-Jam2 antibody may be 
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interfering with a different interaction, and possibly a separate function of Jam2 (Ludwig 
et al., 2005). 
 
Jam2-Jam3 interactions were shown to exist not only between endothelial Jam2 and 
lymphocyte Jam3/α4β1, but also between endothelial cell Jam2 and Jam3.  Jam2 was 
shown to recruit Jam3 to the cell surface of endothelial cells, with a ratio of 60:40 
Jam2:Jam3 expressing cells resulting in the biggest redistribution of Jam3 apical staining.  
Inhibition of the Jam2-Jam3 interaction with Jam3 neutralising antibody resulted in 
redistribution of Jam3 from junctional sites to the apical membrane.  The released Jam3 
was then shown to bind Mac-1, the Jam3 counter-receptor expressed on leukocytes, as 
demonstrated by an increase in adhesion of Mac-1 expressing monocytoid cells to Jam3 
expressing lymph node sections. The authors proposed that as Jam2 expression is 
detected around sites of inflammation and tumour foci, the increase in Jam2 may have a 
role in affecting leukocyte recruitment to these areas by altering the availability of Jam3 
for binding to leukocyte receptors (Lamagna et al., 2005b; Liang et al., 2002). 
 
A more specific role for the endothelial Jam2-Jam3 interaction was shown by Bradfield 
et al in 2007.  Jam2-Jam3 interaction between endothelial cells was shown to maintain 
leukocytes in the abluminal compartment after having undergone transendothelial 
migration.  Use of Jam3 blocking antibodies specific for the Jam2-Jam3 interaction, 
soluble Jam3, or small interfering ribonucleic acid (siRNA) for Jam3 increased the 
number of reverse transmigrated leukocytes in circulation, which were detected by lack 
of expression of cell surface L-selectin. Blockage of Jam2-Jam3 interaction resulted in a 
faster transmigration time compared to untreated cells.  Furthermore, inhibition of the 
Jam2-Jam3 interaction was shown to affect the reverse transmigration step alone, as 
leukocyte capture, rolling or transmigration were unaffected (Bradfield et al., 2007). 
 
A second role for Jam2 in the rolling and adhesion stages of leukocyte trafficking was 
later shown by Ludwig et al (2009), who found that use of a Jam2 blocking antibody in 
mice reduced rolling interactions of labelled lymphocytes with skin post-capillary 
venules compared to isotype control antibody.  These interactions were all shown to be 
mediated through Jam2-α4β1 integrin binding, rather than Jam2-Jam3 binding.  Use of 
either anti-α4 or -β1 antibody alone could block lymphocyte rolling on glass slides 
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coated with Jam2, whereas a reduction in adhesion was seen when using both antibodies 
in combination (Ludwig et al., 2009).  Further evidence that Jam2 has distinct roles in 
these processes from Jam3 is suggested by the staining pattern of these molecules at sites 
of leukocyte migration.  Jam2 expression is much higher in blood endothelial vascular 
cells, than in lymphatic endothelial cells, which is not the case for Jam1 or Jam3, 
suggesting that Jam2 is specifically involved in migration across vascular but not 
lymphatic barriers (Lamagna et al., 2005b; Pfeiffer et al., 2008).  Most recently Jam2 
expression was investigated in BMVECs of the BBB.  Interestingly, Jam2 transcript 
expression was shown to increase when these cells were exposed to HIV-1 TatB and 
TatC proteins.  This up-regulation was accompanied by down-regulation of tight junction 
protein Zo-1, a decrease in TER and an increase in monocyte transmigration. (Gandhi et 
al., 2010). 
 
1.2.2.4.3 Other locations of Jam2 expression 
The expression of Jam2 has also been reported on several other cell types, though the 
function of Jam2 within these cell types has yet to be fully investigated.  Jam2 is 
expressed on a small subset of retinal ganglion cells (RGCs) which are distributed evenly 
across the retina in mice, which detect upward motion in the visual field.  However, the 
function of Jam2 in these cells was not investigated, nor was any analysis of the eye sight 
of Jam2-deficient mice reported by Sakaguchi et al (2006), therefore, the role of this 
expression currently remains unknown (Kim et al., 2008; Sakaguchi et al., 2006).  
Expression of Jam2 on conventional DCs and bone-marrow derived dendritic cells (BM-
DCs) was recently reported.  The involvement of the Jam2-Jam3 interaction was 
investigated, however, Jam3 binding was found not to be involved, as blocking of Jam2 
did not prevent adhesion of the DCs to recombinant Jam3 and BM-DCs derived from 
Jam2 deficient mice also failed to bind (Zimmerli et al., 2009).  The results of this study 
conflict with a previous study that did not detect Jam2 expression on these cells, therefore 
the expression of Jam2 in DCs remains to be confirmed (Cera et al., 2004).  Jam2 
expression has also been detected on the intermediate trophoblasts of the placenta, an 
invasive cell type that degrade the extracellular matrix (ECM), and are involved in 
vascular remodelling during implantation (Liang et al., 2002).  The role of Jam2 in this 
process has yet to be addressed however.  Jam2 (and Jam3) expression has also been 
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found on ependymal cells in the mouse brain and on oligodendrocytes of human brain, 
although no further detail was provided by the authors (Tenan et al., 2009). 
1.2.2.4.4 Jam2 expression in disease states and pathologies 
As has been shown to be the case with Jam1 and Jam3, Jam2 expression has been 
associated with various pathological states including inflammation, cancer, and HIV-1 
infection.  Jam2 expression in relation to cancer was first reported by Aurrand-Lions et al 
(2001), who observed expression of Jam2 transcripts in the epithelial carcinoma cell line 
KLN 205.  Jam2 protein expression was investigated in this cell line and found to be 
located “hazily” at lateral cell borders (Aurrand-Lions et al., 2001b).  The expression of 
Jam2 was also observed in vessels adjacent to tumour sites, but not in normal tissues 
investigated, which included pulmonary, testicular, colonic and mammary 
adenocarcinomas (Liang et al., 2002).  Jam2 expression has also been detected in 23 out 
of 25 gliomas analysed (Tenan et al., 2009).  Jam2 expression was found on the majority 
of the cells within the tumours, with homogeneous membrane staining being observed.  
In addition, Jam3 and Jam2 expression levels were found to strongly correlate on human 
glioma cell lines.  However, no correlation between Jam2 or Jam3 expression and tumour 
grade was found, suggesting that both may be up-regulated early in the process of tumour 
cell progression.  Culturing of GL261 mouse glioma cell line, used as a model for Jam2 
and Jam3 expressing gliomas, with soluble Jam2 which binds to Jam3, led to rapid 
increase in c-Src activation in GL261 cells.   Treatment of mice with a Jam2-Jam3 
blocking antibody when injected with glioma cell line GL261, inhibited tumour growth 
significantly and reduced tumour cell dissemination.  Although survival rate of the mice 
was not affected, this was suggested to be due to the aggressive nature of the cancer cell 
line used. The authors also noted that tumours were also more rounded in shape in the 
Jam2-Jam3 antibody treated mice compared to those treated with control antibody (Tenan 
et al., 2009).   
 
Jam2 expression has also been detected on several tissues with chronic inflammatory 
diseases.  These include lungs with asthma, pneumonia and chronic obstructive 
pulmonary disease, kidneys with chronic lymphocytic interstitial nephritis, and livers 
with hepatitis and alcoholic cirrhosis. Jam2 expression was also found to be located in 
arterioles within or adjacent to areas of lymphocytic inflammation of diseased lungs and 
kidney, but not in the liver, suggesting that up-regulation of Jam2 at sites of inflammation 
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is not universal  (Liang et al., 2002).  Finally, Jam2 gene expression in BMVECs was up-
regulated when these cells were exposed to HIV-1 Tat proteins, and even more so in 
conjunction with cocaine, indicating a potential role for Jam2 in migration of HIV 
infected blood cells across the BBB, which is known to cause neurological problems in 
HIV patients (Gandhi et al., 2010).   
 
1.2.2.5 Regulation of Jam2 expression 
To date only one paper has directly addressed the mechanism of Jam2 regulation, and this 
was in regard to Jam2 expression in mouse sertoli cells.  The regulation of Jam2 
expression by the first 499bp of the Jam2 promoter region was investigated by Wang et al 
(2009), who found that Interleukin-1α (IL-1α) positively regulates promoter activity in 
this region, whereas Transforming growth factor-β2 (Tgf-β2) negatively regulates 
promoter activity.  Mutation of distinct areas within this region revealed that constitutive 
expression of Jam2 is a result of Sp proteins, ETS domain transcription factor (Elk-1), 
Neuron restrictive silencer factor (Nrsf) and E2F transcription factor 3 (E2F3) binding to 
DNA motifs including TG interacting factor (Tgif), Elk-1, Nrsf, and pSp1+E2F1.  IL-1α 
was shown to positively regulate Jam2 expression by facilitating the binding of Elk-1 to 
Tgif and pSp1+E2F3 motifs in a p38-dependant manner.  Tgf-β2 was found to negatively 
regulate Jam2 expression by activating Smad proteins which compete with Sp proteins 
for binding to Tgif motif.  Interestingly, inclusion of -1000 to -1935 region of the Jam2 
promoter region led to a decrease in promoter activity, this was not investigated further 
however (Wang and Lui, 2009).  
 
Other studies whose main focus has not been the regulation of Jam2 have yielded some 
additional information. The following cytokines did not up-regulate Jam2 cell surface 
protein expression on human umbilical vein endothelial cells (HUVECs) following 72 
hours of treatment: Tumour necrosis factor-α (Tnf-α), Tgf-β, IL-1, IL-4, Interferon-γ 
(Ifn-γ), Exodus-2, stromal cell-derived factor-1α, stromal cell-derived factor-1β and 
Granulocyte macrophage colony stimulating factor (GM-CSF) (Liang et al., 2002).  
Culturing of primary neurospheres with Epidermal growth factor (Egf) and Fgf-2 was 
found to increase amount of Jam2 mRNA expression compared to absence of these 
growth factors (Sakaguchi et al., 2006).  Stimulation of HUVECs with Tnf-α resulted in 
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up-regulation of Jam2 protein expression as shown by immunofluorescence (Ludwig et 
al., 2009).  Finally, qualitative polymerase chain reaction (PCR) analysis of Jam2 gene 
expression showed that Jam2 expression is positively regulated by exposure of BMVECs 
to HIV-1 Tat proteins, with expression increasing further when the cells are exposed to 
cocaine in addition to the HIV-1 proteins (Gandhi et al., 2010). 
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1.3 Epithelial to Mesenchymal Transition 
1.3.1 EMT overview 
EMT is an essential cell-remodelling program during which epithelial cells undergo 
specific cellular changes to exhibit a mesenchymal phenotype.  EMT is vital during 
embryonic development and has been shown to contribute to the pathological processes 
of fibrosis and tumour cell metastasis (Thiery, 2002; Vićovac and Aplin, 1996; Viebahn, 
1995; Zeisberg et al., 2007c).  Loss of cell surface E-cadherin is a defining step in EMT.  
Epithelial cells display apico-basal polarity and form adhesions through adherens and 
tight junctions in their lateral sides, allowing the cells to function as one tissue.  The 
apical side of an epithelium is frequently unattached and covered in microvilla or cilla, 
whereas the basal side is attached to the basement membrane with cortical actin 
cytoskeleton arrangement (Davies and Garrod, 1997).  In contrast, the mesenchymal 
phenotype exhibits polarised actin arrangement, increased motility and invasiveness and 
the capability of degrading and moving through the ECM. Mesenchymal cells rarely form 
cell-cell contacts and it is only during transient periods that cell-cell junctions form (Hay, 
2005).  Epithelial cells responding to EMT signals lose their apical-basal polarity and 
down-regulate adhesion molecules and associated junctions.  Cytoskeletal alterations 
allow for cell migration to occur and the up-regulation of proteases permits the cells to 
degrade the basement membrane as they migrate through it, away from the epithelium 
from which they originate (Figure 1.4) (Hay, 1995). 
 
Adherens junction
Actin cytoskeleton
Extracellular matrix
Basement membrane
(a) (b) (c) (d) (e)
 
Figure 1.4 Cellular alterations during EMT  (a) Epithelial cells exhibit apico-basal polarity via adherens 
junctions containing E-cadherin.  (b) As EMT proceeds, E-cadherin is down-regulated, adherens junctions 
disassemble and the rigid structure of the epithelial cell is lost.  (c) Newly expressed proteases degrade the 
basement membrane and (d+e) the cell begins to invade the ECM moving away from the tissue in which it 
originated. 
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EMTs, and the reverse process MET, are essential during embryo development as the 
epithelial cells of the epiblast must eventually generate all cell types of the adult 
organism.  EMT- and MET-like processes are also used by adult tissues undergoing 
wound repair to heal damaged areas of tissue.  A great deal of attention has been given to 
the study of EMT due to the association of EMT events with pathological conditions such 
as fibrosis and metastatic cancer progression. It has recently been suggested that EMTs 
are classified as being one of three types; type 1, these encompass the EMTs that take 
place during embryo development including gastrulation and neural crest formation; type 
2, are defined as EMTs that are induced by persistent inflammation and result in 
fibroblast formation; and finally type 3 EMTs are those involved in the metastatic 
progression of epithelial carcinoma cells  (Zeisberg and Neilson, 2009).  The following 
sections utilise this method of classification by discussing each of these EMTs type in 
turn, developmental, fibrosis-related and finally, those involved in tumour metastasis. 
 
Although these three types of EMT are involved in seemingly very diverse biological 
processes, all three exhibit many similar characteristic events.  These include the down-
regulation of adhesive proteins such as E-cadherin and loss of cell-cell junctions, the loss 
of apical-basal cell polarity, the up-regulation of proteases, Snail family transcription 
factors and mesenchymal cell markers, and the involvement of the Tgf-β family 
signalling pathway, often involved in cross-talk with other pathways, through receptor 
tyrosine kinase (RTK) activation (Thiery, 2002; Viebahn, 1995; Yang and Liu, 2001). 
 
1.3.2 EMTs in development 
Several rounds of EMT followed by either apoptosis or MET and further EMTs take 
place during embryo development, as cells develop into their final differentiated cell type, 
these are classed as type 1 EMTs. 
 
1.3.2.1 Implantation 
The first EMT to take place during embryo development is during implantation of the 
blastocyst into the uterine wall.  As the trophectodermal cells of the trophoblast, 
specifically the extravillous cytotrophoblast (trophoblast stem cells) undergo EMT, they 
anchor to and infiltrate into the endometrium of the uterus.  This results in the 
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remodelling of the uterine environment and maternal arteries, and in the formation of the 
placenta (placentation) (Vićovac and Aplin, 1996).  Strict control of this invasion is 
provided by signalling from the uterine environment, for example E-cadherin expression 
is down-regulated during the EMT and up-regulation of Mmp activity and mesenchymal 
integrins such as α5β1 is seen (Babawale et al., 1996; Damsky et al., 1992; Fisher et al., 
1989).  E-cadherin has been shown to be vital at this stage of development as Ecad-/- 
embryos fail to form trophectoderm and do not implant (Larue et al., 1994).  Furthermore, 
the precise regulation of E-cadherin has been shown to be important during pregnancy as 
pre-eclampsia, which occurs when trophoblast invasion into the uterine wall is too 
shallow, has been found to correlate with high expression of E-cadherin in cells in which 
E-cadherin is typically down-regulated (Zhou et al., 1997). 
 
1.3.2.2 Gastrulation 
Another EMT event during embryo development takes place during gastrulation, the 
procedure by which the body plan is determined.  Prior to gastrulation all cells of the 
epiblast are epithelial cells (primary ectoderm). To develop into all the structures and cell 
types required to make a fully formed organism the epiblast cells must undergo several 
alterations in the form of EMT and MET.  Epiblast cells of the primitive streak 
undergoing EMT exit the primitive streak and migrate away to form endoderm and 
mesoderm.  The remaining epiblast cells not programmed to undergo EMT become 
ectoderm, giving rise to the third primary germ layer. The mesoderm and endoderm then 
participate in further rounds of EMT and MET to form the various cell types of the body 
(Viebahn, 1995). 
 
The EMT of gastrulation has been shown to be triggered initially by Wnt signalling, then 
Tgf-β superfamily members Nodal and Vg1 continue the process, and Fgf signalling 
maintains EMT by controlling the specification of the cells (Liu et al., 1999). These 
signalling pathways activate transcription factors that induce EMT, including Snail (Cano 
et al., 2000) , E12/E47 (Perez-Moreno et al., 2001), Slug (Bolos et al., 2003), and Sip1 
(Vandewalle et al., 2005).  Tgf-β induces Snail and Slug expression initially, and Fgf 
maintains their up-regulation.  These factors act not only to down-regulate the expression 
of E-cadherin but also other epithelial associated molecules such as claudins, and also 
disrupt cell polarity complexes (Peinado et al., 2007; Whiteman et al., 2008).  In addition, 
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Snail up-regulates Mmp expression, resulting in cleavage of E-cadherin protein at the cell 
surface that acts as a positive feedback loop for transcriptional repression as well as 
allowing invasion of the epiblast (Jorda et al., 2005; Joseph et al., 2009; Miyoshi et al., 
2004).  Snail has been shown to be essential for gastrulation as mesenchymal cells of 
Snail-deficient embryos are unable to down-regulate E-cadherin (Carver et al., 2001), 
although Snail-deficient embryos are able to form neural crest but exhibit cranio-facial 
defects (Murray and Gridley, 2006).  E-cadherin down-regulation during EMT of 
gastrulation also results from the destabilisation of the E-cadherin protein by p38 MAP 
kinase and p38-interacting protein (Zohn et al., 2006).   
 
1.3.2.3 Neural crest formation 
During neural crest formation epithelial cells near the dorsal midline of the neural tube 
undergo EMT to develop into migratory neural crest cells. This results in the formation of 
the peripheral nervous system and the vertebrate head.  The EMT of neural crest 
formation is induced by a similar set of triggers as that of gastrulation, including Wnt, 
Fgf and Bone morphogenetic protein (Bmp) signalling (Villanueva et al., 2002). The 
noticeable difference between this EMT and that of gastrulation, is that the EMT during 
neural crest formation involves down-regulation of N-cadherin, as opposed to E-cadherin, 
and up-regulation of less-adhesive type 2 cadherins such as cadherins 7 and 11 
(Nakagawa and Takeichi, 1995; Vallin et al., 1998).  N-cadherin down-regulation has, 
like E-cadherin, been shown at the protein level, as cleavage of the N-cadherin protein by 
an Adam10-dependant mechanism results in a soluble cytoplasmic N-cadherin fragment, 
which has been found to be involved in transcriptional regulation of downstream targets 
such as Cyclin D1 (Shoval et al., 2007). 
 
1.3.2.4 Endothelial to mesenchymal transition 
Endothelial to mesenchymal transition (EndMTs) also participate in embryo development.  
Various areas of the heart develop as a result of EndMTs, including mesenchymal cells of 
the atrioventricular cushion, the primordia of the valves and septa of the adult heart.  
Neural cell adhesion molecule expression is down-regulated, and Tenascin is up-
regulated.  Similar signalling pathways to EMTs are involved as blockage of Tgf-β 
signalling has been shown to block formation of mesenchyme and  Snail, Slug, and β-
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catenin signalling have been shown to be involved (Eisenberg and Markwald, 1995; 
Liebner et al., 2004; Niessen et al., 2008). 
 
1.3.2.5 Wound healing and tissue repair 
An EMT-like process is also used by the body in wound healing, tissue repair and 
ovulation (Ahmed et al., 2006).  Although wound healing has yet to be confirmed as a 
definite type of EMT, many similarities in cell behaviour and phenotype are seen as 
keratinocytes migrate across the wound area.  These include the up-regulation of Mmps, 
expression of Snail transcription factors, reduction in cell-surface E-cadherin expression 
and associated cell-cell junctions, and reorganisation of the cytoskeleton (Arnoux et al., 
2005). 
 
1.3.3 EMTs in disease 
1.3.3.1 Fibrosis 
Fibrosis results from fibroblasts excreting excessive amounts of ECM components such 
as collagen.  This results in fibres that negatively affect organ function, which ultimately 
results in organ failure.  Organs such as the kidney possess some fibroblasts in a normal 
state and these are responsible for ECM production, expression of growth factors and 
mediation of inflammatory responses (Qi et al., 2006).  The fibroblasts responsible for 
fibrosis however, have been shown to come from two sources; either pre-existing 
fibroblasts lying resident in the organ, or they have originated from epithelial cells which 
have undergone a type 2 EMT in response to injury.  It has been demonstrated that over a 
third of these fibroblasts are as a result of EMT (Iwano et al., 2002). 
 
Fibrosis occurs in several organ and tissue types including renal tubes and ducts, lens 
epithelium, endothelium, hepatocytes and cardiomyocytes (Strutz et al., 2002; Willis et 
al., 2005; Zeisberg et al., 2007b; Zeisberg et al., 2007c).  The EMT that takes place 
during fibrosis exhibits cellular changes characteristic of all types of EMT.  These 
include loss of cell-cell contact and apical-basal polarity, which is accompanied by loss 
of epithelial membrane and tight junction proteins, re-organisation of the cytoskeleton, 
degradation of basement membrane, up-regulation of Mmps, increased cell motility and 
up-regulation of mesenchymal markers (Yang and Liu, 2001). 
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The EMT during fibrosis has been shown to be induced by several growth factors 
including Tgf-β, Platelet-derived growth factor (Pdgf), Egf, and Fgf-2.  These growth 
factors are released either by macrophages drawn to site of inflammation or by the 
epithelial cells themselves, resulting in the activation of fibroblasts already present in the 
area and induction of EMT in the epithelial cells (Strutz et al., 2002).  Tgf-β1 has been 
demonstrated to be the most potent initiator of EMT in kidney fibrosis, during which 
tubuloepithelial cells of the kidney undergo EMT to form myofibroblasts (Yang and Liu, 
2001).  Downstream of Tgf-β1 signalling, Smad and Integrin-linked kinase (Ilk) are 
activated.  Importantly, it was shown that blockage of this EMT blocks renal fibrosis 
(Burns et al., 2007).  Tgf-β1 has also been shown to induce EMT in epithelial alveolar 
cells, as following exposure to Tgf-β1 cells displayed an altered morphology, up-
regulation of fibroblast associated markers including α-smooth muscle actin and 
Vimentin, and a reduction in epithelial markers (Willis et al., 2005).  Fibrosis has recently 
been shown to result from EndMTs of cardiac endothelial cells to fibroblasts.  This was 
also shown to be induced by Tgf-β1 and involved downstream Smad signalling (Zeisberg 
et al., 2007b).  Mmp2 can also initiate EMT in renal tubuloepithelial cells and, consistent 
with all other types of EMT, Snail transcription factors are involved in instigating the 
EMT of fibrosis (Boutet et al., 2006; Burns et al., 2007). 
 
It has also recently been shown that the fibroblasts responsible for depositing ECM 
components and causing fibrosis in liver disease may also originate from EMT events.  
Cells which were originally hepatocytes, induced by Tgf-β1 signalling to undergo EMT, 
exhibit increased motility, increased Fibroblast specific protein 1 and decreased E-
cadherin expression (Zeisberg et al., 2007c). 
 
1.3.3.2 Cancer 
1.3.3.2.1 EMT during carcinoma progression   
The similarity between cells undergoing EMT and the metastatic progression of 
carcinoma cells has been noted for many years.  Interestingly, the controlled invasion of 
the uterine wall by blastocysts during implantation was observed as being similar to the 
uncontrolled behaviour of highly invasive tumours (Vićovac and Aplin, 1996).  It has 
only recently become more accepted that cancer cells undergo an EMT as they progress 
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to a more aggressive phenotype although it remains a contentious issue.  The main 
argument against EMT in tumour cell metastasis comes from not being able to witness 
the EMT event itself in vivo.  The cells are either observable as being of either epithelial 
or mesenchymal phenotype, whereas the transition between the two is unobservable due 
to the unpredictable nature of the disease.  However, there are numerous correlations in 
gene expression patterns, signalling events, cellular phenotypes, and behaviours that 
strongly indicate an EMT-like event taking place as cells metastasise.  In support of this, 
the discovery of tumour cells exhibiting the hallmarks of EMT at the invasive front of 
tumour masses has been reported (Prall, 2007). 
 
EMT exhibited by tumour cells as they progress from the benign to metastatic state 
comprise cellular events and alterations comparable to those seen in developmental EMT.  
Disruption of cell-cell contacts occurs and the cells lose intracellular junctions and cell 
polarity, cytoskeletal rearrangements are observed, and the cells become more motile 
(Birchmeier and Behrens, 1994).  At the molecular level E-cadherin is down-regulated, 
EMT-associated transcription factors such as Snail, Slug, Sip1, Zeb1, and Twist may be 
up-regulated (Comijn et al., 2001; Hajra et al., 2002; Matsuo et al., 2009; Sivan Elloul et 
al., 2005; Spaderna et al., 2008) and protease expression and activity increases (Miyoshi 
et al., 2004). Down-regulation of E-cadherin during EMT is often accompanied by the 
up-regulation of N-cadherin, resulting in an E- to N-cadherin switch (Hazan et al., 2004).  
The result is a motile and invasive cell capable of migrating away from the primary 
tumour by degrading the surrounding ECM.  Through this method the invasive cancer 
cell can then enter the blood or lymph system by intravasation, eventually establishing a 
secondary tumour site elsewhere in the body upon exiting the circulation by extravasation 
(Birchmeier and Behrens, 1994).  It has also been shown that tumour cells that have 
undergone EMT are more resistant to cell death via apoptosis, which is associated with 
expression of Snail transcription factors (Kajita et al., 2004).  Furthermore, cells that have 
undergone EMT are more resistant to chemotherapy and radiotherapy (Kurrey et al., 
2009). 
 
E-cadherin expression levels have been repeatedly shown to be a key player in the 
process of EMT.  Decreased E-cadherin expression has been shown to correlate with poor 
survival rates in patients with various cancers, including gastric and oesophageal 
carcinomas (Shino Y et al., 1995; Tamura et al., 1996).  The expression of E-cadherin in 
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mesenchymal cells reverses the mesenchymal phenotype to an epithelial phenotype and 
the expression of E-cadherin in metastatic cancer cells reduces the invasiveness of these 
cells (Hsu et al., 2000; Luo et al., 1999).  For these reasons E-cadherin is considered to be 
a gate keeper for epithelial integrity and loss of E-cadherin expression or function is 
considered to be a hallmark of EMT (Birchmeier and Behrens, 1994).  Somatic mutations 
within the E-cadherin gene can lead to loss of E-cadherin function, which has shown to 
be the case for some hereditary gastric cancers (Berx et al., 1998).  Through either 
transcriptional repression (e.g. Snail transcription factors) or regulation at protein level 
(up-regulation of Mmp expression), an inverse correlation between Snail and E-cadherin 
expression has been shown in multiple cancer cell types (Jiao et al., 2002; Yokoyama et 
al., 2001).  In addition to loss of cell-cell adhesion and cell polarity, loss of E-cadherin 
from cells results in EMT-inducing signalling as membrane bound β-catenin becomes 
available for Tcf/Lef signalling and Wnt pathway involvement (Eger et al., 2004). 
 
1.3.3.2.2 Triggers of EMT during tumour progression 
Signals that trigger EMT of tumour metastasis include activation of RTKs by various 
growth factors, oncogenic Ras, and Tgf-β signalling (Huber et al., 2005).  The signal can 
originate from the tumour stroma, Tgf-β for instance, or it can be autocrine in nature, for 
instance production of the Egf family members, Fgf, Hepatocyte growth factor (Hgf) and 
Insulin-like growth factor (Igf) 1 and 2, which drive the EMT forward (van Zijl et al., 
2009).  Interestingly, EndMTs have been shown to be responsible for producing a 
significant portion of cancer-associated fibroblasts (CAFs) of the tumour stroma 
(Zeisberg et al., 2007a).  CAFs contribute to tumour progression as they secrete Hgf and 
Tgf-β that can induce EMT in nearby carcinoma cells, and Vascular endothelial growth 
factor (Vegf) can induce angiogenesis (Kalluri and Zeisberg, 2006). Downstream of the 
initial EMT trigger, several signalling pathways are activated.  These can include Wnt, 
Notch, and Hedgehog signalling pathways, in addition to the downstream signalling 
events of the RTK activators Egf, Igf, Pdgf, and Hgf (Huber et al., 2005).  Hypoxia has 
also been shown to induce EMT by up-regulating Twist expression (Yang et al., 2008).  
Recently, micro RNA (miRNAs) have been found to be involved in EMT, as miR-200 
and miR-205 have been shown to repress Zeb1 and Sip1 expression, and blocking of 
these miRNAs results in up-regulation of expression of Zeb1 and Sip1 and induction of 
EMT (Gregory et al., 2008).  Kruppel like factor 8 (Klf8) has also been shown to induce 
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EMTs in epithelial cells by repressing E-cadherin through binding within GC boxes in 
the E-cadherin promoter (Wang et al., 2007). 
 
1.3.4 In vitro models of EMT 
The majority of studies on EMT use either immortalised epithelial or cancer cell lines in 
vitro stimulated with one or more of the known EMT-stimulating growth factors such as 
Tgf-β or Hgf, or over-expression of EMT transcription factors such as Snail, Twist or 
Zeb1(Davies et al., 2001; Ikenouchi et al., 2003; Matsuo et al., 2009; Willis et al., 2005).  
However, a new method of mimicking EMT has recently emerged utilizing ES cells 
either grown on mouse embryonic fibroblast (MEF) feeder layers for extended periods, or 
induced to differentiate by culturing the cells in synthetic serum replacement media in the 
absence of Leukaemia inhibitory factor (Lif).  Denker et al (2007) found that by culturing 
rhesus monkey ES cells on MEFs for up to 10 days resulted in multilayered disc-like 
colonies of cells.  These layers comprised of an upper epithelial layer exhibiting apical-
basal polarity and cell junctions, and a lower mesenchymal layer.  In the centre of each 
colony appeared to be a pit in which cells were passing through from top to bottom via 
EMT.  In these cells, loss of E-cadherin expression was seen and this correlated with a 
10-fold increase in Slug expression.  The movement of cells through this pit was 
suggested to be mimicking the ingression of the primitive streak during gastrulation.  
Therefore this method of ES cell culture provides a potential in vitro model of the EMT 
of gastrulation, and therefore embryogenesis (Denker et al., 2007).  At a similar time 
Eastham et al (2007) and Spencer at al (2007) reported an EMT-like event during human 
and mouse ES cell differentiation.   HUES4 human ES cells, when cultured on gelatin-
treated organ dishes in the absence of a fibroblast feeder layer, exhibited an E- to N-
cadherin switch, up-regulation of Snail, Slug and Sip1 transcripts and proteins, which 
was associated with increased motility and protease activity (Eastham et al., 2007).  
Mouse ES cells demonstrated identical changes when cultured in synthetic serum 
replacement media in the absence of Lif (Spencer et al., 2007).  These methods of ES cell 
culture therefore provide a simple, reproducible model system in which to study EMT, 
and therefore further elucidate the molecular and cellular events that take place during 
embryonic development and, possibly, tumour cell metastasis.  
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1.4 Embryonic Stem Cells  
1.4.1 Stem cell overview 
ES cells are defined as unspecialised cells capable of indefinite self-renewal whilst 
retaining the ability to differentiate into cell lineages representative of the 3 primary germ 
layers; mesoderm, endoderm and ectoderm (pluripotency).  ES cells originate from the 
inner cell mass (ICM) of the pre-implantation embryo, a transient state as these cells 
subsequently differentiate during embryogenesis, gradually losing their “stemness” 
(except for germ cells).  Following removal from the ICM, stem cells will maintain their 
pluripotent, self-renewing state for prolonged periods of time when cultured under 
optimum conditions (Smith, 2001). The maintenance of the pluripotent ES cell state can 
be monitored by analysing various markers including the transcription factors Oct-3/4 
(Niwa et al., 2000) and Nanog (Mitsui et al., 2003) and the carbohydrate adhesion 
molecule Stage-specific embryonic antigens (SSEA-1 in mouse, SSEA-3 and -4 in human) 
(Henderson et al., 2002; Solter and Knowles, 1978).  In addition, assessment of 
pluripotency is also achieved by analysing the ability of the cells to form teratomas 
following injection of the ES cells into nude mice, and assessing the capacity of the stem 
cells to give rise to cells of all three germ layers either through EB formation or by 
inducing the cells to spontaneously differentiate (Smith, 2001).  
 
The research and therapeutic potential of the stem cell-based investigations are both vast 
and exciting.  For example, the culture of ES cells provides an easily manipulated system 
in which to study embryo development particularly by utilising knock-out mice generated 
from mutant ES cells, or in vitro analysis (Haegel et al., 1995; Larue et al., 1994; Mitsui 
et al., 2003; Sakaguchi et al., 2006).  The pluripotent nature of ES cells also offers major 
potential in the area of cell-based regenerative medicine.  Much ES cell research is 
directed to the controlled differentiation of ES cells into cells of specific lineages, such as 
neurons for the treatment of Alzheimer’s disease and the insulin-producing β-cells of the 
pancreas for the treatment of diabetes (Mfopou et al., 2010; Moghadam et al., 2009).  
Furthermore, ES cell research may also have applications in the study of cancer cell 
biology.  Cancer cells have long been observed as behaving like stem cells as embryonal 
carcinoma cells, stem cells derived from teratomas, are able to contribute to the 
development of normal adult mice when incorporated into the embryo (Illmensee and 
Mintz, 1976).   
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Stem cells have also been discovered in various adult tissues, termed adult or somatic 
stem cells.  Tissues and organs in which adult stem cells have been discovered to date 
include the heart, blood, teeth, retina, skeletal muscle, skin, liver, testis and brain (Bu et 
al., 2009; Dabeva and Shafritz, 2003; Ghazizadeh and Taichman, 2001; Gritti et al., 1996; 
Kossack et al., 2009; Seale and Rudnicki, 2000; Sloan and Waddington, 2009; Tropepe et 
al., 2000).  These differ from ES cells in that they exist in vivo as long-term populations 
of cells, located in stem cell niches within the adult tissues.  Furthermore, adult stem cells 
exhibit only multipotency, the ability to form cells of the lineage from which they are 
derived e.g. haematopoietic stem cells give rise to blood cells, and neural stem cells give 
rise to cells of the brain and central nervous system. Therefore, the function of adult stem 
cells is thought to be to replace cells of the specific lineage to which they belong.  
Although adult stem cells are most likely to give rise to the cell types of the tissue in 
which they reside, these cells have shown the capacity to be manipulated in vitro to 
derive cells of other lineages, a process known as transdifferentiation (Anderson et al., 
2001).  Although haematopoietic stem cells have been successfully used in regenerative 
medicine for over four decades for bone marrow transplantation, the research progress for 
these cell lines has been limited compared to ES cells for two main reasons.  The first is 
that adult stem cells are rare, making them difficult to isolate from adult tissues, and 
secondly, optimum in vitro culture conditions have yet to be defined for adult stem cells.  
For example, although the culturing of mouse muscle stem cells on scaffolds that mimic 
the rigidity of the in vivo stem cell niche substantially improved the regenerative 
potential of the cells following engraftment into recipient mice compared to cells grown 
in standard plastic microwells, the rate of engraftment was still only 25% (Gilbert et al., 
2010). 
 
1.4.2 Embryonic stem cells  
1.4.2.1 Mouse ES cells 
Mouse ES cells were the first ES cells to be isolated and were initially successfully 
cultured using conditioned media and a fibroblast feeder layer (Evans and Kaufman, 
1981; Martin, 1981).  Martin (1981) speculated that conditioned media may provide a 
specific pluripotency retaining factor and the current standard method for culturing 
mouse ES cells to maintain pluripotency involves culturing the cells in serum-based 
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media supplemented with the cytokine Lif (Smith et al., 1988).  Lif acts by binding to Lif 
receptor β and gp130.  This complex then phosphorylates and activates Janus-associated 
tyrosine kinases which in turn activate Stat3 (Niwa et al., 1998).  Following activation, 
Stat3 dimerises and translocates to the nucleus where it regulates the expression of 
downstream target genes, such as c-Myc (Cartwright et al., 2005).  Lif has been shown to 
be only partly responsible for the maintenance of pluripotency as cells cultured with Lif 
but without serum differentiate.  The presence of serum is thought to be necessary to 
provide additional factors involved in the maintenance of ES cell pluripotency, such as 
Bmps.  For example, mouse ES cells can be maintained in a pluripotent state when 
cultured in defined media (in the absence of serum) in the presence of Lif and Bmps, 
which maintain pluripotency through the activation of Inhibitor of differentiation proteins  
(Ying et al., 2003).  Wnt signalling has also been implicated in ES cell pluripotency as 
addition of a Wnt pathway activator to serum-, Lif- and feeder-free media could maintain 
both human and mouse ES cells in a pluripotent state (Sato et al., 2004).  Recently Ying 
et al. (2008) proposed that current ES cell culture media prevents differentiation rather 
than promoting self-renewal.  They reported the maintenance of pluripotency in mouse 
ES cells by culturing them in chemically defined media in the presence of Fgf RTK, 
Extracellular signal-related kinase, and Gsk-3 inhibitors (Ying et al., 2008). 
 
Recently, the derivation of a novel embryonic stem cell line from a later stage during 
development was reported by two groups.  These cells are derived from the post-
implantation epiblast, and have been termed Epiblast stem cells, or EpiSC.  Interestingly, 
these cells can be cultured in the same chemically defined media that maintains human 
ES cells in a pluripotent state (see section 4.2.2), relying upon Activin/Nodal signalling 
instead of Lif and Bmps to prevent differentiation.  Additionally, these cells grow in 
colonies that are more similar to human ES cells colonies than mouse ES cells, growing 
in monolayers rather than as domed colonies.  Transcriptional profiling has revealed 
EpiSCs to have more in common with their originating tissue (late epiblast) than 
established mouse ES cell lines.  Although germ-line transmission was not observed 
when EpiSC were injected into blastocysts, in vitro differentiation of these cells resulted 
in formation of cell lineages representative of all three germ layers, and teratoma 
formation was also observed (Brons et al., 2007; Tesar et al., 2007). 
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1.4.2.2 Human ES cells 
Human ES cells (hES) were first isolated in 1998 (Thomson et al., 1998).  These cells 
were isolated from pre-implantation blastocysts from embryos originally created for In 
Vitro Fertilisation procedures.  hES cells utilize different signalling pathways to maintain 
pluripotency as Lif and Bmps are not sufficient to prevent hES cells from differentiating.  
Instead, hES can be grown on a feeder layer in the presence of Fgf-2 and have been 
shown to maintain pluripotency through the Activin/Nodal signalling pathway (Vallier et 
al., 2005).  Much hES cell research is focussed on developing methods for feeder-free 
culture to eliminate contamination risk of mouse retroviruses.  Advancements have 
included the growth of hES cells on matrigel or laminin instead of fibroblasts, cultured in 
pre-conditioned media (Xu et al., 2001) and the culture of cells on a fibronectin matrix in 
serum replacement media supplemented with Lif, Tgf-β1, and Fgf-2 (Amit et al., 2004).  
More recently, several fully defined medias have been developed for feeder- and xeno-
free hES cell culture, some of which are commercially available, including StemPro 
(Invitrogen) and TeSR1 (Stem Cell Technologies) (Ludwig et al., 2006; Swistowski et al., 
2009). 
 
1.4.3 Maintenance of the pluripotent state 
To maintain their pluripotent state, ES cells (both mouse and human) tightly control their 
transcriptional activity through three master regulators, Oct-3/4, Nanog, and Sox2.  A 
very precise level of Oct-3/4 expression has been shown to be required for the 
maintenance of pluripotency in ES cells, as increased expression results in differentiation 
into endoderm and mesoderm, whereas a decrease in expression results in differentiation 
into trophectoderm (Niwa et al., 2000).  Endogenous expression of Nanog in mouse ES 
cells cultured in either the absence of Lif or presence of a Lif antagonist remained 
pluripotent, whereas parental cells differentiated.  In addition, cells with exogenous 
Nanog expression remained undifferentiated when cultured with compounds that promote 
differentiation (Chambers et al., 2003).  Furthermore, Nanog-/- ES cells differentiate into 
endodermal lineages when cultured on a feeder layer (Mitsui et al., 2003).  Sox2 was also 
shown to be indispensable for ES cell pluripotency as Sox2-/- ES cells differentiate into 
trophectodermal-like cells, similar to Oct-3/4-/- ES cells.  Sox2 appears to regulate the 
expression of Oct-3/4 as endogenous expression of Oct-3/4 in Sox2-/- ES cells restored 
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pluripotency in these cells, as determined by primary germ layer formation in EBs and 
chimeric embryo formation (Masui et al., 2007). 
 
1.4.4 Induced pluripotent stem cells 
The genetic reprogramming of differentiated cells into ES-like cells, termed induced 
pluripotent stem cells (iPS), has recently been reported for both mouse and human cells.  
The re-expression of Oct-4, Sox2, Klf4, and c-Myc in mouse or human fibroblasts 
resulted in the de-differentiation of the cells into pluripotent, self-renewing iPS cells 
(Takahashi et al., 2007; Takahashi and Yamanaka, 2006).  This de-differentiation of 
fibroblasts has been shown to resemble MET as epithelial genes such as E-cadherin and 
Occludin are up-regulated whereas mesenchymal-associated genes such N-cadherin and 
Twist are down-regulated (Li et al., 2010).  iPS cells mimic ES cells in several ways; they 
express pluripotency markers, can differentiate into cells of the three germ layers, form 
teratomas, and contribute to germ line transmission when injected into mouse embryos.  
Although the iPS cells are phenotypically indistinguishable from hES cells, analysis of 
their gene expression reveals differences significant enough to lead to authors to propose 
that iPS cells should be treated as a unique type of pluripotent cell (Chin et al., 2009). 
 
iPS cells provide another potential system for generating cells for use in regenerative 
medicine, as immune rejection issues are avoided by use of cells from the patient 
themselves.  In addition, the generation and use of iPS cells is not coupled with the 
ethical issues that are associated with the acquirement and use of ES cells.  However, the 
current method for gene delivery in the creation of iPS cells uses a virus gene delivery 
system and un-regulated gene expression.  Furthermore, un-regulated expression of c-
Myc is associated with many cancers (Felsher and Bishop, 1999; Flores et al., 2004).  
Advancements in the techniques for generation of iPS cells have ruled out the need for c-
Myc (Nakagawa et al., 2008) and the successful use of the following combinations of 
genes have now been reported: Oct-4, Sox2, Nanog and Lin28 in human fibroblasts (Yu 
et al., 2007); Estrogen-related receptor β (Esrrb), Oct-4, Sox-2 in mouse fibroblasts (Feng 
et al., 2009).  Furthermore, the number of required transcription factors has been reduced 
to just Oct-4 and Sox-2 in human fibroblasts (Huangfu et al., 2008), and to just Oct-4 in 
NS cells, however, these cells endogenously express Klf4, Sox-2 and c-Myc (Kim et al., 
2009).  Most recently, mouse iPS cells were successfully generated from MEFs using 
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Oct-4, Sox-2, Klf-4 and c-Myc recombinant proteins, ruling out the need for genetic 
manipulation (Zhou et al., 2009).  An improved efficiency in iPS cell generation was 
shown by Chen et al (2010) who found a four-fold increase in iPS formation if E-
cadherin was ectopically expressed alongside the four transcription factors (Chen et al., 
2010).  iPS cells have also been generated from rhesus monkey fibroblasts and rat 
fibroblasts and primary bone marrow cells, all using the original mouse cocktail of genes 
(Oct-4, Sox2, Klf4 and c-Myc) (Liao et al., 2009; Liu et al., 2008).   
 
1.4.5 E-cadherin and embryonic stem cells. 
E-cadherin is expressed by the cells of the early embryo and is essential during embryo 
development as Ecad-/- embryos fail to form a trophectodermal layer and die at the time 
of implantation (Larue et al., 1994). Expression of E-cadherin is maintained by ES cells 
when grown in cell culture in conditions that maintain pluripotency and self-renewal 
(Spencer et al., 2007).  Increasing the stability of E-cadherin in hES cells via Rho-
associated kinase inhibition has been shown to increase cell survival 30-fold following 
single-cell dissociation by trypsinisation (Xu et al., 2010).  Recent studies have shown 
that both mouse and human ES cells can be maintained in a pluripotent state by culturing 
the cells on E-cadherin-Fc fusion protein-treated plates.  This method of cell culture was 
able to substitute Matrigel culture of hES cells and reduce Lif-dependency in mouse ES 
cells (Nagaoka et al., 2006; Nagaoka et al., 2010).  Abrogation of E-cadherin homophilic 
binding has recently been shown to provide ES cells with the ability to remain pluripotent 
when grown in suspension in shake flask bioreactors.  Ecad-/- ES cells, and WT ES cells 
cultured with an E-cadherin neutralising antibody, remained viable and pluripotent when 
cultured in suspension for up to 16 days (Mohamet et al., 2010).   
 
In addition to providing ES cells with stable cell-cell contacts, E-cadherin has recently 
been shown to be involved in pluripotency-related signalling in mouse ES cells (Soncin 
et al., 2009).  Abrogation of E-cadherin function through RNAi, gene deletion, or peptide 
inhibition, was shown to alter the growth factor dependency of ES cells; instead of using 
the Lif/Bmp pathways to maintain pluripotency Ecad-/- ES cells utilised Activin/Nodal 
signalling for maintenance of pluripotency and Fgf-2 for optimal self-renewal (Soncin et 
al., 2009).  Furthermore, Ecad-/- ES cells also exhibit lower levels of Stat3 activation, 
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DNA binding and transcriptional activity than their parental cell line (Arulanandam et al., 
2009).  
Alterations in various cell surface molecules have also been observed in Ecad-/- ES cells.  
These include the pro-migratory molecule 5T4 oncofetal antigen (Spencer et al., 2007), 
heparan sulphate proteoglycan Perlecan (Soncin, unpublished data) and various Ephrin 
ligands and receptors including EphrinA2, B2 and B1 and EphA2 (Orsulic and Kemler, 
2000).  Ecad-/- ES cells display increased motility, increased proliferation and a more 
fibroblast-like phenotype compared to the WT counterparts.  These characteristics are all 
associated with metastatic carcinoma progression, indicating that Ecad-/- ES cells may 
represent a useful model for the study of this process (Spencer et al., 2007). 
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1.5 Aims 
The aims of this study were to investigate the transcriptional regulation of Jam2 by E-
cadherin and to determine the function of Jam2 in ES cell pluripotency and EMT. 
 
Ecad-/- ES cells and their parental cell line WT D3 ES cells cultured in standard ES cell 
media (FBS +Lif) and microarray analysis was performed in triplicate on extracted RNA 
from three separate cultures of each cell line using Affymetrix genome mouse 430 v.2 
chips.  Principal component analysis confirmed reproducibility of the triplicate samples 
and statistical significance was set at q<0.05.  Transcripts exhibiting a fold change >2.5 
or <-2.5 were considered of interest.  Four probes identified Jam2 transcripts as being 
down-regulated in Ecad-/- ES cells compared to WT D3, with fold changes of -235, -173, 
-56 and -16, and corresponding q vaules of 3.1x10-7, 3.2x10-7, 1.7x10-4 and 1.3x10-3 
respectively (Soncin et al, unpublished).  The first aim of this study was to confirm the 
microarray findings by assessing Jam2 transcript and protein expression in Ecad-/- ES 
cells and in WT ES cells exhibiting inhibition of E-cadherin using RNA interference 
(RNAi) or neutralising antibody treatment. In addition, forced expression of full length or 
truncated portions of E-cadherin protein in Ecad-/- ES cells was utilised to determine the 
region of E-cadherin responsible for positive regulation of Jam2 transcripts in WT ES 
cells. Furthermore, Jam2 RNAi knockdown in WT ES cells and a Jam2-/- ES cell line 
were used to determine whether loss of this protein in Ecad-/- ES cells contributes to the 
phenotype of Ecad-/- cells, such as altered growth factor response, increased proliferation 
and motility and impaired EB formation. 
 
The second aim of this study was to examine the transcriptional regulation of Jam2 in 
mouse ES cells. Sequences of the Jam2 promoter were cloned up-stream of a luciferase 
reporter gene and assessed for activity in WT and Ecad-/- ES cells. In addition, conserved 
consensus sequences within the Jam2 promoter were determined using in silico analysis. 
Together, these studies have allowed the formation of a hypothesis for the transcriptional 
regulation of Jam2 in ES cells and the alterations in signalling pathways following loss of 
E-cadherin in these cells. 
 
Due to the importance of E-cadherin in maintaining epithelial integrity and its anti-
metastatic effect in tumour cell models, the decrease in Jam2 expression observed in 
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Ecad-/- ES cells suggested that Jam2 may also be of significance during ES cell EMT.  
The third aim of this study was to determine if absence of Jam2 expression in WT ES 
cells affects the ability of the cells to undergo an EMT-like event observed when ES cells 
are induced to spontaneously differentiate. Jam2-/- ES cells were compared to the 
parental line, E14tg2a, in their ability to undergo EMT by assessing expression of E- and 
N-cadherin, EMT associated transcription factors and protease activity. 
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2.1 Mouse ES Cell Culture 
2.1.1 Mouse ES cell lines 
Mouse ES cell lines used in this project were as follows: 
D3 (WT D3), strain 129S2/SvPas, ATCC number CRL-11632 (Ecad-/- and β-cat-/- 
parental cell line) 
MESC20 (WT MESC), strain 129/OLA, donated by Dr R. Elder 
E14tg2a (WT E14), strain 129/OLA, donated by Dr A. Okuda (Jam2-/- parental cell line) 
E-cadherin knockout (Ecad-/-), D3 strain 129Sv, donated by Dr R. Kemler 
β-catenin knockout (β-cat-/-), R1 strain 129X1/SvJ and 129S1/SV-+p+Tyr-cKitlSl-J/+ 
hybrid, donated by Dr R. Kemler 
Junctional adhesion molecule 2 knockout (Jam2-/-), E14tg2a, donated by Dr A. Okuda. 
1D2, MA4, and Control RNAi ES cell lines were previously constructed in the Ward lab 
by Dr F. Soncin.  To generate the 1D2 and Control RNAi cell lines MESC20 ES cells 
were transfected with Ecad RNAi or Luciferase RNAi plasmids respectively.  Further 
transfection of the 1D2 cell line with Tet Repressor plasmid resulted in the generation of 
the MA4 cell line. 
 
2.1.2 Mouse ES cell culture 
All mouse ES cell lines were cultured in gelatin-treated 6-well plates (Greiner Bio-One, 
Gloucestershire, UK) prepared by adding 0.1% w/v gelatin (Sigma-Aldrich, Dorset, UK) 
per well for a minimum of 24 hours.  The gelatin was removed and the wells allowed to 
air dry prior to use.  To maintain pluripotency and an undifferentiated phenotype, ES 
cells were cultured with Knock-out DMEM supplemented with 10% v/v fetal bovine 
serum (FBS), 2mM L-glutamine, 50μM 2-mercaptoethanol (all from Invitrogen, Paisley, 
UK), 6mls of 100x non-essential amino acids (PAA, Somerset, UK), and 1000 U/ml Lif 
(ESGRO, Millipore, Livingston, UK) at 37oC/5%CO2.  Cells were passaged every 2 days 
prior to confluence by washing twice with 2ml phosphate buffer solution (PBS) (PAA, 
Somerset, UK), incubating with 1.5ml trypsin (PAA, Somerset, UK) and replating onto 
gelatin-treated plates in fresh media.  To differentiate the cells, FBS was replaced with 
10% v/v knock-out serum (KSR, Invitrogen, Paisley, UK), Lif was excluded from the 
media, and the media was replaced every two days.   
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For EB formation 1x106 cells were seeded into 15ml FBS media without Lif into 
bacterial grade Petri dishes (Sterilin, Caerphilly, UK), the media was changed every 2 
days. 
 
2.1.3 Media supplements 
Additional media supplements were as follows:  
For abrogation of E-cadherin mediated cell-cell contacts, WT ES cells were cultured in 
FBS+Lif media with 12-32μg/3ml E-cadherin neutralising antibody DECMA-1 (nAb), or 
anti-rat IgG antibody as a control (cAb) (both Sigma-Aldrich, Dorset, UK).  Inhibition of 
β-catenin degradation was achieved by culturing cells with 1-4μM Gsk-3β inhibitor 
(2’Z,3’E)-6-Bromoindirubin-3′-oxime (BIO, Sigma-Aldrich, Dorset, UK) reconstituted in 
Dimethyl sulfoxide (DMSO), or an equal volume of DMSO as a control.  
 
2.2 Proliferation Assay 
WT D3, Ecad-/-, WT E14 and Jam2-/- ES cell growth rates were compared over 12 days.  
Cells were seeded at 4x105 cells per well in FBS ES cell media and cell number and 
viability were determined every 2 days using a Countess automated cell counter 
(Invitrogen, Paisley, UK), prior to being reseeded at 4x105 cells per well.  Triplicate wells 
were plated for each cell line at each time point and each well was counted in triplicate.  
Population doubling times were calculated using Doubling Time Software 
v1.0.10 (http://www.doubling-time.com) (Roth, V. 2006), using the following equations: 
doubling time = ln(2)/growth rate. Growth rate = (ln(X2)-ln(X1))/(t2-t1), where X2  = 
final number of cells, X1 = initial number of cells, T1 = start time and T2 = end time.  
Cumulative cell counts were determined and analysed using unpaired T-test.  Data are 
presented as mean +/- standard deviation and significant difference was set at p<0.05. 
 
2.3 Cell Motility Assay 
Transwells (5μm pore size using a 24-well plate, Corning Life Sciences, Amsterdam) 
were immersed in 0.1% w/v gelatin overnight and rinsed in PBS.  Prior to use, the 
transwells were blocked in FBS-containing medium for 30 min and washed in PBS.  
1x105 ES cells collected in 100μl media were added to each transwell, was placed in a 
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well containing 500μl media and left overnight at 37oC/5% CO2.  The transwell was 
removed, and the well of the plate was washed twice with PBS before staining with 
crystal violet.  The number of cells that had migrated to the bottom of the plate was 
counted.  p values were calculated using unpaired T-test and significant difference was 
set at p<0.05. 
 
2.4 Plasmid Design and Construction  
2.4.1 Jam2 RNAi plasmids 
RNAi sequences were designed to target the beginning, middle and end of the Jam2 
transcript using Genscript RNAi target sequence finder using accession number 
NM_023844.  RNATin-H1.2/Hygro plasmids containing these sequences plus a 10 
nucleotide hairpin loop were produced in-house by Genscript (New Jersey, USA).  
Plasmids were transfected into WT D3 and E14 ES cells as described in section 2.5, and 
cultured in 150μg/ml hygromycin (Invitrogen, Paisley, UK) for seven days for selection.  
Clones were picked and analysed for Jam2 knockdown by fluorescent flow cytometry.  
Jam2 knockdown clones were cultured in FBS+Lif media supplemented with 150μg/ml 
hygromycin to maintain selection of ES cells containing functioning RNAi plasmids only. 
Further details of RNATin-H1.2/Hygro plasmid and Jam2 RNAi hairpin loop sequences 
are provided in Figure 2.1. 
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RNAi 1 GGATCCCGTTACTGTGACTTCTTGACGGTTTGATATCCGACCGTCAAGAAGTCACAGTAATTTTTTCCAAAAGCTT
BamH1                    Antisense                     Loop        Sense                       term sig      HindIII
RNAi 2 GGATCCCGTTTCCTTCTTTATCCTGGCATTTGATATCCGATGCCAGGATAAAGAAGGAAATTTTTTCCAAAAGCTT
RNAi 3 GGATCCCGTAGTGACTTTAGATGCAGGACTTGATATCCGGTCCTGCATCTAAAGTCACTATTTTTTCCAAAAGCTT 
(a)
(b)
 
Figure 2.1  pRNATin-H1.2/Hygro plasmid map and Jam2 RNAi sequences. 
(a)  Plasmid map depicting location of features on pRNATin-H1.2/Hygro plasmid; inducible H1.2 
promoter, multiple cloning site (MCS), cytomegalovirus (CMV) promoter, green fluorescent 
protein marker (cGFP), SV40 promoter driving Hygromycin resistance gene, origin of replication 
(pUC ori), Ampicillin resistance gene, and T7 primer site.  (b) Jam2 hairpin loop RNAi sequences 
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2.4.2 Jam2 cDNA plasmids 
To generate mouse Jam2 cDNA, primers were designed to amplify the coding region of 
Jam2 cDNA including 152 and 204bp of the 5’ and 3’ UTR respectively; forward primer 
CCTCTGCTTCCACCTCTCAG, reverse primer TCAGACACAAGATGCCAGGT, 
product size 1227, annealing temperature 65oC.  Restriction enzyme binding sequences 
(forward primer GATATC, EcoRV; reverse primer GGATCC, BamH1) and a 4 base pair 
overhang (GATC) were included at the 5’ end of each primer to facilitate restriction 
enzyme binding.  Mouse Jam2 cDNA was cloned using WT D3 mouse ES cell cDNA 
obtained as described in section 2.7.  For the PCR 8μl Extensor reddymix (Abgene, 
Epsom, UK), 1μl WT D3 cDNA, and 50pM forward and reverse primers (Invitrogen, 
Paisley, UK) were combined and run at 94oC for 2 min, then 35 cycles of 94oC for 10 sec, 
65 oC for 30 sec, and 68oC for 5 min, followed by 68oC for 7 min, using a 2720 Thermal 
Cycler (Applied Biosystems, California, USA).  The cDNA products were extracted from 
the PCR reaction mixture using QIAquick Gel Extraction Kit (Qiagen, Crawley, UK) 
following the manufacturer’s instructions.  Inserts of Jam2 cDNA and pIRES puro3 
plasmid (Clontech, France) were digested with EcoRV and BamH1 restriction enzymes 
(New England Biolabs, Hitchin, UK) and digested inserts and plasmids were ligated with 
T4 Ligase.  Correct insertion of the fragments into the plasmid was confirmed by in-
house DNA sequencing using ABI Prism 3100 Genetic Analyser (Applied Biosystems, 
California, USA).  For further details of the pIRES Puro3 plasmid map see Figure 2.2, the 
full sequence of the Jam2 cDNA is shown in Figure 2.3 and is correct according to MGI 
accession number 1933820. 
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(a)
(b)
 
 
 
 
 
 
 
Figure 2.2.  pIRES Puro3 plasmid map and multiple cloning site sequence.  (a) Plasmid map 
depicting location of features on pIRES Puro3 plasmid; CMV promoter (PCMV), MCS, internal 
ribosome entry site (IRES), Puromycin resistance gene (Puror), the polyadenylation signal from 
SV40, origin of replication (ColE1 ori), and Ampicillin resistance gene.  (b) MCS sequence 
showing restriction enzyme sites. 
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CCTCTGCTTCCACCTCTCAGGGACCTCCTCTGCTCCGCCGCCGGGCGAAGTGCTGGGAGAC
CCAGCCGCCTGTCGCGCTCCTGCAGGGGGACCCTCAGCTAGGCAGCCAGCTGGCGCCCGC
GTAGATGGCGAGGAGCCCCCAAGGCCTCCTGATGCT
TAA
GCTGCTGCTACACTACTTGATCGTC
GCCCTGGACTATCATAAGGCAAATGGGTTTTCTGCATCAAAAGACCACCGTCAAGAAGTCA
CAGTAATAGAGTTCCAAGAGGCTATTTTGGCTTGTAAAACCCCAAAGAAGACTACCTCCTC
CAGACTGGAGTGGAAGAAGGTGGGACAGGGGGTCTCCTTGGTCTACTACCAACAGGCTCT
CCAAGGTGACTTTAAAGACCGTGCTGAGATGATAGATTTCAATATACGAATCAAAAATGTTA
CAAGAAGTGATGCTGGAGAGTATCGCTGTGAAGTCAGCGCTCCGACTGAGCAAGGCCAGA
ACCTGCAGGAAGATAAAGTCATGCTAGAAGTACTAGTGGCTCCTGCTGTTCCTGCCTGTGA
AGTGCCCACTTCTGTTATGACTGGAAGTGTGGTGGAGCTACGATGCCAGGATAAAGAAGGA
AACCCAGCTCCGGAGTACATCTGGTTTAAAGATGGCACAAGTTTGCTAGGGAATCCAAAAG
GCGGCACACACAACAACAGCTCGTACACAATGAACACGAAGTCTGGAATTCTGCAATTCAA
CATGATTTCCAAGATGGACAGTGGAGAGTATTACTGCGAAGCCCGGAACTCTGTCGGACAC
CGCAGGTGCCCTGGGAAGCGAATGCAAGTAGATGTTCTCAACATAAGCGGCATCATAGCA
ACGGTTGTGGTGGTGGCCTTCGTGATTTCTGTATGTGGCCTTGGCACATGCTATGCTCAGAG
GAAAGGCTACTTTTCAAAAGAAACTTCCTTCCAGAAGGGCAGTCCTGCATCTAAAGTCACT
ACGATGAGCGAAAATGATTTCAAGCACACAAAATCCTTTATAATT AAGAATTCCAGTTTT
GAGCTGCACCAAAACCAGTTGTCACATGTTATTAAAATATTGTAAAACTCTGTGTCTTACACTT
GCAAAGTGATGAAGAAATATGAAAGTGGGAGTTCATCAGAAGTTTTATGATCTCTAACTCACAA
GAAATATTTTAAGCAAAATGTTCTTGCCATCACTAAATTACAACCTGGCATCTTGTGTCTGA
 
Figure 2.3.  Jam2 cDNA sequence. Jam2 cDNA sequence encoded by 3-2, 3-4 and 3-5 plasmids.  
Forward and reverse primer sites (underlined), start and stop codons (red), untranslated regions 
(grey) and coding sequence (black) are shown. 
 
 
 
 
2.4.3 Jam2 promoter plasmids 
To generate mouse Jam2 promoter regions, primers were designed to flank different 
lengths (459, 1062, 2022 and 4629 base pairs) of the Jam2 promoter, with the reverse 
primer positioned at +260 (459, 1062, 2022) or +48 (4629) in the 5’ untranslated region 
(UTR) of the Jam2 gene.  Restriction enzyme binding sequences (forward primer 
GCTAGC, Nhe1; reverse primer CTCGAG, Xho1) and a 4 base pair overhang (GATC) 
were tagged to the 5’ end of each primer.  Full details of the primer sequences and 
annealing temperatures are shown in Table 2.1.  WT D3 ES cell genomic DNA was 
extracted from cells using QIAamp DNA Kit (Qiagen, Crawley, UK) following the 
manufacturer’s instructions.  For the PCR, 8μl Extensor reddymix (Abgene, Epsom, UK), 
1μl WT D3 genomic DNA and 50pM forward and reverse primer (Invitrogen, Paisley, 
UK) were combined and run at 94oC for 2 min, then 35 cycles of 94oC for 10 sec, 
required annealing temperature (Table 2.1) for 30 sec, and 68oC for 5 min, followed by 
68oC for 7 min, using a 2720 Thermal Cycler.  The PCR product was purified using 
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QIAquick Gel Extraction Kit (Qiagen, Crawley, UK) following the manufacturer’s 
instructions.   Inserts of Jam2 promoter and pGL3-Basic plasmid (Promega, Southampton, 
UK) were digested with 2000U Nhe1 and Xho1 restriction enzymes (New England 
Biolabs, Hitchin, UK) and digested inserts and plasmid were ligated with T4 Ligase.  
Correct insertion of the fragments into the plasmid was confirmed by in-house DNA 
sequencing using ABI Prism 3100 Genetic Analyser.  For further details of the pGL3-
Basic plasmid map and the Jam2 promoter region see Figures 2.4 and 2.5 respectively.  
Identification of regions of high conservation within the Jam2 promoter region was 
undertaken using ECR Browser software (http://ecrbrowser.dcode.org/). 
 
 
 
 
 
Table 2.1 Jam2 promoter primer sequences. 
 
Name Start Finish Size Forward Sequence Reverse Sequence oC
0.5 -459 +260 719 TAAGAAGCCAAGAGCCCAGA 
CCTGAGAGGTGG
AAGCAGAG 69 
1 -1062 +260 1322 GCTACCAGCTCCATTTTTGC 
CCTGAGAGGTGG
AAGCAGAG 69 
2 -2022 +260 2282 CAAGGCCTTAGCTTGTACAGG 
CCTGAGAGGTGG
AAGCAGAG 69 
5 -4629 +48 4677 TCATGTACTGGGGGTGGAAT 
CTAGCCTCTTGAG
GGAGAACC   60 
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MCS
 
 
 
Figure 2.4.  pGL3-Basic plasmid map.  Map of pGL3-Basic plasmid depicting origin of 
replication (f1 ori), MCS, luciferase gene (luc+), SV40 poly A signal, and Ampicillin resistance 
gene (Ampr). 
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GATGGGCAGGCATTCAAAAATATGCGCCCATGAGGGCCATTCTTATTCAAACCACCACACATTGTCACTGACTGGAAGACCTTTTACTT
GGCCCCAACTCCTAAAAGTCCACAGCCCCTCCCAGGATCACCCCCTCTCTGGACCAAACGTCTTTGTGAGGACTTTTGGGAGGAAGCAA
GGTCATCTCATGTACTGGGGGTGGAATGCTGAGCCAAGGGACACTCATGTCTGAGGTCTGAGGAGGTGACATGCCATAGGGAAGCTGGG
TAATGAGGGACTTTCAAAGAGACCTTGACTCTTATCCATAGAAGGTTAAGCTTTATCTGTGAGATAGTTGAGAATTCTCGTGGTACTGG
AAACAGGAGATTTGTTTTCTGCTCTCTGAAAATTACAGCGTGGGCACACTTCCCAGCACCTTCTCCACACCCATGAGGAAAAATAACCC
TTGCAACACAGAGACACCAACTCTGAGACACTGTTGAGAAGTCACTCGGTTTAGACTCAGCCCTTTCCTTCGTCGCTTGTTTTAAGAAA
TACGCCTCCACACCTCTTCAAGGCTATTTGAATTCAGAATTAGAGTGGGTGGAAGGGAGAGAAATGGTGTTGAGTCCCAAAATACCAAG
TCTCCATTTGTGTTTACCTGAAAAATCCTGTTTATAAACTTAAAGCGAAAGTGAGTCTGGGCGTTTTGGGGATGGGAGCAGAGATCAAA
GGGGCGGGGCTTCAGTGGGCTACGGGTGTTTATTTCTGTAACTAGTTTCAGTAACACTATACATAATGCTCCCACTTTTTCCTTTCCTT
CGGGCCTCTCTCACCCTCACCTACAGCTAATTGGAAGCATAATCTTGCTTATCAGGTTTGTGAAAAAGCAACAGACTTCGCGGTCCATT
CCTACTTTCTGTCTGCCGTCCAGTTCCTCGGTTTACACCTTTGTCCTTTTCATGGACGATAACAATGGCTTTAGGCTTGCCTGAGGCAC
TGTTTCTCTCATCTCCAACCTACCCTGTCTGTGATAACAGAAACATTTTATGCTTGCGTAATTCTAGATCGCACCTCCTTTTCCACCAA
AGTGTCTATTGGAAACAACAAGTGTGGCAAGTAGGACCGAAGAATTGAATTTTAAAATTAAATTAAATTCAAACTTACATAGTCATCTG
ATTCTAGAGCCTACTATACTGGATAACAGAGTTCTAAAATACGGTGCTTATGCTGGTCATTGTAGAGAGGCAGGGGGATTGAAAGTTTG
AGGCAGGAGACGGTTCTGGAAGACAAAGGAAGCTGTGAAAGTCAATGAGATCAAACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
GTGTGTGTGTGTGTGTGTTGGGGGGCACATAAGTAGCTACAGTAAGAAGTGAGATGAGAGCCAGCTTGGTGGTGGCGGGGGGGGGGGGG
GGGGGGGGCGCATGTCTTGAATCCCAGCAGTTAGGCTGCAGAGGCAGGCAAATCTCTGAAGCTCTGGGTTCAAAGCCAGCTTGGTCTAC
AGAGTGAAGTCCAGGACAGCCAGGGCTACAATAGTGATACCTTGTCTGAAAAACAAAATAAGGAAGGGAAGGAGGAGGGAGAGGAGGGT
GGATGGAGAGGGGAGAGAGGGAAAGGAAACCCCAGAGAAAGAACACAGGAAAGATAAATCTAAACTGTAAGGAATGAGTTAGGAGCAAA
CCTGCCGTCCCAGGTGGCCTTGTTAATAGCACCTGAGCTATGTGGTATGACGCTGCTTTAGTTAACCTGTATCTTCTCCTCCCCTGCCA
CATTGCTTTCAAAGGACTCATTTCCTGCAGCATGACGTCCAGAGTCAGTAGTACCGTGCTGAATAGCATTCTTACGTAACCCAGTCTCT
CGCTTTTCCCCTGCTATGTCCTCTGTCCAATTCCGTTTATATTCTAGGGCTGGAGAGTCTTGGTTCTCCTAAGCAAACCCCAGTTTTAG
ATCTCCCAGCTATCACCACTACTATTTGTCCTACCTGAAATGTCCACCCTTTACTTCTTTCCTTTCCAATAGTCCATATTTGAAGACCT
AAGAAATACAGCCCTGACCTCATGCCCATCAGGGAGACCATCCCCTTTTCCTTGACTTTGGGTGAGCCACGGGGCACCTCTCAGCCCAG
TTTTCCTCATCTGTAAAGTGGGAATGCTAACATTTCCTCCTTTGGGGAAGATTAAGTATTGCTACTTTTAAACTCTACCATTACGAAAG
CATAAAATAAAGCCAGCTGTTGTGGCCCCCATCCCAACAGTTATCATGTGATGTTAGAAATATTTACAAATGGAACTGTCTCACTCCTG
GAGACTGTGAGTTTATTAAGAGCAAAGCTTGGTCTTACTCAGTGCTCTCCCTGGAGATACACTGTAGCCATTGGACAGATGCCTTGGCC
AGCTTGTTAATGAATGAGTCAATGACTAAATAGAATGTCACAGAATAAGCTCTCTGTCTTTTTTTTTTTCATGATTTTTTTTTTAAGGA
AGAGCAAAAAAGACAGAGTTATAGCAAAGATGAGGGAGAAGGACTATAACAACTTCGTCTTGTAAAAATGTATTAAAATTTTGGGTCCG
CTGTGGTGGTACAAGGAAACAGAGGGAAGCAGATCTCTATGAGTTCGAGGTCAGCCTGGTCTACAGAGTGAGTTCCAGGACAGCCAGAG
CTATATATAGAGAGAGCTTGTCTCAAATAACCAACAGCAACTATGATGGTTGACATTACATTTAAAGTTTATATTTACTATGCTTGAGA
GACCAAAAAAAGAAAAAAAATGCCTCTAACATGCAAGGCCTTAGCTTGTACAGGCTCTACCCTACAAGCCCACTTCTCCCAGACATTAA
AGATTAATCTTAAAGAGACTGGTCGTATAAAATTTGCTGTTCTAGCAAGTAGTAGGTCAACTTCAATTTCTGCCTTCGTAATCAAACTT
GATTACTCTGCTCAAAAAATATGACTAGGACCAATACAAAACATATATGTTAAATTAGACGCTGCCTATAGGTATAATCGTGTGGGGTT
TGCCTTTGTATGCCTTAGGCTGCTTTGTCTAGAGGCTGTGTCTTGGGATCACTCTCAGATGCTGTTTTGGCAAACAAATAAACAAAAAC
AAAAAACACCCTCTTTCTATTAAAATTTATTTATGGTCATGGTGAATCTCTGAGTGACCCCAGACCCATAAAACACCAACAACAAAATG
ACAGATTAATCTAAGAAAACAGATTAAACAGTCTCTAAAGAGGCACATGCGTCTCTCACTCTCAACATCAGAACCACTGAAGCAAACAA
TGCCAAGGCAATGGATATTTCCCCAAGGCATCTCATCCGAGAGAAGGGGGAGGCGCCATCTAGAGGGGCCACTCACAATTCCCGTGGTT
CTAAGAACCTGTCTTACCACCCTATAGGACGAGACTGAAGACCAGACAATGGCTTAGATGTGGGCTGCATGGATGTGTGGATCCTTGGC
TCTGTATTTTATCTCACTTCAGGGCCCCAAAGACAGACTTGGGGTTCACTGGAACTCTACAATGTGGCTATATCGAATCAATCAATCAA
TCAATCAATATCTCTCCCTTTCTCTTCTCAGTTTTCACGACTAATTTGACTCTTTTAATTGGATTGTCAAGGACAATTGACTTAACCTG
TCTCTGAGCACAGGCCTTAAGTCTTTTTTTTTTTTTTTTTTTTTTTTTGCCTTAAGTCTTAAGTTAGATGACACCCTTACTCCCTTACT
GTTTGTGAGTTTGGGCTACCAGCTCCATTTTTGCCTTTTTTTTTTTTTTTTTTTTTAACTTTGCTTTTCTTGCCCTCAGGGGTCTTCTG
TCCCCTCCCCTTCCCCATGAGGGCCAAAGCTTTCATCACTGTTGCCCAGGCAACAGTGGGGATGCCTCATTCCTCACAGCTCTGCATAT
CTAAGTATATCTTAAGCCTTTGTCCGCAAGGCTGGCTCAATTCTTTGTAAGTGGTCCACCACTAAATCAGCCATCCTCTACACATAATT
ATTTATTATTTAGCTTTATTTAAAACGATTTTAAAAAATGTCTTCACCTGACAACGGCCTTTACACAGACGGGTCAATTTTCTTGAATG
CCCCAGCCATCAGTTCTGGAGAGGAAATGTGAAAATCGCCTTTGCAAGTGCACGCTTCCGAAGTGCGGGTCAATTTTAAAGCACGCACT
GGAGCATTCATAATGGATTTCCCTTTTAAAAGCACATGAGACCAAAAATAAACCTGACAAAAGGGCAGCTGTAGAGTTTTAACATGTGG
AAAACTCCACAGGCGGCAGTTACATAACGGGGAAGAAACAAGATAAATATTTCACACCGTTAGATGAACTTCCAGATGACAACTAAGAA
GCCAAGAGCCCAGAACACACCTTAACTCTCTAAGGGGTTGGGGGGACGGGGAGGACGGACTTGAAGCCAGAAGAGGCTAAGCCTGATGA
TAAAATCTGGGACCTGACTTGCAACTTGAGTGATGCCTTTGTCCCCCGCCCCCTCCGCCCCTCCCCACCCCCCCTTTCTAGAGGCAGGG
GCTGAGCTCATGCCCCTATACTTTAAGAGCGCTTCGCCAGCGGTTTTGTCCGCTAGATAGAAATTTTCCAAAAAATATCTCCCACGCTA
GGCAAAACACTGAAAAGGAAGTTTTTTTGCGCCAAGAGGAGAGACATGGCGAGACAGACCGAGCCACTACCGCTCCCAACACACACACA
CCCTGCCCATCCCACCCGGCTGCGCTCCTCCTGCCCCCAGCTCCTCGCCCTGGGGACAGCTGGCAGCCTAGCGCGGGACTAGACACAAA
GCGGATCAGTCTGGGGGCGGGGGGCCGACCTGCAGGGTTCTCCCTCAAGAGGCTAGTCCTCTGCCGCCACTCGCTTAGGACCCTGCGGA
CACCGCGTCCCGCGTCCACGCCCTCCCCTCAACCCTCTTCCACCCTTCAAAAGAAGGACTGTCCCAGACACCACGTCCTAGGGCCAGAA
GACCTGCCCCCACGACAGTCGCTGGAGACACCCCAGACCGGAGAGACTGACATCGGGACAGGACCCGCCCCTCTGCTTCCACCTCTCAG
GGACCTCCTCTGCTCCGCCGCCGGGCGAAGTGCTGGGAGACCCAGCCGCCTGTCGCGCTCCTGCAGGGGGACCCTCAGCTAGGCAGCCA
GCTGGCGCCCGCGTAGATG 
 
 
 
 
Figure 2.5.  Sequence of Jam2 promoter region.  The first 4814 base pairs upstream of the Jam2 
gene, 332 of the untranslated region (yellow highlight) and the ATG start codon are shown.  Blue 
highlighted text shows positions of forward (within promoter) and reverse (within UTR) primers 
used for generation of 0.5, 1, 2 and 5k plasmid constructs.  
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2.5 ES Cell Transfection 
Cells were transfected using an Amaxa NucleofectorII and ES cell electroporation kit 
(Amaxa Biosystems, Koln, Germany) following the manufacturer’s instructions.  Cells 
were passaged as normal and allowed to grow for 24 hours prior to washing twice with 
2mls PBS and removed from the plate with trypsin.  2 x 106 cells were resuspended in 
100μl Amaxa ES cell solution containing 2μg of RNAi, cDNA or promoter (plus 0.5μg 
renilla plasmid, Promega, Southampton, UK) plasmid as appropriate.  Cells were 
electroporated using program A30 on the Amaxa Nucleofector II, replated in 6-well 
plates and cultured in ES cell media for 24 hours.  Transient transfections were assessed 
immediately (luciferase-promoter constructs, E-cadherin and Jam2 cDNA transfections), 
whereas stable transfections were cultured in the presence of appropriate antibiotic for 
seven days to allow for selection of plasmid-containing cells only (Jam2 RNAi).  Single 
clones were picked and analysed for successful knock-down or gene expression thereafter.   
 
2.6 Luciferase Assay 
WT D3 and Ecad-/- ES cells were transfected as described in section 2.5 with 0.5μg 
Renilla plasmid and 2μg promoter plasmid, then collected and analysed after 24 hours 
using Dual Luciferase Reporter Assay System (Promega, Southampton, UK) following 
the manufacturer’s instructions.  Measurements of renilla and luciferase activity for each 
transfection were made using an Orion L Microplate Luminometer (Berthold Detection 
Systems, Germany).  Data was analysed by dividing the luciferase measurement by the 
renilla measurement to give relative promoter activity and results were plotted as fold 
change in promoter activity compared to control plasmid containing no promoter region.  
Results were compared using paired 2-tailed T-test.  The assay was repeated 5 times and 
the assay shown is representative of all.  During each assay, all samples were measured in 
triplicate.  Data are presented as mean +/- standard deviation and significant difference 
was set at p<0.05. 
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2.7 RT-PCR 
2.7.1 RNA extraction 
Total RNA was extracted from cells using 500μl TRI reagent (Sigma-Aldrich, Dorset, 
UK), treated with DNase (Promega, Southampton, UK) and stored at -20oC prior to RNA 
extraction, if the extraction was not to be performed immediately.  For the extraction, 
50μl chloroform (Sigma-Aldrich, Dorset, UK) was added to each sample and the 
suspension was centrifuged at 10,000 r.p.m. for 15 min at 4 oC.  The supernatant was 
transferred to a new tube and the RNA was precipitated by adding 200μl isopropanol and 
centrifuging for 15 min at 10,000 r.p.m.  The resulting pellet was washed twice in 800μl 
70% ethanol, prior to being resuspended in 40μl nuclease-free water (Applied 
Biosystems, Warrington, UK). 
 
2.7.2 DNase treatment of RNA 
The RNA was treated with 2.5u (units) RQ1 DNase, 5μl 10x RQ1 DNase 1 buffer, 40u 
RNAsin (all Promega, Southampton, UK) and 1.5μl nuclease-free water.  The mixture 
was incubated at 37 oC for 60 min and cooled on ice for 2 min prior to addition of 10μl 
Stop buffer (Promega, Southampton, UK).  The cDNA was precipitated using 10μl 3M 
NaOAc pH4.8, 150μl 95% ethanol and 1μg glycogen (Roche, Hertfordshire, UK).  The 
resulting pellet was washed once with 50μl 80% ethanol and resuspended in 20μl 
nuclease-free water. 
 
2.7.3 cDNA synthesis 
cDNA was synthesised using 1μg RNA in 20μl nuclease free water incubated at 65oC for 
3 min prior to treatment with 5μl 100mM DTT, 1.25μg oligoDT, 40u RNAsin, 10μl RT 
enzyme buffer, 10u AMV reverse transcriptase, 5μl 250μM dNTP (all Promega, 
Southampton, UK) and 6μl nuclease free water at 42oC for 1 hour.  The reaction was 
terminated by incubating at 95oC for 5 min prior to cooling on ice.  Samples were stored 
at -20oC if not required for immediate use. 
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2.7.4 PCR 
For the PCR 1μl cDNA, 1μl 50pmol/μl forward and reverse primers (Invitrogen, Paisley, 
UK) and 8μl Reddymix (Abgene, Epsom, UK) diluted 1:1 with nuclease-free water, were 
combined and run at 94oC for 5 min, then 35 cycles of 94oC for 30 sec, 55/60oC (refer to 
Table 2.2 for correct annealing temperature) for 40 sec and 72oC for 45 sec, followed by 
72oC for 7 min, using a 2720 Thermal Cycler.  Samples were visualised alongside 
Hyperladder IV molecular marker (Bioline, London, UK) on 2% w/v agarose gel 
(Melford, Suffolk, UK) containing 8% SafeView Nucleic Acid Stain (NBS Biologicals, 
Huntingdon, UK), using a Uvi Pro Platinum Gel Doc (UVItec, Cambridge, UK).  All 
primers used in this study are exon-spanning, and details of all primer sequences, 
annealing temperatures and product sizes are shown in Table 2.2. 
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Table 2.2  List of primer sequences used in this study. 
 
 
Name Forward Reverse Size oC 
Afp GAAGAATTGCAGAAACACATCG AGCCAAAAGGCTCACACC 699 55 
Brachyury CATTACACACCACTGACG GATATAGGACCCTACCTAGC 472 60 
CD133 GAAAAGTTGCTCTGCGAACC TCTCAAGCTGAAAAGCAGCA 196 60 
E12/E47 GAGGAGTGGCCTCACAAGTGG GTGCGTGGGACCTTCAGGT 232 60 
E-cadherin GAGGTCTACACCTTCCCGGT CGAAAAGAAGGCTGTCCTTG 108 60 
Eno2 CCAAGTCACCCAGAACACCT AAACACCCCAACACACCAAT 236 60 
Fgf5 GGCAGAAGTAGCGCGACGTT TCCGGTTGCTCGGACTGCTT 515 55 
Gata6 GCCAACTGTCACACCA TGTTACCGGAGCAAGCTTTT 190 60 
Goosecoid GAAGCCCTGGAGAACCTCTT CCGAGTCCAAATCGCTTTTA 247 60 
Jam1 GGTCAGCATCCACCTCACTGT AGGTCAGCACTGCCCTGTTC 96 60 
Jam2 CCTGGACTATCATAAGGCAAAT CATCTTAAACCAGATGTACTCCG 457 60 
Jam3 TCGACATGGCGCTGAGC CAGTGTTGCCGTCTTGCCTACAG 460 60 
Mmp-2 TGGGTGGAAATTCAGAAGGTGC ATCTACTTGCTGGACATCAGGGGG 695 60 
Mmp-9 TGCGACCACATCGAACTTCG CCAGAGAAGAAGAAAACCCTCTTGG 687 60 
Musashi ATGGTGGAATGCAAGAAAGC TAGGTGTAACCAGGGGCAAG 191 60 
Myh6 CTGCTGGAGAGGTTATTCCTCG GGAAGAGTGAGCGGCGCATCAAGG 312 60 
Myh7 TGCAAAGGCTCCAGGTCTGAGGGC GCCAACACCAACCTGTCCAAGTTC 491 60 
Myl2 TGTGGGTCACCTGAGGCTGTGGTTCAG GAAGGCTGACTATGTGTCCGGGAGATGC 298 60 
Nanog AGGGTCTGCTACTGAGATGCTCTG CAACCACTGGTTTTTCTGCCACCG 364 60 
N-cadherin CCCAAGTCCAACATTTCCATCC AAAGCCTCCAGCAAGCACG 781 60 
Oct-3/4 AGAAGGAGCTAGAACAGTTTGC CGGTTACAGAACCATACTCG 415 60 
Runx1 CCAGCAAGCTGAGGAGCGGCG CGGATTTGTAAAGACGGTGA 347 55 
Sip1 CGTTCAAACACAAACACC CCAGTCTCTTCCTCATCC 454 60 
Slug CACTCCACTCTCCTTTACC CAGACTCCTCATGTTTATGC 597 60 
Snail CAGCTGGCCAGGCTCTCGGT GCGAGGGCCTCCGGAGCA 381 60 
Sox2 CACAACTCGGAGATCAGCAA CTCCGGGAAGCGTGTACTTA 541 60 
    Timp1 CTTGCATCTCTGGCATCTGG AAGTAGACAGTGTTCAGGC 654 60 
Timp2 GAGATCAAGCAGATAAAGATG GACCCAGTCCATCCAGAGGC 321 60 
Transthyretin GGTATTTGTGTCTGAAGCTGG GGTTGCTGACGACAGCCGTGG 392 60 
Twist AATTCACAAGAATCAGGGCGTGGG TCTATCAGAATGCAGAGGTGTGGG 117 60 
Zeta-Globin GATGAAGAATGAGAGAGC AGTCAGGATAGAAGACAGG 406 60 
β3-tubulin TGAGGCCTCCTCTCACAAGT CGCACGACATCTAGGACTGA 207 60 
β-tubulin TCACTGTGCCTGAACTTACC GGAACATAGCCGTAAACTGC 317 60 
 
 
2.8 Fluorescent Flow Cytometry 
Cells were harvested from the 6-well plates by incubating at 37oC with cell dissociation 
buffer (PAA, Somerset, UK) for 10 min.  Cells were then transferred to a 1.5ml 
eppendorf, centrifuged at 5,000 r.p.m. for 2 min, washed once with 900μl PBS, 
centrifuged as before and incubated with primary antibody (or control) diluted 1:100 
(unless otherwise stated) in FACS buffer (0.2% BSA w/v, 0.1% sodium azide w/v in PBS) 
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for 30 min on ice.  Primary antibodies were as follows: rat anti-mouse E-cadherin 
(DECMA-1, 1:500 dilution, Sigma-Aldrich Dorset, UK); anti-mouse SSEA1 (Santa Cruz, 
California, USA); rat anti-mouse Jam2 (RnD Systems, Oxfordshire, UK) and rabbit anti-
mouse N-cadherin (Santa Cruz, California, USA). Isotype control antibodies were used at 
the same concentration as primary antibodies and were as follows:  goat IgG (Abcam, 
Cambridge, UK), rat IgG (RnD Systems, Oxfordshire, UK), rabbit IgG (Santa Cruz, 
California, USA) and mouse IgM (Santa Cruz, California, USA).  Following incubation 
with primary or isotype control antibody, cells were washed in 900μl PBS and incubated 
with the appropriate phycoerythrin (PE)- or Fluorescein isothiocyanate (FITC)-
conjugated secondary antibody (all Santa Cruz, California, USA, 1:200) for 30 min on ice.  
Cells were washed as before, resuspended in 300μl 1% w/v Paraformaldehyde (PFA), 
and cell fluorescence analysed using a FACScalibur (BD Biosciences, Oxford, UK).  
Viable cells were gated using forward and side scatter (Figure 2.6a) and all data 
represents 10,000 cells from this population.  Cells incubated with isotype control 
antibody were used to determine negative staining (Figure 2.6b). 
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Figure 2.6  Fluorescent flow cytometry analysis.  (a) Viable cells are gated based on forward and 
side scatter.  (b) Fluorescence in either FL-1 (FITC, not shown) or FL-2 (PE, shown) was 
measured on 10,000 cells gated within the area shown in (a).  Cells stained with isotype control 
antibody establish negative expression, with any events to the right of this negative peak 
determined as positive expression.  Histograms are overlaid to improve visual analysis. 
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2.9 Immunofluorescent Imaging of ES Cells 
Cells were cultured in 6-well plates and fixed with either 4% w/v PFA (Oct-3/4, Nanog) 
or ice-cold 1:1 v/v acetone:methanol (E-cadherin, β-catenin) in situ.  Cells were washed 
twice with 2ml PBS and treated with blocking buffer (0.1% w/v BSA, 1% serum, 0.1% 
Triton-X, in PBS) for 30 min.  Cells were incubated with primary antibody diluted 1:100 
in blocking buffer for 2 hours at room temperature.  Primary antibodies were as follows: 
anti-Oct3/4 (Santa Cruz, California, USA); anti-Nanog (Chemicon, California, USA); 
anti-E-cadherin and anti-β-catenin (BD Biosciences, Oxfordshire, UK). Cells were 
washed a minimum of 4 times with 2ml PBS and incubated in Alexa Fluor 488 
conjugated secondary antibody (all Invitrogen, Paisley, UK) diluted 1:200 in blocking 
buffer for 1 hour.  Cells were washed as described above, mounted using 4',6-diamidino-
2-phenylindole (DAPI) Vector shield (Vector, Peterborough, UK) and visualised on a 
Leica DM5000 B fluorescence microscope (Milton Keynes, UK).  Non-specific staining 
for each antibody type was assessed using relevant isotype control antibodies and found 
to be absent for all antibodies (data not shown). 
 
2.10 Zymogram Analysis 
To determine the activity of gelatinases secreted by differentiating WT E14 and Jam2-/- 
ES cells, cells were cultured in KSR media without Lif for 4, 6 and 8 days.  25μl of 
culture medium was removed from the cells, mixed with 25μl Zymogram Sample Buffer 
and separated on a precast 10% gelatin gel at 125V for 90 min, alongside Precision Plus 
Protein Standard.  The gel was incubated with Zymogram Renaturation buffer for 1 hour 
at room temperature and developed overnight in Zymogram Development Buffer.  The 
gel was stained for 1 hour using Coomassie R-250 and briefly washed with destaining 
solution (Methanol:Acetic acid:Water, 50:10:40).  Images were captured using a 
Fluorchem 5500 light cabinet (Alpha Innotech, California, USA).  All reagents were 
purchased from Bio-Rad, Hertfordshire, UK. 
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3.1 Abstract 
The down-regulation of E-cadherin is considered a defining step during embryo 
development and metastatic cancer progression.  Whereas the mechanisms of E-cadherin 
repression such as promoter methylation, genetic mutation and transcriptional repression 
by Snail, Slug, and Sip1 transcription factors are well-defined, events that occur 
downstream of E-cadherin loss remain predominantly elusive.  We have found that loss 
of E-cadherin confers an alternative signalling pathway for self-renewal and pluripotency 
in mouse ES cells and that loss of E-cadherin also results in the loss of cell surface 
Perlecan expression, a heparan sulphate proteoglycan involved in extracellular matrix 
interactions.  Here we show that E-cadherin down-regulation is associated with the 
repression of Jam2, a cell-surface protein with no previously reported connection to E-
cadherin.  We demonstrate that Jam2 transcript expression is regulated by E-cadherin 
protein with the terminal 71aa of the cytoplasmic domain of E-cadherin required for 
restoration of Jam2 expression in Ecad-/- ES cells.  Whilst the 71 amino acid cytoplasmic 
domain contains the binding region for β-catenin, we show that β-catenin signalling plays 
no role in Jam2 transcript expression.  Furthermore, we show that absence of Jam2 in 
Ecad-/- ES cells is not responsible for Lif-independent self-renewal, inability to form EBs 
or the increased cell proliferation and motility displayed by Ecad-/- ES cells.  Our study 
provides novel insight into events downstream of E-cadherin loss and further confirms 
the redundancy of Jam2 function in ES cell self-renewal and pluripotency. 
 
3.2 Introduction 
E-cadherin is a cell surface glycoprotein involved in calcium-dependent cell adhesion 
(Overduin et al., 1995).  In adult tissues it is located in adherens junctions of epithelial 
cells where it forms homotypic interactions with E-cadherin molecules on adjacent cells 
(Capaldo and Macara, 2007).  The structure of E-cadherin is typical of all type 1 classical 
cadherins, consisting of 5 extracellular domains, 1 transmembrane domain, and a short 
intracellular domain (Overduin et al., 1995).  The intracellular domain of E-cadherin 
contains several phosphorylation sites and binding domains for p120-catenin, β-catenin, 
Ptpμ and Ps-1 (Baki et al., 2001; Brady-Kalnay et al., 1998; Chen et al., 1999; Davis et 
al., 2003).  β-catenin functions as a signalling molecule in the canonical Wnt pathway, 
during which β-catenin enters the nucleus and activates Wnt-target genes such as c-Myc, 
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Cyclin D1 and Snail (Logan and Nusse, 2004).  β-catenin also anchors E-cadherin to the 
actin cytoskeleton through binding of α-catenin (Nagafuchi and Takeichi, 1988).  During 
embryo development E-cadherin is first detected at the 2-cell stage, and has been found 
to be essential for the differentiation of cells into epithelial structures, as Ecad-/- ES cells 
fail to form a trophectodermal epithelium and die at the implantation stage (Larue et al., 
1994).   
 
E-cadherin has been shown to be down-regulated in many metastatic carcinomas, with 
loss of E-cadherin expression characteristic of the transition from benign to metastatic 
carcinomas (Birchmeier and Behrens, 1994).  The down-regulation of E-cadherin is 
considered to be one of the most significant events during carcinoma progression 
(Christofori and Semb, 1999).  Several studies have shown that re-expression of E-
cadherin in metastatic cancer cell lines reverts cells to a less metastatic and invasive 
phenotype, indicating that E-cadherin is a metastatic-suppressor gene (Hsu et al., 2000; 
Luo et al., 1999). Several mechanisms of E-cadherin down-regulation have been 
identified: epigenetic changes such as promoter hypermethylation (Matsumura et al., 
2001); gene-silencing through mutation, most commonly in gastric cancers (Berx et al., 
1998); and gene repression by transcription factors including Snail, Slug, Sip1 and Twist 
(Bolos et al., 2003; Cano et al., 2000; Comijn et al., 2001; Vesuna et al., 2008).  Although 
the numerous events that regulate E-cadherin expression/repression are well characterised, 
and the outcome of decreased adhesion and increased invasiveness and motility are well 
documented, to date little is known about precisely how the loss of E-cadherin from cells 
exert these effects.  Several theories relating to the involvement of E-cadherin in cell 
signalling have been suggested including the sequestration of cell-signalling molecules 
such as growth factors by E-cadherin to the cell membrane, thereby inhibiting the 
signalling properties of these molecules (Perrais et al., 2007).  Another possibility is that 
the cis-dimerisation of E-cadherin brings cytoplasmically-bound co-factors into closer 
proximity to each other, resulting in the activation of downstream target molecules.  A 
further idea is that the trans-interaction of E-cadherin molecules on neighbouring cells 
may result in an altered E-cadherin conformation which then changes the interactions of 
the intracellular binding domains (McCrea et al., 2009). 
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E-cadherin is expressed by pluripotent human and mouse ES cells, and expression is 
down-regulated as cells differentiate, providing an easily manipulated in vitro system in 
which to study E-cadherin function (Spencer et al., 2007).   Studies using the Ecad-/- 
mouse ES cell line have so far revealed roles for E-cadherin in cell proliferation, motility 
and basement membrane formation (Soncin et al., 2009).  In addition, E-cadherin has 
been found to be important in cell-signalling as Ecad-/- ES cells remain pluripotent when 
cultured in the absence of Lif, instead relying on Activin and Nodal for self-renewal, and 
Fgf-2 for proliferation.  Furthermore, β-cat-/- ES cells were also found to be able to 
maintain pluripotency in the absence of Lif using a similar mechanism to that observed in 
Ecad-/- ES cells (Soncin et al., 2009).  
 
Jam2 is a member of the recently discovered Ig superfamily of cell-surface proteins 
which includes Jam1, Jam2, Jam3, and the less-related Jam4, JamL, Esam and Car 
(Mandell and Parkos, 2005).  Jam1, 2 and 3 are structurally similar consisting of an 
extracellular domain containing two IgV loops, a single transmembrane domain, and a 
short cytoplasmic tail (Ebnet et al., 2004).  Jam1 is mainly expressed in epithelial and 
endothelial cells of various tissues, whereas Jam2 and Jam3 expression is found 
predominantly in vascular and lymphatic endothelial cells (Aurrand-Lions et al., 2001b).  
Jam2 expression is located at the lateral boundaries of HEVs where it functions as an 
adhesion molecule for Jam3 and α4β1 integrin on circulating lymphocytes (Cunningham 
et al., 2002; Ludwig et al., 2009; Palmeri et al., 2000).  Jam2 and Jam3 have also been 
found to directly associate with the polarity protein Par3 when transfected into CHO cells 
(Ebnet et al., 2003).  Although Jam2 expression has been detected in undifferentiated 
embryonic, neural and haematopoietic stem cells, with expression down-regulated as 
cells differentiate (Ivanova et al., 2002), a role for Jam2 in maintaining pluripotency of 
ES cells was ruled out by Sakaguchi et al (2006), who found that Jam2 knock-out mice 
display apparent normal phenotypes, and Jam2-/- mouse ES cells remain pluripotent and 
maintain the capacity to self-renew (Sakaguchi et al., 2006). 
In this study we have utilised WT, Ecad-/-, β-cat-/- and Jam2-/- ES cells to investigate 
the relationship between E-cadherin expression and regulation of Jam2 protein and 
transcripts.  We show that E-cadherin positively regulates Jam2 expression at the 
transcript level and that a 71 amino acid terminal region of the cytoplasmic domain of E-
cadherin is essential for this regulation.   We believe this is the first demonstration of E-
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cadherin exerting positive regulation of ES cell transcripts and that loss of Jam2 is 
mediated by a β-catenin independent mechanism.  These results highlight the complex 
role of E-cadherin in ES cell behaviour and may be relevant to events occurring during 
tumour progression. 
 
 
3.3 Materials and Methods 
Mouse ES Cell Culture 
WT D3 (Ecad-/- and β-cat-/- parental cell line), WT MESC, E14tg2a (WT E14, Jam2-/- 
parental cell line), Ecad-/-, β-cat-/- and Jam2-/- (a kind donation from A. Okuda, Japan) 
mouse ES cell lines were cultured in gelatin-treated 6-well plates (Greiner Bio-One, 
Gloucestershire, UK) with Knock-out DMEM supplemented with 10% v/v FBS, 2mM L-
glutamine, 50μM 2-mercaptoethanol (all from Invitrogen, Paisley, UK), 1:100 non-
essential amino acids (PAA, Somerset, UK), and 1000 U/ml Lif (ESGRO, Millipore, 
Livingston, UK) at 37oC/5%CO2.  Cells were passaged every 2 days prior to confluence 
by washing twice with 2ml PBS (PAA, Somerset, UK) and incubating with 1.5ml trypsin 
(PAA, Somerset, UK).  Gelatin-treated plates were prepared by adding 0.1% w/v gelatin 
(Sigma-Aldrich, Dorset, UK) per well for a minimum of 24 hours.  The gelatin was 
removed and the wells allowed to air dry prior to use.  To differentiate the cells, FBS was 
replaced with 10% v/v KSR (Invitrogen, Paisley, UK) and cells were grown in the 
absence of Lif, a method of differentiation previously shown to induce EMT-like events 
in mouse ES cells (Spencer et al., 2007).  Additional media supplements were as follows: 
abrogation of E-cadherin in WT ES cells was achieved using 1-2.66μl/ml E-cadherin nAb 
DECMA-1, or anti-rat IgG antibody as the cAb (both Sigma-Aldrich, Dorset, UK).  
Inhibition of β-catenin degradation was achieved by culturing cells with 1-4μΜ Gsk-3β 
inhibitor BIO (Sigma-Aldrich, Dorset, UK) or an equal volume of DMSO as a control.  
For EB formation, 1x106 cells were seeded into 15ml FBS media without Lif into 
bacterial grade Petri dishes (Sterilin, Caerphilly, UK), the media was changed every 2 
days.  All cell culture experiments were repeated in triplicate with the results shown 
representing all three repeats. 
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Proliferation Assay 
Cells were plated at 4x105 cells per well in FBS media and cell number and viability were 
determined every 2 days using Countess automated cell counter (Invitrogen, Paisley, UK) 
prior to being reseeded at 4x105 cells per well.  Triplicate wells were plated for each cell 
line at each time point, and each well was counted in triplicate.  Population doubling 
times were calculated using Doubling Time Software 
v1.0.10 (http://www.doubling-time.com) (Roth, V. 2006), using the following equations: 
doubling time = ln(2)/growth rate. Growth rate = (ln(X2)-ln(X1))/(t2-t1), where X2  = 
final conc. of cells, X1 = initial conc. of cells, T2 = end time and T1 = start time.  
Cumulative cell counts were analysed using unpaired T-test.  Three independent assays 
were performed and the results shown are representative of all.  Data are presented as 
mean +/- standard deviation, significant difference was set at p<0.05. 
 
Cell Motility Assay 
Transwells of 5μm pore size of a 24-well plate (Corning Life Sciences, Amsterdam) were 
immersed in 0.1% w/v gelatin overnight and rinsed in PBS.  Transwells were blocked in 
FBS-containing medium for 30 minutes and washed in PBS.  1x105 ES cells were added 
to each transwell in 100μl media, which was then placed in a well containing 500μl 
media, and left overnight at 37oC/5% CO2.  The transwell was removed and the well of 
the plate was washed twice with PBS before staining with crystal violet.  The number of 
cells on the bottom of the plate was counted.  The assay was perfomed three times and p 
values were calculated using unpaired T-test. 
 
Fluorescent Flow Cytometry 
Cells were harvested from 6-well plates using cell dissociation buffer (PAA, Somerset, 
UK), transferred to a 1.5ml eppendorf, washed once with 900μl PBS and incubated with 
primary antibody (or control) diluted 1:100 (unless otherwise stated) in FACS buffer 
(0.2%BSA w/v, 0.1% sodium azide w/v in PBS) for 30 min on ice.  Primary antibodies 
were as follows: rat anti-mouse E-cadherin (DECMA-1, 1:500 dilution, Sigma-Aldrich 
Dorset, UK); anti-mouse SSEA1 (Santa Cruz, California, USA); and rat anti-mouse Jam2 
(RnD Systems, Oxfordshire, UK). Isotype control antibodies were used at the same 
concentration as primary antibodies and were as follows:  goat IgG (Abcam, Cambridge, 
UK), rat IgG (RnD Systems, Oxfordshire, UK), and mouse IgM (Santa Cruz, California, 
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USA). Cells were washed in 900μl PBS and incubated with the appropriate PE- or FITC-
conjugated secondary antibody (all Santa Cruz, California, USA, 1:200) for 30 min on ice.  
Cells were washed as before, resuspended in 300μl 1% w/v PFA, and cell fluorescence 
analysed using a FACScalibur (BD Biosciences, Oxford, UK).  Viable cells were gated 
using forward and side scatter and all data represents cells from this population.  All plots 
are representative of three independent analyses. 
 
Immunofluorescent Imaging of ES Cells 
Cells were cultured in 6-well plates and fixed with either 4% w/v PFA (Oct-3/4, Nanog) 
or ice-cold 1:1 v/v acetone:methanol (E-cadherin, β-catenin) in situ.  Cells were washed 
twice with 2ml PBS and treated with blocking buffer (0.1% w/v BSA, 1% serum, 0.1% 
Triton-X, in PBS) for 30 min.  Cells were incubated with primary antibody diluted 1:100 
in blocking buffer for 2 hours at room temperature.  Primary antibodies were as follows: 
anti-Oct3/4 (Santa Cruz, California, USA); anti-Nanog (Chemicon, California, USA); 
anti-E-cadherin and anti-β-catenin (BD Biosciences, Oxfordshire, UK). Cells were 
washed a minimum of 4 times with 2ml PBS and incubated in Alexa Fluor 488 
conjugated secondary antibody (all Invitrogen, Paisley, UK) diluted 1:200 in blocking 
buffer for 1 hour.  Cells were washed as before, mounted using DAPI Vector shield 
(Vector, Peterborough, UK), and visualised on a Leica DM5000 B fluorescence 
microscope (Milton Keynes, UK).  All images are representative of three independent 
repeats. 
 
RT-PCR 
Total RNA was extracted from cells using TRI reagent (Sigma-Aldrich, Dorset, UK), 
treated with DNase (Promega, Southampton, UK) and phenol/chloroform extracted (as 
described previously (Ward et al., 2003)).  cDNA was synthesised using 1μg RNA in 
20μl nuclease free water (Applied Biosystems, Warrington, UK), 5μl 100mM DTT, 
1.25μg oligoDT, 40u RNAsin, 5μl RT enzyme buffer, 10u AMV reverse transcriptase 
and 5μl 250μM dNTP (all Promega, Southampton, UK) at 42oC for 1 hour.  For the PCR 
1μl cDNA, 1μl 50pmol/μl forward and reverse primers (Invitrogen, Paisley, UK) and 8μl 
Reddymix (Abgene, Epsom, UK) were combined and run at 94oC for 5 min, then 35 
cycles of 94oC for 30 sec, 60oC for 40 sec and 72oC for 45 sec, followed by 72oC for 7 
min, using a 2720 Thermal Cycler (Applied Biosystems, California, USA).  Samples 
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were visualised on 2% w/v agarose gel (Melford, Suffolk, UK) containing 8% SafeView 
Nucleic Acid Stain (NBS Biologicals, Huntingdon, UK) using a Uvi Pro Platinum Gel 
Doc (UVItec, Cambridge, UK).  All experiments were repeated in triplicate and the 
results presented are representative of all.  Details of all primer sequences, annealing 
temperatures and product sizes are shown in Table 3.1. 
 
Table 3.1  List of primer sequences used in this study. 
 
Name Forward Reverse Size oC 
E-cadherin GAGGTCTACACCTTCCCGGT CGAAAAGAAGGCTGTCCTTG 108 60 
Jam1 GGTCAGCATCCACCTCACTGT AGGTCAGCACTGCCCTGTTC 96 60 
Jam2 CCTGGACTATCATAAGGCAAAT CATCTTAAACCAGATGTACTCCG 457 60 
Jam3 TCGACATGGCGCTGAGC CAGTGTTGCCGTCTTGCCTACAG 460 60 
Oct-3/4 AGAAGGAGCTAGAACAGTTTGC CGGTTACAGAACCATACTCG 415 60 
Nanog AGGGTCTGCTACTGAGATGCTCTG CAACCACTGGTTTTTCTGCCACCG 364 60 
Transthyretin GGTATTTGTGTCTGAAGCTGG GGTTGCTGACGACAGCCGTGG 392 60 
Brachyury CATTACACACCACTGACG GATATAGGACCCTACCTAGC 472 60 
Zeta-Globin GATGAAGAATGAGAGAGC AGTCAGGATAGAAGACAGG 406 60 
β-tubulin TCACTGTGCCTGAACTTACC GGAACATAGCCGTAAACTGC 317 60 
 
 
Design of RNAi plasmids 
RNAi sequences were designed to target the beginning, middle and end of the Jam2 
transcript using Genscript RNAi target sequence finder.  RNATin-H1.2/Hygro plasmids 
containing these sequences were produced in-house by Genscript (New Jersey, USA).  
Plasmids were transfected into WT D3 and E14 ES cells as described above and cultured 
in 150μg/ml hygromycin for selection.  Clones were picked and analysed for Jam2 
knockdown by fluorescent flow cytometry. Further details of RNATin-H1.2/Hygro 
plasmid and Jam2 RNAi hairpin loop sequences are provided in Supplementary data 1. 
 
ES Cell Transfection 
Cells were transfected using an Amaxa NucleofectorII and ES cell electroporation kit 
(Amaxa Biosystems, Koln, Germany) following the manufacturer’s instructions.  Briefly, 
2 x 106 cells were resuspended in 100μl Amaxa ES cell solution containing 2ug plasmid.  
Cells were electroporated using program A30 on the Amaxa Nucleofector II and replated 
in 6-well plates and left to grow for 24 hours.  Transient transfections were assessed 
immediately, whereas stable transfections were cultured in appropriate antibiotic for 
seven days to allow for selection of plasmid-containing cells only.  Single clones were 
picked and analysed for successful knock-down or gene expression thereafter.   
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3.4 Results 
 
Expression of Jam2 in undifferentiated and differentiated WT and Ecad-/- ES cell 
lines 
WT D3 and Ecad-/- ES cells were assessed for general morphology (phase contrast) and 
expression of the pluripotency proteins Oct-3/4 and Nanog (Figure 3.1a (i)).  Ecad-/- ES 
cells exhibit a more mesenchymal-like phenotype and expressed Oct-3/4 and Nanog 
proteins at a similar level to WT D3 (Figure 3.1a (ii)).  Analysis of microarray data 
comparing WT D3 and Ecad-/- ES cell gene expression revealed a 235-fold decrease in 
Jam2 expression in Ecad-/- ES cells compared to WT D3 (data not shown, Soncin et al, 
manuscript in preparation).  To confirm this result Jam 1, 2 and 3 transcript expression 
was assessed in undifferentiated WT D3 and Ecad-/- ES cells by RT-PCR (Figure 3.1b).  
Jam1, 2 and 3 transcript expression was detected in the WT D3 ES cells whereas Ecad-/- 
ES cells lacked transcripts for Jam2 (Figure 3.1b). Assessment of E-cadherin and Jam2 
expression at the protein level using fluorescent flow cytometry showed that WT D3 ES 
cells express both molecules at the cell surface (Figure 3.1c, WT D3).  In contrast, Ecad-
/- ES cells lacked both E-cadherin and Jam2 cell surface expression (Figure 3.1c, Ecad-/-).  
Cell-surface expression of the pluripotency marker SSEA-1 further demonstrated the 
undifferentiated phenotype of both WT D3 and Ecad-/- ES cell lines (Figure 3.1c, SSEA-
1).  
 
To determine Jam2 and E-cadherin expression in differentiating ES cells, WT D3 and 
E14 ES cells were induced to spontaneously differentiate by culturing in KSR 
supplemented media without Lif as previously described (Spencer et al., 2007) for 4 and 
6 days respectively, and assessed for Jam2, E-cadherin and pluripotency marker 
expression by fluorescent flow cytometry and RT-PCR (Figure 3.1d and e).  In both cell 
lines E-cadherin, Jam2 and SSEA-1 cell surface expression was decreased in 
differentiating cells compared to undifferentiated cells (Figure 3.1d), whereas transcript 
expression levels appeared to be unaltered (Figure 3.1e).  The presence of Oct-3/4 and 
Nanog transcripts in the KSR-Lif cell population may be explained by the use of KSR-Lif 
rather than other methods of inducing ES cell differentiation, such as FBS-Lif or EB 
formation.  KSR-Lif may be selecting for Oct-3/4 and Nanog positive cells as KSR is 
also routinely used in conjunction with Lif to maintain ES cell pluripotency.  However, 
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the growth of ES cells in KSR-Lif provides a method of ES cell differentiation that 
induces the cells to pass through an EMT-like event and therefore allows for the study of 
E-cadherin down-regulation in relation to this cellular event. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  The Relationship Between E-cadherin and Jam2 in Mouse ES Cells  87
E-cadherin SSEA-1Jam2
WTD3
Ecad-/-
Ecad    J1     J2     J3    Oct    Nan β-tub 
(a)
WT D3
Ecad-/-
Nanog Oct-3/4
(ii)
(c)(b)
(d)
E-cadherin SSEA-1Jam2
(i)
(ii)
(e)
DAPI DAPI
Ecad    J1     J2     J3    Oct    Nan β-tub 
D3+LIF
D3-LIF
E14+LIF
E14-LIF
(i)
Phase Contrast
WT D3
Ecad-/-
 
 
 
Figure 3.1  Jam2 expression is detected in undifferentiated WT D3 ES cells, but not in Ecad-/- 
cells and is lost upon differentiation.  (a)  Phase contrast and immunofluorescence microscopy 
analysis of pluripotency markers Oct-3/4 and Nanog, in WT D3 ES cells (i) and Ecad-/- ES cells 
(ii), scale bars 50μm. (b) RT-PCR analysis of WT D3 and Ecad-/- ES cell cDNA for E-cadherin 
(Ecad), Jam1 (J1), Jam2 (J2), Jam3 (J3), Oct-3/4 (Oct), Nanog (Nan), and β-tubulin (β-tub, 
control) transcript expression.  (c)  Cell surface E-cadherin, Jam2 and SSEA-1 were assessed in 
WT D3 and Ecad-/- ES cells by fluorescent flow cytometry.  E-cadherin/Jam2/SSEA-1, green 
profile; control, purple profile.  (d)  WT D3(i) and E14(ii) ES cells were cultured in KSR-Lif for 
4 and 6 days respectively and assessed for cell surface E-cadherin, Jam2 and SSEA-1 expression 
using fluorescent flow cytometry.  FBS+Lif, green profile; KSR-Lif, pink profile; control, purple 
profile.   (e)  RT-PCR was performed on the cells described in (d) above to assess E-cadherin 
(Ecad), Jam1 (J1), Jam2 (J2), Jam3 (J3), Oct-3/4 (Oct), Nanog (Nan) and β-tubulin (β-tub, 
control) transcript expression.  D3 FBS+Lif (D3+Lif), D3 day 4 KSR-Lif (D3-Lif), E14 FBS+Lif 
(E14+Lif), E14 KSR-Lif day 6 (E14-Lif). 
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Jam2 transcripts are up-regulated in Ecad-/- ES cells when full length, but not 
truncated, E-cadherin protein is exogenously expressed. 
To determine if loss of Jam2 expression in Ecad-/- ES cells could be reversed, E-cadherin 
cDNA was transfected into Ecad-/- ES cells and Jam2 protein and transcript expression 
assessed (Figure 3.2).  In addition, the function of specific cytoplasmic domains of the E-
cadherin protein in regulating Jam2 expression was assessed using truncated E-cadherin 
proteins.  The experiment was repeated three times and the results shown represent all 
three repeats.  Cells transfected with the control empty vector containing no E-cadherin 
cDNA grew as single cells (Figure 3.2a (i)) and lacked expression of E-cadherin and 
Jam2 transcripts and protein (Figure 3.2a (ii)-(iii)).  Transfection of Ecad-/- ES cells with 
a vector encoding E-cadherin lacking the entire cytoplasmic domain (EC0, Figure 3.2b) 
or the terminal 71aa of the cytoplasmic domain (EC81, Figure 3.2c) resulted in 
expression of E-cadherin transcripts and protein, but did not result in restoration of cell-
cell contacts or in expression of Jam2 transcripts or protein.  Transfection of cDNA 
encoding full length E-cadherin (EHA) restored cell-cell contacts in the majority of cells 
(Figure 3.2d (i)), and expression of E-cadherin transcripts and cell-surface protein (Figure 
3.2d (ii) and (iii) respectively).  In addition, Jam2 transcripts were detected at days 2 and 
3 post transfection (Figure 3.2d (ii)), although Jam2 cell-surface expression was not 
detected (Figure 3.2d (iii)). These results indicate that the terminal 71aa of the E-cadherin 
cytoplasmic domain are required for positive regulation of Jam2 transcript expression and 
this is associated with E-cadherin mediated cell-cell contact.  
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Figure 3.2  Jam2 transcripts are up-regulated in Ecad-/- ES cells when full length, but not 
truncated, E-cadherin cDNA is exogenously expressed.  Ecad-/- ES cells were transfected with 
plasmids containing (a) no E-cadherin (empty vector), (b) the extracellular domain of E-cadherin 
(EC0), (c) the extracellular domain and first 81 amino acids of the intracellular region containing 
the p120-catenin binding domain but not the β-catenin binding domain (EC81), and (d) full 
length E-cadherin (EHA).  (i) phase contrast microscopy of cells day 1 following transfection, 
scale bar 100μm.  (ii) RT-PCR analysis of E-cadherin, Jam2 and β-tubulin (control) transcripts at 
day 1, 2 and 3 following transfection.  (iii)  Cell surface E-cadherin (Ecad) and Jam2 at day 1, 2 
and 3 after transfection assessed by fluorescent flow cytometry.  E-cadherin/Jam2, green profile; 
control, purple profile.  (e) WT D3 ES cells were used as a positive control for Jam2 (i) and E-
cadherin (ii) fluorescent flow cytometry analysis.  E-cadherin/Jam2, green profile; control, purple 
profile. 
Chapter 3  The Relationship Between E-cadherin and Jam2 in Mouse ES Cells 90
Jam2 transcript and protein is absent in WT ES cells following RNAi knockdown of 
E-cadherin. 
To confirm that E-cadherin protein regulates Jam2 transcript and protein expression, WT 
MESC ES cells stably expressing an E-cadherin RNAi plasmid were analysed for 
expression of Jam2. WT MESC ES cells transfected with control RNAi plasmid 
displayed normal cellular morphology (Figure 3.3a (i)) and expressed E-cadherin and 
Jam2 transcripts and cell-surface protein (Figure 3.3a (ii)-(iv)). In contrast, WT MESC 
cells transfected with E-cadherin hairpin loop RNAi (1D2) exhibited loss of cell-cell 
contact (Figure 3.3b (i)), lower levels of E-cadherin transcripts and no detectable Jam2 
transcripts or protein (Figure 3.3b (ii)-(iv)).  Reversal of E-cadherin RNAi inhibition in 
1D2 cells was achieved by transfection of the Tet repressor plasmid (MA4, Figure 3.3c).  
These cells exhibit increased E-cadherin protein and restoration of cell-cell contacts 
(Figure 3.3c (i) and (iii-iv)).  Furthermore, Jam2 transcripts and protein were detected in 
the MA4 cell line, confirming that E-cadherin positively regulates expression of Jam2 in 
ES cells.  
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Figure 3.3  Jam2 transcript and protein is absent in WT ES cells exhibiting RNAi knockdown of 
E-cadherin.  WT MESC ES cells were transfected with (a) luciferase RNAi (control), (b) E-
cadherin RNAi (1D2) and (c) E-cadherin RNAi and Tet repressor plasmids (MA4).  (i) Phase 
contrast microscopy of control, 1D2, and MA4 cell lines, scale bar 100μm.  (ii) RT-PCR analysis 
of E-cadherin (Ecad), Jam2 and β-tubulin (β-tub, control) transcripts in control, 1D2 and MA4 
cell lines.  (iii) Cell surface E-cadherin and Jam2 expression in control, 1D2 and MA4 was 
assessed using fluorescent flow cytometry.  E-cadherin/Jam2, green profile; control, purple 
profile.  (iv) E-cadherin protein expression in control, 1D2 and MA4 cell lines was assessed using 
immunofluorescence microscopy, scale bar 10μm.  
 
 
Chapter 3  The Relationship Between E-cadherin and Jam2 in Mouse ES Cells 92
Loss of E-cadherin mediated cell-cell contact alone is not responsible for down-
regulation of Jam2 in Ecad-ve cell lines. 
Loss of E-cadherin from the cell-surface is associated with loss of cell-cell contact.  It 
was important therefore to establish whether the regulation of Jam2 expression is merely 
a consequence of gain and loss of E-cadherin mediated cell-cell contact rather than gain 
and loss of E-cadherin protein itself.  To determine whether loss of cell-cell contact in 
Ecad-/- ES cells regulates Jam2 expression, Ecad-/- ES cells were grown at high 
confluency for 2 passages to induce cell-cell contact (Figure 3.4a).  The experiment was 
repeated three times and the results shown are representative of all three repeats. 
Transcript analysis on day 4 revealed no up-regulation of Jam2 expression (Figure 3.4a 
(ii)).  The early differentiation marker Transthyretin (Ttr) was also assessed in parallel to 
confirm that the absence of Jam2 up-regulation was not a consequence of differentiation 
of the cells (Figure 3.4a (ii), Ttr).  To confirm this result the E-cadherin-knockdown 1D2 
cell line were cultured under identical conditions and demonstrated lack of both Jam2 and 
Ttr transcripts (data not shown). 
 
To further confirm that loss of cell-cell contact is not responsible for the repression of 
Jam2 transcripts and protein, WT D3 ES cells were cultured in the presence of the E-
cadherin neutralising antibody DECMA-1, which inhibits E-cadherin mediated cell-cell 
contacts (Figure 3.4b (i)).  Cells were cultured in the presence of 12μg/3ml DECMA-1 or 
control antibody for 6 days, and Jam2 transcript and cell surface protein expression was 
assessed every 24 hours.  The experiment was repeated three times and the results shown 
are representative of all three repeats.  RT-PCR analysis revealed no decrease in Jam2 
transcripts when cultured with control or neutralising antibody (Figure 3.4b (ii)), and 
Jam2 cell surface expression was also found to be unaltered (Figure 3.4b (iii), day 5 
shown only).  In addition, use of increased concentrations of DECMA-1 (12-32μg/3ml) 
did not alter Jam2 expression in WT D3 ES cells as Jam2 transcripts remained unaltered 
irrespective of DECMA-1 concentration (Figure 3.4b (iv)).  Similar results were also 
obtained in WT MESC ES cells (data not shown). These results demonstrate that loss of 
Jam2 expression in Ecad-/- ES cells is unlikely to be due to loss of E-cadherin mediated 
cell-cell contact. 
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Figure 3.4.  Loss of E-cadherin mediated cell-cell contact alone is not responsible for down-
regulation of Jam2 in Ecad-ve cell lines.  (a) Ecad-/- ES cells were cultured at high confluence to 
force cell-cell contact, (split ratios; 1:6 normal, 2-5:6 high) for 4 days.  (i) Phase contrast 
microscopy of Ecad-/- ES cells at day 2, scale bar 100μm.  (ii) RT-PCR analysis of Jam2, 
Transthyretin (Ttr, differentiation), Oct-3/4 (pluripotency) and β-tubulin (control) transcripts. (b)  
WT D3 ES cells were cultured with 12μg/3ml E-cadherin neutralising antibody DECMA-1 (nAb) 
or control IgG antibody (cAb) for 6 days.  (i) Phase contrast microscopy of cAb and nAb treated 
cells at day 5, scale bar 100μm.  (ii) RT-PCR analysis of Jam2 and β-tubulin (control) transcripts 
every 24 hours.  (iii) Cell surface Jam2 expression on cAb and nAb treated cells at day 5 was 
assessed by fluorescent flow cytometry.  cAb treated cells, green profile; nAb treated cells, pink 
profile; control, purple profile.  (iv) WT D3 ES cells were cultured with increased concentrations 
of nAb for 4 days. RT-PCR analysis of Jam2 and β-tubulin (control) transcripts at day 4. 
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β-catenin does not regulate Jam2 expression in ES cells. 
The inability of E-cadherin lacking the terminal 71aa cytoplasmic region to reverse 
repression of Jam2 expression in Ecad-/- ES cells (as shown in figure 3.2d) suggests a 
potential role for β-catenin signalling since the binding domain for β-catenin is within 
this region of E-cadherin.  In addition, restoration of E-cadherin expression in the E-
cadherin RNAi knockdown clone MA4 shows that β-catenin is only distributed at the cell 
periphery in the cells expressing E-cadherin (Figure 3.5a (i) control, and (iii) MA4).   
 
To investigate a potential role for β-catenin in the regulation of Jam2 in mouse ES cells 
we utilised a small molecule inhibitor of Gsk-3β, BIO, the activity of which can be 
demonstrated by measuring alterations in phosphorylated β-catenin.  WT D3 ES cells 
were cultured in the presence of increasing concentrations of BIO and Jam2 transcripts 
assessed by RT-PCR every 24 hours for 4 days.  The experiment was repeated three times 
and the results shown are representative of all three.  Cells cultured in the presence of 
BIO resulted in some cell toxicity and cells grew as highly compacted cell colonies 
compared to cells cultured in DMSO alone (Figure 3.5b (i)).  No alteration in Jam2 
transcripts was observed at any time point for any of the BIO concentrations (Figure 3.5b 
(ii)).  This result suggests that β-catenin is unlikely to repress Jam2 expression in Ecad-/- 
ES cells.  
To determine expression of Jam2 in the absence of β-catenin, we utilised a β-catenin null 
mouse ES cell line (β-cat-/-).  β-cat-/- ES cells displayed a mesenchymal-like 
morphology, similar to that observed in Ecad-/- ES cells (Figure 3.5c (i)).  RT-PCR 
analysis revealed that Jam2 transcripts are absent in β-cat-/- ES cells whereas both Jam1 
and Jam3 transcripts are expressed (Figure 3.5c (ii)).  Fluorescent flow cytometry 
analysis showed that Jam2 cell surface protein expression was also absent in β-cat-/- ES 
cells (Figure 3.5c (iii)) whereas some E-cadherin protein was detected.  The presence of 
Oct-3/4 and Nanog transcripts (Figure 3.5c (ii)), and SSEA-1 cell surface expression 
(Figure 3.5c (iii)) confirms that β-cat-/- ES cells are pluripotent, as previously described 
by Soncin et al (2009).  These results further suggest that β-catenin is unlikely to be a 
negative regulator of Jam2 expression in Ecad-/- ES cells. 
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Figure 3.5.  β-catenin does not regulate Jam2 expression in mouse ES cells.  (a) 
Immunofluorescent microscopy analysis of β-catenin expression in (i) control, (ii) 1D2 (RNAi) 
and (iii) MA4 (RNAi-repressed) cells, scale bar 10μm.  (b) WT D3 ES cells were cultured in 1-
4μM Gsk-3β inhibitor BIO or DMSO (control) for 4 days.  (i) Phase contrast microscopy at day 2 
of WT D3 ES cells cultured in 1, 2, 3 and 4 μM BIO and 4ul DMSO, scale bar 100μm.  (ii) RT-
PCR analysis of Jam2 and β-tubulin (β-tub, control) transcripts from WT D3 ES cells cultured in 
1-4μM BIO or DMSO at 24, 48, 72 and 96 hours.  (c) β-cat-/- ES cells were assessed for Jam2 
expression.  (i) Phase contrast microscopy of WT D3 and β-cat-/- ES cells, scale bar 100μm.  (ii) 
RT-PCR analysis of E-cadherin (Ecad), Jam1 (J1), Jam2 (J2), Jam3 (J3),Oct-3/4 (Oct), Nanog 
(Nan), and β-tubulin (β-tub, control) transcripts in WT D3 and β-cat-/- ES cells.   (iii) Cell 
surface E-cadherin, Jam2 and SSEA-1 expression in WT D3 and β-cat-/- ES cells was assessed 
by fluorescent flow cytometry.  WT, green profile; β-cat-/- pink profile; control, purple profile.  
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Absence of Jam2 in ES cells does not affect E-cadherin protein localisation or 
pluripotency marker expression.  
Ecad-/- ES cells grow as single cells and maintain pluripotency when cultured in the 
absence of Lif, utilising Activin, Nodal and Fgf signalling for self-renewal and 
proliferation (Soncin et al., 2009).  In addition, Ecad-/- ES cells are more motile and have 
a shorter doubling time than their wild-type counterparts (D3).  Therefore, we assessed 
whether absence of Jam2 may be responsible for some or all of these properties by 
analysing Jam2-/- and RNAi knock-down mouse ES cells. 
 
Jam2-/- ES cells, like their parental line E14tg2a (E14), form compact colonies (Figure 
3.6a) and express the pluripotency markers Oct-3/4, Nanog and E-cadherin protein 
(Figure 6b and d) and transcripts (Figure 3.6c).  To corroborate the results of the Jam2-/- 
ES cell line we created Jam2 knockdown lines using short hairpin RNAi.  Multiple RNAi 
clones were analysed (n=6, data for 1 clone shown) and although Jam2 transcripts were 
detected, Jam2 cell surface expression was absent (Figure 3.6e and f).  Jam2 RNAi 
knockdown ES cells expressed Oct-3/4, Nanog and E-cadherin transcripts and cell 
surface E-cadherin (Figure 3.6e, f and g).   
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Figure 3.6.  Absence of Jam2 in ES cells does not affect E-cadherin protein localisation or 
pluripotency marker expression.  (a) WT E14 and Jam2-/- ES cell morphology compared by 
phase contrast microscopy, scale bar 100μm.  (b)  Immunofluorescent microscopy analysis of 
Oct-3/4, Nanog and E-cadherin expression in WT E14 and Jam2-/- ES cells, scale bar 20μm.  (c)  
RT-PCR analysis of E-cadherin (Ecad), Jam1 (J1), Jam2 (J2), Jam3 (J3), Oct-3/4 (Oct), Nanog 
(Nan) and β-tubulin (β-tub, control) transcripts in WT E14 and Jam2-/- ES cells.  (d)  Cell 
surface E-cadherin, Jam2 and SSEA1 expression on WT E14 and Jam2-/- ES cells was assessed 
by fluorescent flow cytometry.  E-cadherin/Jam2/SSEA1, green profile; control, purple profile.  
(e)  RT-PCR analysis of E-cadherin (Ecad), Jam2 (J2), Oct-3/4 (Oct), Nanog (Nan) and β-tubulin 
(β-tub, control) transcript expression of WT E14 cells transfected with control plasmid (C) or 
Jam2 RNAi.  (f)  Cell surface expression of E-cadherin, Jam2 and SSEA1 expression on control 
(C) and Jam2 RNAi cells was assessed by fluorescent flow cytometry.  E-cadherin/Jam2/SSEA1, 
green profile; isotype controls, purple profile.  (g)  Immunofluorescent microscopy analysis of E-
cadherin expression on control (C) and Jam2 RNAi cells. 
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Absence of Jam2 protein in WT ES cells does not alter cellular proliferation, 
pluripotency pathways, EB formation or motility.  
Recently published data has shown that Ecad-/- ES cells maintain pluripotency in the 
absence of Lif, instead using Activin/Nodal signalling.  To assess whether Jam2 is 
involved in this altered growth factor response, Jam2-/- and WT E14 ES cells were 
cultured in the presence of an Activin/Nodal inhibitor (SB431542) for 2 passages and 
pluripotency marker expression assessed.  The experiment was repeated three times and 
the results shown are representative of all three.  WT D3 ES cells tended to form tighter 
more “balled up” colonies when treated with SB (Figure 3.7a (i), D3) but maintained 
expression of SSEA1 at cell surface (Figure 3.7a (ii), D3) and continued to express both 
Oct-3/4 and Nanog (Figure 3.7a (iii)-(iv), D3), although transcripts for Transthyretin 
were detected at low levels (Figure 3.7a (iv), D3).  Ecad-/- ES cells, however, showed a 
considerably altered phenotype when exposed to SB, similar to that of differentiated cells 
(Figure 3.7a (i), Ecad-/-).  Furthermore, Ecad-/- ES cells rapidly lost SSEA1 expression 
(Figure 3.7a (ii), Ecad-/-) and exhibited markedly reduced Nanog and Oct-3/4 transcript 
and protein expression (Figure 3.7a (iii)-(iv), Ecad-/-).  Jam2-/- ES cells displayed no 
marked alteration in phenotype compared to WT E14 ES cells and maintained WT levels 
of all differentiation markers, as shown by fluorescent flow cytometry, 
immunofluorescence and RT-PCR (Figure 3.7a (i-iv), E14 and Jam2-/-).   
 
To determine whether the loss of E-cadherin mediated cell-cell contact in combination 
with the absence of Jam2 expression is responsible for Ecad-/- ES cells maintaining 
pluripotency through Activin and Nodal signalling, as opposed to Lif, Jam2-/- ES cells 
were cultured in the presence of SB431542 and the E-cadherin neutralising antibody 
DECMA-1 for 2 passages, and pluripotency marker expression was assessed.  The 
experiment was repeated three times and the results shown are representative of all three.  
Abrogation of E-cadherin mediated cell-cell contact in Jam2-/- ES cells did not result in 
loss of pluripotency when cultured in the presence of the Activin/Nodal inhibitor, as cell 
surface expression of the pluripotency marker SSEA-1 remained unaltered in comparison 
to cells cultured with control antibody (Figure 3.7b).  Therefore, Jam2-/- ES cells are not 
reliant upon Activin/Nodal signalling for self-renewal, and loss of Jam2 in Ecad-/- ES 
cells is unlikely to play a role in this mechanism.   
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Figure 3.7.   Absence of Jam2 protein does not alter growth factor response of mouse ES cells.  
(a) WT D3, Ecad-/-, WT E14 and Jam2-/- ES cells were grown in the presence of SB431542 for 2 
passages and assessed at day 4.  (i) Cellular morphology was assessed by phase contrast 
microscopy, scale bar 100μm.  (ii) Cell surface SSEA-1 expression was assessed by fluorescent 
flow cytometry. SSEA1, green profile; control, purple profile.   (iii) Immunofluorescent 
microscopy analysis of Nanog and Oct-3/4 expression (green) and DAPI (blue), scale bar 10μm.  
(iv) RT-PCR analysis of E-cadherin (Ecad), Jam2 (J2), Oct-3/4 (Oct), Nanog (Nan), Brachyury 
(Bchy), Transthyretin (TTR), Zetaglobin (ZG) and β-tubulin (β-tub, control) transcripts.  (b) WT 
D3, Ecad-/-, WT E14 and Jam2-/- ES cells were grown in the presence of SB431542, and either 
DECMA-1 neutralising Ab or rat IgG control (cAb) and SSEA-1 expression was assessed after 4 
days by fluorescent flow cytometry.  SB and cAb, green profile; SB and nAb, pink profile; 
control, purple profile.   
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It has been shown previously that Ecad-/- ES cells exhibit increased proliferation 
compared to WT ES cells (Soncin et al., 2009).  To identify whether Jam2 repression 
confers a growth advantage to the cells a proliferation assay was performed using Jam2-/- 
and WT E14 ES cells.  WT D3 and E14, and Jam2-/- and Ecad-/- ES cells were plated at 
4x105 cells per well and sampled every 2 days to determine cell number and viability and 
subsequently reseeded at the same density.  Ecad-/- ES cells (pink) grew significantly 
faster than WT D3 ES cells (blue, p=0.029) with a final cumulative cell number of 
7.4x1010 and 1.7x1010 respectively after 10 days (Figure 3.8a (i)), and doubling times of 
13.9 hours and 17.26 hours respectively.  However, Jam2-/- ES cells (pink) exhibited no 
significant alteration in proliferation compared to WT E14 ES cells (blue, p=0.23) with a 
final cumulative cell number of 6.3x109 and 4.2x109 respectively after 10 days (Figure 
3.8a (ii)), and doubling times of 20.76 and 22.09 hours respectively.  
A further phenotype observed in Ecad-/- ES cells is that they fail to develop EBs when 
grown in suspension in the absence of Lif.  They fail to form a fully intact basement 
membrane, forming loosely attached aggregates that eventually disaggregate completely.  
To determine if loss of Jam2 from Ecad-/- ES cells plays a role in the formation of EBs, 
Jam2-/- ES cells were cultured in suspension and morphology assessed at days 2, 4 and 6. 
In keeping with previously published data, the Ecad-/- ES cells failed to form complete 
EBs, instead forming loosely associated clusters of cells which by day 6 had largely 
disaggregated (Figure 3.8b (i), Ecad-/-), unlike WT D3 ES cells which formed adherent 
and tightly packed EBs which were maintained over the course of the experiment (Figure 
3.8b (i), D3).  Jam2-/- ES cells were also able to form and maintain EBs, similar to their 
wild-type counter parts (E14) (Figure 3.8b (ii)).  Therefore it can be concluded that loss 
of Jam2 is not responsible for the inability of Ecad-/- ES cells to form complete EBs in 
suspension.  
 
Ecad-/- ES cells display increased motility compared to WT D3 cells.  To determine if 
absence of Jam2 from Ecad-/- ES cells is responsible for this altered phenotype, WT D3, 
Ecad-/-, WT E14 and Jam2-/- ES cells were assessed for their ability to migrate through 
5μm pore size transwell plates (Figure 3.8c).  Whereas Ecad-/- ES cells displayed a 
significant increase in cell motility (p=0.0012), Jam2-/- ES cells exhibited no significant 
difference in motility compared to WT E14 (p=0.14), therefore loss of Jam2 is unlikely to 
be the cause of the increase in motility seen in Ecad-/- ES cells. 
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Figure 3.8. Absence of Jam2 protein in mouse WT ES cells does not alter cellular proliferation, 
EB formation or motility.  (a)  WT D3, Ecad-/-, WT E14 and Jam2-/- ES cells were plated at 
4x105 per well and cell counts performed in triplicate every 2 days for 5 passages.  Graphs show 
total cell number for each time point +/- SD.  WT D3 are compared to E-cad-/- (i, D3 blue, Ecad-
/- pink) and WT E14 to Jam2-/- (ii, E14 blue, Jam2-/- pink).  (b)  (i) WT D3 and Ecad-/-, (ii) WT 
E14 and Jam2-/-  ES cells were cultured in FBS-Lif in suspension and embryoid body formation 
was monitored by phase contrast microscopy at days 2, 4 and 6, scale bar 100μm.  (c) Cellular 
motility of WT E14 and Jam2-/- ES cells was assessed using 5μm pore size transwell plates.  
Data represents percentage of 1x105 cells plated that migrated through the pores after 24 hours, 
error bars show +/-1SD. 
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3.5 Discussion 
Loss of E-cadherin from numerous cancer cell lines has been shown to result in 
consistent alterations including; decreased cell-adhesion, increased cell proliferation, 
increased motility, cytoskeletal re-arrangements and changes in responses to signalling 
pathways (Andl et al., 2006; Beavon, 2000; Gottardi et al., 2001; Hsu et al., 2000; Yang 
et al., 2006).  Studies within our lab on Ecad-/- ES cells have shown that the same is true 
following loss of E-cadherin from mouse ES cells, demonstrating the utility of ES cells as 
a model system for investigations into the metastatic properties conferred upon cells 
following loss of E-cadherin (Spencer et al., 2007).  As a consequence of this, the 
substantial down-regulation in Jam2 expression seen in microarray data comparing WT 
D3 to Ecad-/- mouse ES cells led us to investigate firstly the existence of any E-cadherin-
Jam2 relationship and, secondly, the potential role that the down-regulation of Jam2 in 
ES cells may have in the altered phenotypes displayed by mouse ES cells following loss 
of E-cadherin.  We confirm the existence of a link between E-cadherin and Jam2 
expression and we show that Jam2 is unlikely to be involved in the ability of Ecad-/- ES 
cells to proliferate and self-renew in the absence of Lif, the increase in proliferation or 
motility displayed by Ecad-/- ES cells nor the inability of these cells to form fully intact 
EBs.  
 
The down-regulation of E-cadherin is considered a defining step during embryo 
development and metastatic cancer progression (Birchmeier and Behrens, 1994; Viebahn, 
1995).  Although a great deal is known regarding the events that regulate E-cadherin 
repression, little is known regarding the down-stream effects.  Our findings confirm that 
E-cadherin protein positively regulates Jam2 transcript expression, where loss of E-
cadherin in WT mouse ES cells results in loss of Jam2, and stable re-expression of 
exogenous E-cadherin in Ecad-/- ES cells restores Jam2 expression.  These results 
therefore represent the discovery of a novel outcome following the down-regulation of E-
cadherin: the repression of a cell-surface adhesion molecule with no previously reported 
connection to E-cadherin.  
 
It has been shown previously that the presence of the complete intracellular domain of E-
cadherin is essential to restore Lif-dependant self-renewal and maintenance of 
pluripotency in mouse ES cells (Soncin et al., 2009).  We show that this is also the case 
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for re-expression of Jam2 in mouse ES cells: the terminal 71 amino acids of the E-
cadherin cytoplasmic domain are essential to restore Jam2 transcript expression in Ecad-
/- ES cells.  Although the terminal 71aa of the cytoplasmic domain of E-cadherin encodes 
the β-catenin binding domain, our investigations have so far ruled out the involvement of 
β-catenin in the negative regulation of Jam2, as the release of non-cell surface bound β-
catenin by Gsk-3β inhibition does not result in a reduction in Jam2 transcripts in WT ES 
cells. Further confirmation of this is provided through analysis of a β-cat-/- ES cell line.  
If the repression of Jam2 expression in Ecad-/- ES cells was due to β-catenin preventing 
transcription of Jam2, then Jam2 transcripts would be detected in β-cat-/- ES cells, as β-
catenin is not available to repress Jam2 transcription.  However, Jam2 transcripts are not 
detected in β-cat-/- ES cells, indicating that this is not the case. Previous studies have also 
shown that the full intracellular domain is also required for the correct conformation of 
the extra-cellular domain of E-cadherin and hence its ability to form the homodimers 
required for cell-cell adhesion (Nagafuchi and Takeichi, 1988; Soncin et al., 2009).  
However, we have ruled out the involvement of non-E-cadherin-based cell-cell 
interactions in the regulation of Jam2 in Ecad-/- and E-cadherin-knockdown ES cells, as 
cells grown under conditions that force cell-cell contact did not up-regulate Jam2 
expression. 
 
In contrast to the pathways involved in the regulation of E-cadherin expression, little is 
known regarding the signalling pathways involved in the up- or down-regulation of Jam2 
expression and nothing at all is known regarding its regulation in ES cells. The only 
associated published data to date is for mouse sertoli cells in which Tgf-β2 and IL-1α 
have been found to down- and up-regulate Jam2 transcript expression respectively (Wang 
and Lui, 2009) and for human vascular endothelial cells in which Tnf-α stimulation has 
been found to result in the up-regulation of Jam2 protein (Ludwig et al., 2009).  The 
results of our study suggest that in mouse ES cells expression of Jam2 may be regulated 
either by the same pathway that confers Lif-dependency on WT ES cells and Lif-
independency on β-cat-/- and Ecad-/- ES cells or, alternatively, via as yet unidentified 
signalling alterations that may exist following loss of E-cadherin from ES cells.  Ongoing 
work within the Ward laboratory focussing on the exact mechanism and pathways 
involved in the alteration in signalling in Ecad-/- ES cells may in turn shed further light 
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on the regulation of Jam2 by E-cadherin, and serve to either confirm or rule-out these 
hypotheses.     
 
To date, although Jam2 expression has been found on various cell types including 
endothelial, glial, retinal, sertoli, and embryonic, neural and haematopoietic stem cells, 
the exact function of Jam2 in the majority of these cell types remains unclear (Kim et al., 
2008; Pfeiffer et al., 2008; Sakaguchi et al., 2006; Tenan et al., 2009; Wang and Lui, 
2009).  In mouse ES cells the possibility that Jam2 functions as a “stemness” gene was 
ruled out by Sakaguchi et al (2006) who showed that Jam2-/- ES cells are pluripotent and 
Jam2-/- mice are fertile with no apparent abnormalities (Sakaguchi et al., 2006).  Our 
results corroborate these findings; Jam2 RNAi knockdown cells retain pluripotency 
marker expression when cultured in the presence of Lif and Ecad-/- ES cells, which lack 
Jam2 expression, maintain pluripotency marker expression both in the presence and 
absence of Lif.  In addition our results show that although the expression of Jam2 in 
Ecad-/- ES cells is 235-fold lower than in WT the absence of Jam2 from Ecad-/- ES cells 
is not responsible for any of the phenotypes or behaviours conferred upon ES cells 
following the down-regulation of E-cadherin.  These include the ability of the cells to 
proliferate and self-renew via Activin/Nodal and Fgf-2 signalling in the absence of Lif 
and cell-cell contact, to proliferate faster than WT cells, to fail to form fully intact EBs or 
to display increased motility compared to WT cells.  
 
Jam2 belongs to the Ig superfamily of cell-surface proteins, and of the other members 
Jam1 and Jam3 are the most closely related to Jam2 (Ebnet et al., 2004).  Expression 
patterns of all 3 molecules, although overlapping in some cases (endothelial cells), is 
mainly distinctive both in localisation within the cells, and in expression across cell types 
and tissues (Mandell and Parkos, 2005).  In keeping with this, our results suggest that 
Jam1 and Jam3 are unlikely to be regulated by the same mechanisms as Jam2 in mouse 
ES cells, as Jam1 and Jam3 transcripts remain unchanged in both β-cat-/- and Ecad-/- ES 
cells compared to expression in WT ES cells.  In addition, analysis of microarray data 
shows only a 3.8-fold increase of Jam3 expression in Ecad-/- ES cells compared to WT 
D3, indicating that the effect of E-cadherin loss on Jam3 expression is not only minimal 
but also inverse to that of Jam2.  This implies that the as yet undetermined role of Jam2 
in ES cells is distinct from that of both Jam1 and Jam3, just as it has been found to be in 
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other identified biological settings such as during leukocyte extravasation (Ludwig et al., 
2009). 
 
Together these data demonstrate that although loss of Jam2 from ES cells may be of no 
major consequence to ES cell function and maintenance, further investigation into the 
Jam2-E-cadherin relationship will almost certainly shed further light on the as yet mostly 
unknown events that take place downstream of E-cadherin loss, a major factor during 
both embryo development and cancer cell progression.    
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4.1 Abstract 
Jam2 is a member of the Ig superfamily of cell surface proteins that includes Jam1, Jam3, 
Jam4, Esam and Car.  Although the expression of Jam2 has been detected across several 
stem cell lines, at present the function of Jam2 within these cells remains unknown.  Our 
recent data demonstrated that E-cadherin positively regulates Jam2 expression in mouse 
ES cells; with forced expression of full length E-cadherin in Ecad-/- ES cells able to 
restore Jam2 expression.  Utilising increasing lengths of the Jam2 promoter positioned 
upstream of the luciferase gene, we have identified regions of the Jam2 promoter 
associated with positive regulation of Jam2 in WT ES cells and negative regulation in 
Ecad-/- ES cells.  We demonstrate that the Jam2 promoter is subject to different 
regulation in WT D3 compared to Ecad-/- ES cells, most likely through binding of 
regulatory factors within 4 conserved regions.  Our results indicate that the first 459bp of 
the Jam2 promoter are required for the expression of Jam2 in WT D3 ES cells, and the -
2023 to -4629 region of the Jam2 promoter is required for the repression of Jam2 
expression in Ecad-/- ES cells.  Furthermore, ECR browser analysis indicates the 
involvement of Sp1, E-boxes, Ahr/Arnt, and Zeb1 transcription factors in the regulation 
of Jam2 expression in mouse ES cells. These results demonstrate that loss of E-cadherin 
from mouse ES cells results in the altered regulation and consequent altered expression of 
downstream targets such as Jam2, and suggests that the identification of the regulatory 
factors involved could have important implications in E-cadherin-associated research 
areas such as cancer and development. 
 
 
4.2 Introduction 
Jam2 is a member of the Ig superfamily, a group of cell surface proteins that includes 
Jam1, Jam3, Jam4, Esam and Car (Ebnet et al., 2004).  In adult tissues Jam2 expression 
on vascular endothelial cells has been shown to facilitate the transmigration of leukocytes 
from peripheral circulation to sites of inflammation, through interactions with Jam3 and 
α4β1 integrin (Ludwig et al., 2009).  Jam2 expression is also found in the sertoli-sertoli 
tight junctions of spermatogenetic cells, where it functions during maturation of mouse 
spermatids (Gliki et al., 2004).  In addition, Jam2 expression is also located at the cell 
surface of mouse ES, HS and NS cells (Ivanova et al., 2002).  However, its exact function 
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in stem cells remains unknown at present, as a previous study has shown that Jam2 
knockout mice are viable and fertile and that Jam2-/- ES cells maintain pluripotency 
(Sakaguchi et al., 2006).  Regulation of Jam2 transcript expression in mouse sertoli cells 
has been shown to be positively and negatively influenced by IL-1α and Tgf-β2 
respectively (Wang and Lui, 2009), and Tnf-α stimulation of HUVECs has been shown 
to up-regulate Jam2 cell surface expression (Ludwig et al., 2009).  Most recently, we 
have demonstrated that loss of E-cadherin expression in mouse ES cells results in 
repression of Jam2 protein and transcript expression (Ritson, unpublished),  although the 
exact mechanism associated with this repression is yet to be determined.  
E-cadherin is a cell-surface glycoprotein involved in calcium-dependent cell adhesion 
(Overduin et al., 1995).  In adult tissues it is located in adherens junctions of epithelial 
cells, where it forms homotypic interactions with E-cadherin molecules on adjacent cells 
(Capaldo and Macara, 2007).  During embryo development E-cadherin is first observed at 
the 2-cell stage and is essential for the formation of epithelial structures since E-cadherin 
null (Ecad-/-) ES cells fail to form a trophectodermal epithelium and die at implantation 
(Larue et al., 1994).  During development, down-regulation of E-cadherin is observed as 
cells of the epiblast undergo EMT to enable migration through the primitive streak 
(Viebahn, 1995). This is associated with increases in Snail, Slug, Sip1, Zeb1 and 
E12/E47 transcription factor expression, which bind to E-boxes within the E-cadherin 
promoter, resulting in transcriptional repression (Bolos et al., 2003; Cano et al., 2000; 
Gregory et al., 2008; Perez-Moreno et al., 2001; Vandewalle et al., 2005).  Down-
regulation of E-cadherin is also a defining step during cancer progression, as loss of E-
cadherin results in cells progressing from an epithelial to invasive phenotype, displaying 
decreased cell-cell adhesion, increased motility, and loss of cell polarity (Birchmeier and 
Behrens, 1994).  Although several of the events upstream of the E-cadherin repression 
that occur during EMT and cancer progression have been identified, less is known about 
the cellular events that function downstream of this process.  Recent work in our lab has 
revealed that E-cadherin has roles in regulating cell-signalling, as the abrogation of E-
cadherin from the surface of mouse ES cells results in cells maintaining pluripotency in 
the absence of Lif, instead relying on Activin and Nodal for pluripotency and Fgf-2 for 
self-renewal (Soncin et al., 2009). In addition, we have shown that loss of E-cadherin 
from mouse ES cells alters the localisation of the promigratory factor 5T4 (Spencer et al., 
2007).  Furthermore, absence of E-cadherin from ES cells results in incomplete EB 
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formation (Mohamet, unpublished) and increased cell proliferation compared to WT ES 
cells (Soncin et al., 2009).  Therefore, E-cadherin appears to function in ES cells to 
maintain epithelial integrity and regulate cell surface localisation of pro-migratory factors.  
 
The aim of this study was to identify the regions of the Jam2 promoter involved in 
expression in WT ES cells and repression in Ecad-/- ES cells to determine not only how 
Jam2 is regulated in ES cells but also to identify further alterations in cellular signalling 
that result from loss of E-cadherin in ES cells.  We demonstrate that the Jam2 promoter 
region contains four highly conserved regions across several species which are likely to 
be involved in the regulation of Jam2 expression in mouse ES cells.  We show that the 
first 459 base pairs of the Jam2 promoter exhibit high promoter activity in WT D3 ES 
cells, whereas the -2023 to -4629 region exhibited significantly decreased promoter 
activity in Ecad-/- ES cells.  Furthermore, we identify 2 additional areas of the Jam2 
promoter which are subject to further regulation in Ecad-/- ES cells, but not in WT D3 
cells.  Taken together our results indicate that putative candidates associated with the 
regulation of Jam2 in mouse ES cells may include Sp1, Zeb1 and Aryl hydrocarbon 
receptor/Aryl hydrocarbon receptor nuclear translocator (Ahr/Arnt) transcription factors, 
and that regulation can be dependent on the expression of E-cadherin. 
.  
 
4.3 Materials and Methods 
Mouse ES Cell Culture 
WT D3 and Ecad-/- mouse ES cell lines were cultured in gelatin-treated 6-well plates 
(Greiner Bio-One, Gloucestershire, UK) with Knock-out DMEM supplemented with 10% 
v/v FBS, 2mM L-glutamine, 50μM 2-mercaptoethanol (all from Invitrogen, Paisley, UK), 
1:100 non-essential amino acids (PAA, Somerset, UK), and 1000 U/ml Lif (Millipore, 
Livingston, UK) at 37oC/5%CO2.  Cells were passaged every 2 days prior to confluence 
by washing twice with 2ml PBS (PAA, Somerset, UK) and incubating with 1.5ml trypsin 
(PAA, Somerset, UK).  Gelatin-treated plates were prepared by adding 0.1% w/v gelatin 
(Sigma-Aldrich, Dorset, UK) per well for a minimum of 24 hours.  The gelatin was 
removed and the wells allowed to air dry prior to use.     
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Fluorescent Flow Cytometry 
Cells were harvested from the 6-well plates using cell dissociation buffer (PAA, 
Somerset, UK), transferred to a 1.5ml eppendorf, washed once with 900μl PBS and 
incubated with primary antibody (or control) diluted 1:100 (unless otherwise stated) in 
FACS buffer (0.2%BSA w/v, 0.1% sodium azide w/v in PBS) for 30 min on ice.  Primary 
antibodies were as follows: rat anti-mouse E-cadherin (DECMA-1, 1:500 dilution, 
Sigma-Aldrich Dorset, UK); anti-mouse SSEA1 (Santa Cruz, California, USA); and rat 
anti-mouse Jam2 (RnD Systems, Oxfordshire, UK). Isotype control antibodies were used 
at the same concentration as primary antibodies and were as follows: rat IgG (RnD 
Systems, Oxfordshire, UK) and mouse IgM (Santa Cruz, California, USA). Cells were 
washed in 900μl PBS and incubated with the appropriate PE- or FITC-conjugated 
secondary antibody (all Santa Cruz, California, USA, 1:200) for 30 min on ice.  Cells 
were washed as before, resuspended in 300μl 1% w/v PFA and cell fluorescence 
analysed using a FACScalibur (BD Biosciences, Oxford, UK).  Viable cells were gated 
using forward and side scatter and all data represents cells from this population.  All plots 
shown are representative of three independent analyses. 
 
RT-PCR 
Total RNA was extracted from cells using TRI reagent (Sigma-Aldrich, Dorset, UK), 
treated with DNase (Promega, Southampton, UK) and phenol/chloroform extracted (as 
described previously (Ward et al., 2003)).  cDNA was synthesised using 1μg RNA in 
20μl nuclease free water (Applied Biosystems, Warrington, UK), 5μl 100mM DTT, 
1.25μg oligoDT, 40u RNAsin, 5μl RT enzyme buffer, 10u AMV reverse transcriptase, 
and 5μl 250μM dNTP (all Promega, Southampton, UK) at 42oC for 1 hour.  For the PCR 
1μl cDNA, 1μl 50pmol/μl forward and reverse primers (Invitrogen, Paisley, UK) and 8μl 
Reddymix (Abgene, Epsom, UK) were combined and run for 94oC for 5 min, then 35 
cycles at 94 oC for 30 sec, 60 oC for 40 sec, 72oC for 45 sec, and then 72oC for 7 min, 
using a 2720 Thermal Cycler (Applied Biosystems, California, USA).  Samples were 
visualised on 2% w/v agarose (Melford, Suffolk, UK) gels containing 8% SafeView 
Nucleic Acid Stain (NBS Biologicals, Huntingdon, UK) using a Uvi Pro Platinum Gel 
Doc (UVItec, Cambridge, UK).  All experiments were repeated in triplicate and the 
results presented are representative of all.  Details of primer sequences, annealing 
temperatures and product sizes can be found in Table 4.1 
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Table 4.1  List of primer sequences used in this study. 
 
Name Forward Reverse Size oC 
E-cadherin GAGGTCTACACCTTCCCGGT CGAAAAGAAGGCTGTCCTTG 108 60 
Jam2 CCTGGACTATCATAAGGCAAAT CATCTTAAACCAGATGTACTCCG 457 60 
Oct-3/4 AGAAGGAGCTAGAACAGTTTGC CGGTTACAGAACCATACTCG 415 60 
Nanog AGGGTCTGCTACTGAGATGCTCTG CAACCACTGGTTTTTCTGCCACCG 364 60 
β-tubulin TCACTGTGCCTGAACTTACC GGAACATAGCCGTAAACTGC 317 60 
 
 
 
Construction of Jam2 cDNA Plasmids 
Primers were designed to amplify the coding region of Jam2 including 152 and 204bp of 
the 5’ and 3’ UTR respectively;  forward CCTCTGCTTCCACCTCTCAG, reverse 
TCAGACACAAGATGCCAGGT, product size 1227, annealing temperature 65oC.  
Restriction enzyme binding sequences (forward primer GATATC, EcoRV; reverse 
primer GGATCC, BamH1) and a 4 base pair overhang (GATC) were included at the 5’ 
end of each primer.  The Jam2 coding region was cloned using the WT D3 mouse ES cell 
line cDNA obtained as described above.  For the PCR 8μl Extensor reddymix (Abgene, 
Epsom, UK), 1μl WT D3 cDNA, and 50pM forward and reverse primers (Invitrogen, 
Paisley, UK) were combined and run for 94oC 2 min, then 35 cycles of 94oC for 10 sec, 
65 oC for 30 sec, and 68oC for 5 min, followed by 68oC for 7 min.  Inserts of Jam2 cDNA 
and pIRES Puro3 plasmid (Clontech, France) were digested with EcoRV and BamH1 
restriction enzymes (New England Biolabs, Hitchin, UK) and ligated with T4 Ligase.  
Correct insertion of the fragments into the plasmid was confirmed by in-house DNA 
sequencing using ABI Prism 3100 Genetic Analyser (Applied Biosystems, California, 
USA).  For further details of the pIRES Puro3 plasmid map see Supplementary data 2, 
the full sequence of the Jam2 cDNA is shown in Supplementary data 3 and is correct 
according to MGI accession number 1933820. 
 
 
Construction of Jam2 Promoter Plasmids 
Primers were designed to flank different size lengths (459, 1062, 2022 and 4629 base 
pairs) of the Jam2 promoter with the reverse primer positioned at +260 (459, 1062, 2022) 
or +48 (4629) in the 5’ UTR of the Jam2 gene.  The nucleotides are numbered with 
reference to the transcriptional start site, with +1 representing the first nucleotide of the 
UTR and -1 representing the first nucleotide upstream of the UTR.  This is in contrast to 
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Wang et al who site +1 as the first nucleotide of the ATG start codon.  For comparison, -
364 position in Wang et al relates to +1 position in this work  Restriction enzyme binding 
sequences (forward primer GCTAGC, Nhe1; reverse primer CTCGAG, Xho1) and a 4 
base pair overhang (GATC) were tagged to the 5’ end of each primer.  Full details of the 
primer sequences and annealing temperatures are shown in Table 4.2.  WT D3 ES cell 
genomic DNA was extracted from cells using QIAamp DNA Kit (Qiagen, Crawley, UK) 
following manufacturer’s instructions.  For the PCR 8μl Extensor reddymix (Abgene, 
Epsom, UK), 1μl WT D3 genomic DNA and 50pM forward and reverse primer 
(Invitrogen, Paisley, UK) were combined and run at 94oC for 2 min, then 35 cycles of 
94oC for 10 sec, required annealing temperature (Table 4.2) for 30 sec, and 68oC for 5 
min followed by 68oC for 7 min.    Inserts of Jam2 promoter and pGL3-Basic plasmid 
(Promega, Southampton, UK) were digested with 2000U Nhe1 and Xho1 restriction 
enzymes (New England Biolabs, Hitchin, UK) and ligated with T4 Ligase (Roche, 
Burgess Hill, UK).  Correct insertion of the fragments into the plasmid was confirmed by 
in-house DNA sequencing using ABI Prism 3100 Genetic Analyser (Applied Biosystems, 
California, USA).  For further details of the pGL3-Basic plasmid map and the Jam2 
promoter region see Supplementary Data 4 and 5 respectively.  ECR Browser software is 
available on http://ecrbrowser.dcode.org/. 
 
 
 
 
Table 4.2 Jam2 Promoter Primer Sequences. 
 
Name Start Finish Size Forward Sequence Reverse Sequence oC
0.5 -459 +260 719 TAAGAAGCCAAGAGCCCAGA 
CCTGAGAGGTGG
AAGCAGAG 69 
1 -1062 +260 1322 GCTACCAGCTCCATTTTTGC 
CCTGAGAGGTGG
AAGCAGAG 69 
2 -2022 +260 2282 CAAGGCCTTAGCTTGTACAGG 
CCTGAGAGGTGG
AAGCAGAG 69 
5 -4629 +48 4677 TCATGTACTGGGGGTGGAAT 
CTAGCCTCTTGAG
GGAGAACC   60 
 
 
 
 
 
 
 
Chapter 4   The Transcriptional Regulation of Jam2 by E-cadherin in Mouse ES Cells 113
ES Cell Transfection 
WT D3 and Ecad-/- ES cells were transfected using an Amaxa NucleofectorII and ES cell 
electroporation kit (Amaxa Biosystems, Koln, Germany) following the manufacturer’s 
instructions.  Briefly, 2 x 106 cells were resuspended in 100ul Amaxa ES cell solution 
containing 2μg Jam2 cDNA plasmid, or 2μg pGL3-Basic plasmid and 0.5μg renilla 
plasmid (Promega, Southampton, UK).  Cells were electroporated using program A30 on 
the Amaxa Nucleofector II and replated in 6-well plates and left to grow for 24 hours 
prior to analysis.   
 
Luciferase Assay 
WT D3 and Ecad-/- ES cells were transfected as previously described with 0.5μg Renilla 
plasmid and 2μg promoter plasmid, then collected and analysed after 24 hours using Dual 
Luciferase Reporter Assay System (Promega, Southampton, UK) following 
manufacturers instructions.  Measurements of renilla and luciferase activity for each 
transfection were made using Orion L Microplate Luminometer (Berthold Detection 
Systems, Germany).  Data was analysed by dividing the luciferase measurement by the 
renilla measurement to give relative promoter activity.  Results were compared using 
paired 2-tailed T-test.  All samples were measured in triplicate, data are presented as 
mean +/- standard deviation and significant difference was set at p<0.05.  The experiment 
was repeated six times and the results shown are representative of all repeats. 
 
 
4.4 Results 
 
Negative regulation of Jam2 expression in Ecad-/- ES cells is not via post-
transcriptional silencing. 
WT D3 and Ecad-/- ES cells express similar levels of pluripotency markers Oct-3/4 and 
Nanog transcripts, but whilst Jam2 and E-cadherin transcripts are present in WT D3 ES 
cells, Jam2 and E-cadherin transcripts are absent in Ecad-/- ES cells (Figure 4.1a).  Flow 
cytometry analysis confirmed that Ecad-/- ES cells express similar levels of pluripotency 
marker SSEA-1 at the cell surface compared to WT D3, whereas the former lack 
expression of E-cadherin and Jam2 at the cell surface (Figure 4.1b).  To determine if the 
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absence of Jam2 expression in Ecad-/- ES cells is due to post-transcriptional silencing of 
Jam2 mRNA, Ecad-/- ES cells were transfected with pIRES Puro3 plasmid encoding full 
length Jam2 cDNA (clones 3-2, 3-4, 3-5) or an empty plasmid (C, control) placed 
downstream of the cytomegalovirus (CMV) promoter.  Cells were assessed for Jam2 
transcript expression 24 hours following transfection.  RT-PCR analysis confirmed Jam2 
transcript expression in the Jam2 cDNA transfected cells (Figure 4.1c, 3-2, 3-4, 3-5) but 
not in cells transfected with the control plasmid (Figure 4.1c, C).  Therefore, we conclude 
that the repression of Jam2 expression in Ecad-/- ES cells is unlikely to be caused by 
post-transcriptional silencing. 
 
 
E-cadherin SSEA-1Jam2
WT D3
Ecad-/-
Ecad      J2     Oct    Nan   β-tub 
(b)
(a)
(c) 
C         3-2        3-4       3-5     
Jam2
β-tub
 
 
 
Figure 4.1  Down-regulation of Jam2 expression in Ecad-/- ES cells is not via post-
transcriptional gene silencing.  (a) RT-PCR analysis of WT D3 and Ecad-/- ES cell cDNA for E-
cadherin (Ecad), Jam2 (J2), Oct-3/4 (Oct), Nanog (Nan), and β-tubulin (β-tub, loading control) 
transcript expression.  (b)  Cell surface E-cadherin, Jam2 and SSEA-1 were assessed in WT D3 
and Ecad-/- ES cells by fluorescent flow cytometry.  WT D3, green profile; Ecad-/-, pink profile; 
control, purple profile.  (c) Ecad-/- ES cells were transfected with Jam2 cDNA plasmid (3-2, 3-4, 
or 3-5) or empty plasmid (control, C).  Assessment of Jam2 and β-tubulin (β-tub, control) 
transcript expression by RT-PCR 24 hours following transfection. 
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Analysis of the Jam2 promoter region reveals several regions of high conservation 
across mouse, human, monkey and cow genomes. 
Given that Jam2 transcripts are detected in Ecad-/- ES cells when the Jam2 gene is under 
the control of an alternative promoter, we set out to determine which regions of the Jam2 
promoter might be involved in regulating the expression of Jam2 in WT D3 and Ecad-/- 
ES cells.  The mouse Jam2 gene is located on chromosome 16, contains 10 exons, and 9 
introns (Figure 4.2a (i)).  Analysis of the Jam2 promoter region using ECR Browser 
software revealed 4 main regions of high conservation (>50% conservation) within the 
first 5000 bases upstream of the Jam2 gene between mouse and human, monkey and cow 
genomes (Figure 4.2a (ii)); +88 to -139 (yellow/light blue, conserved region 1, CR-1), -
417 to -1009 (red, CR-2), -2560 to -2768 (blue, CR-3), and -4097 to -4515 (green, CR-4).  
Although additional areas of conservation are detected between mouse and human at -
3407 to -3519, and mouse and monkey at -2376 to -2560 and -151 to -251, only areas 
conserved between all 4 species were considered further. 
To determine the role of these regions in the expression of Jam2 in undifferentiated 
mouse ES cells, different lengths of the Jam2 promoter were positioned upstream of the 
luciferase gene of the pGL3-basic plasmid.  Promoter-plasmid constructs included 0bp 
(Control), 459bp (0.5k), 1062bp (1k), 2022bp (2k), and 4629bp of promoter (5k, all 
Figure 4.2b).  The 0.5k plasmid includes the first region of high conservation +88 to -139 
(CR-1), both 1k and 2k plasmids include the first and second regions of high 
conservation +88 to -139 and -417 to -1009 (CR-1 and -2), and the 5k plasmid includes 
+88 to -139, -417 to -1009, -2560 to -2768 and -4097 to -4515 regions of high 
conservation (CR-1 to -4), all depicted in Figure 4.2b. 
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Figure 4.2  Analysis of Jam2 promoter reveals several regions of high conservation across 
mouse, human, monkey and cow genomes.  (a) (i) Representation of the gene and 5kb of 
promoter region of mouse Jam2.  (ii) ECR Browser analysis comparing the sequence of the 
region upstream of mouse Jam2 gene to that of human, monkey and cow.  Coloured boxes depict 
areas of high conservation (>50%). Yellow/light blue, +88 to -139; red, -417 to -1009; blue, -
2560 to -2768; green, -4097 to -4515. (b) Jam2 promoter-plasmid constructs encoding +260 to -
459 (0.5k plasmid), +260 to -1062 (1k plasmid), +260 to -2022 (2k plasmid), and +48 to -4629 
base pairs of Jam2 promoter upstream of the luciferase gene on pGL3-Basic plasmid. 
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The Jam2 promoter region is subject to altered regulation in WT D3 and Ecad-/- ES 
cells. 
To address the difference in Jam2 expression observed between WT D3 and Ecad-/- ES 
cells, WT D3 and Ecad-/- ES cells were transfected with renilla plasmid and either 
Control, 0.5k, 1k, 2k, or 5k pGL3-Basic plasmid constructs (shown in Figure 4.2b).  
Renilla and luciferase activity was measured 24 hours following transfection and results 
plotted as luciferase activity/renilla activity to give relative promoter activity (Figure 4.3a 
WT D3, Figure 4.3b Ecad-/-).  Error bars represent the standard deviation of triplicate 
samples.  In WT D3 ES cells a significant increase in promoter activity is seen with the 
0.5k plasmid compared to Control plasmid (p=0.0009).  Promoter activity is also 
significantly higher between Control plasmid and 1k and 2k plasmids (p=0.0007 and 
0.006 respectively), with no significant difference in activity detected between 0.5k, 1k 
and 2k plasmids.  Although a reduction in promoter activity is seen when comparing the 
5k plasmid to 0.5k, 1k and 2k plasmids, the activity still remains significantly higher than 
control plasmid activity (p=0.02).  In Ecad-/- ES cells the 0.5k plasmid results in a 
significant increase in promoter activity compared to control plasmid, although a further 
increase in promoter activity was observed using the 1k plasmid.  Promoter activity was 
reduced slightly with the 2k plasmid whereas promoter activity was reduced to control 
plasmid levels with the 5k plasmid (Control vs. 5k p=0.434, all other comparisons 
p<0.05). 
 
These results indicate that the promoter region of Jam2 is subject to altered regulation in 
Ecad-/- ES cells compared to WT D3 ES cells.  The first 459bp of the promoter appears 
to be sufficient for the positive expression of Jam2 seen in WT D3 cells, whereas the first 
1062bp is required in Ecad-/- ES cells.  The absence of Jam2 expression in Ecad-/- ES 
cells appears to result from either the binding of negative factors within 2023-4629 
region of the promoter or alternatively from the absence of the binding of positive 
regulatory factors to this region.  
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Figure 4.3   The Jam2 gene is subject to alternative regulation in WT D3 and Ecad-/- ES cells.  
(a) WT D3 and (b) Ecad-/- ES cells transfected with luciferase gene under the control of varying 
lengths of the Jam2 promoter.  Luciferase activity was measured in relation to renilla activity.  
Error bars show standard deviation. *p<0.05, **p>0.05 paired 2-tailed T-test.  
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Identification of transcription factor binding sites within the conserved regions of 
the Jam2 promoter region. 
To further investigate the regulation of Jam2 in mouse WT D3 and Ecad-/- ES cells, the 
regions of the promoter identified in the luciferase assay (Figure 4.3) to be involved in 
the regulation of Jam2 promoter activity were searched for potential transcription factor 
binding sites using the ECR Browser software.  Transcription factor binding sites 
predicted by the software within each of the 4 conserved regions of the Jam2 promoter 
are shown in Figure 4.4.  Consensus sequences were identified by grouping transcription 
factor binding sites based on overlapping areas of DNA sequence (Figure 4.4; highlighted 
by black boxes), and the DNA sequences of the groups were used for further analysis.  
Table 4.3 shows the DNA sequence of each consensus sequence as determined by the 
groupings of predicted transcription factor binding sites in Figure 4.4 (No.) within each 
conserved region (CR).  The position within the Jam2 promoter (Position), a summary of 
the search results obtained when searching for the sequence in Pubmed (Pubmed Search 
Results), and transcription factors and binding regions identified by the Pubmed search 
(TF/Binding Region) are also shown in Table 4.3. 
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Figure 4.4   Predicted transcription factor binding sites in Jam2 promoter. Prediction of 
transcription factor binding sites for each of the 4 regions of high conservation in the Jam2 
promoter between mouse and human, monkey and cow genomes using ECR Browser software. 
Transcription factors with overlapping positions are grouped (black outline, numbered 1-30) to 
determine potential consensus sequences.  
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Table 4.3 Analysis of consensus sequences in the Jam2 promoter 
CR No. Consensus Sequence Position Pubmed Search Results 
TF/Binding 
Region 
1 TGCCCCCAG -66, -58 - 
2 CTCCTCGCCCTGGGGA -57, -42 
- 
3 CCCTGGGGA -50, -42 - 
4 GGGGACAGCTG -46, -36 - 1 
5 GGGGGCGGGG +5, +13 
1 citation. Main Sp1 binding site in human 
glucose phosphase isomerise promoter 
(Walker et al., 1990) 
 
 
 
 
Sp1 
6 ATTTTA -648, -643 - 
7 CACGC -639, -635 
5 citations. Core-recognition motif for 
Ahr/Arnt complex in Dioxin Response 
Element within CYP1A1 (Oesch-
Bartlomowicz et al., 2004), mouse 
Dystrophin Dp71 (Bermúdez de León et al., 
2006), human cathepsin D (Wang et al., 
1999).  
8 
CATTCATAATGGAT
TT 
CCCTTTTAAAAGCA
CA 
-627, -596 - 
9 CCAAAAATAAACCTGACA -590, -573 - 
10 CAGCTG -566, -561 
408 citations. E-box in promoters of human 
and mouse genes including mouse growth 
differentiation factor 9 (Yan et al., 2006), 
human β-myosin heavy chain, mouse and 
human Ig-kappa gene subgroup families 
(Aranburu et al., 2001). 
11 CATGTGGAAAACTCCACAG -549, -531 - 
12 CAGTTACATAA -526, -516 - 
13 ACAAGATAAAT -505, -495 - 
14 TTCACACCG -492, -484 - 
15 TGAACT -478, -473 - 
16 GTTGCCCAGGCAAC -949, -934 
- 
17 ATGCCTCATTCCTCACAG -926, -909 - 
18 ACCACTAAAT -841, -832 - 
2 
19 ATC -826, -824 - 
 
 
DRE, 
Ahr/Arnt 
 
 
 
 
 
 
 
E-box 
20 AGTGGGAATG -2662, -2653 - 
21 TAACATTTCCTC -2651, -2639 - 3 
22 TTA -2627, -2625 - 
- 
23 TGGGCACAC -4418, -4410 - 
24 TCCCAGCACCTT -4408, -4397 - 
25 CCACACCC -4394, -4387 
5 citations. CACCC box in human 
thymidylate synthase gene (Horie and 
Takeishi, 1997), mouse and human β-globin 
genes, binds Sp1 and CACD in mouse 
(Broggini et al., 1989; Hartzog and Myers, 
1993).  
26 AAAAT -4380, -4375 - 
27 CTTGC -4370, -4366 - 
28 CAAGTCT -4195, -4189 - 
29 (T)ACCT -4176, -4172 
1 (of 23) relevant citation. C-terminal zinc-
finger of DeltaEF1 binds (T/C)ACCT 
(Sekido et al., 1997). 
4 
30 AAGCGAAAGTG -4149, -4139 - 
 
 
CACCC 
box, 
Sp1, 
CACD 
 
 
 
DeltaEF1 
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Conserved region 1 (CR1) represents the first highly conserved region in the Jam2 
promoter (yellow/light blue box), from +88 to -139, encoded on the 0.5k plasmid.  
Analysis using ECR Browser indicates it contains 5 potential consensus sequences, one 
of which (consensus sequence no.5) has been shown previously to be a binding site for 
Sp1 transcription factor in the human Glucose phosphase isomerase promoter (Walker et 
al., 1990).  Conserved region 2 (CR2) represents the second highly conserved region in 
the Jam2 promoter (red box) from -417 to -1009, encoded on both the 1k and 2k plasmids.  
14 potential consensus sequences are present, of which 2 resulted in Pubmed search hits; 
CACGC (consensus sequence no. 7) is a core-recognition motif for the Aryl hydrocarbon 
receptor/Aryl hydrocarbon receptor nuclear translocator (Ahr/Arnt) complex within the 
Dioxin Response Element (DRE), which is found located in the promoter of several 
mouse and human genes (Bermúdez de León et al., 2006; Oesch-Bartlomowicz et al., 
2004; Wang et al., 1999). The CAGCTG motif (consensus sequence no.10) is an E-box 
sequence also found in the promoter of both human and mouse genes (Aranburu et al., 
2001; Yan et al., 2006).  Conserved regions 3 and 4 (CR3 and CR4) represent the regions 
of high conservation found further upstream in the Jam2 promoter (blue and green boxes 
respectively), encoded by the 5k plasmid.  Of the 11 potential consensus sequences 
encoded, 2 have been previously confirmed as transcription factor binding sites, both of 
which are located in CR4. The CCACACCC motif (consensus sequence no.25) contains a 
CACCC box which is known to bind Sp1 and CACD transcription factors (Broggini et al., 
1989; Hartzog and Myers, 1993; Horie and Takeishi, 1997). The ACCT sequence 
(consensus sequence no.29) has been shown to bind DeltaEF1 (Zeb1) transcription factor 
(Sekido et al., 1997). 
 
Although this method of analysis is unable to provide a comprehensive list of factors 
guaranteed to be affecting Jam2 expression, the results do provide an initial indication of 
specific regions and sequences within the Jam2 promoter that may be responsible for the 
regulation of the Jam2 gene in WT D3 and Ecad-/- ES cells. 
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4.5 Discussion 
Loss of E-cadherin expression is a defining step during both embryo development and 
metastatic cancer progression.  Whilst the events that regulate this loss are well 
understood, events downstream of E-cadherin loss remain less well characterised.  By 
investigating the promoter regulation of Jam2, a molecule whose expression has been 
previously shown to be positively regulated by E-cadherin (Chapter 3), we show that in 
Ecad-/- ES cells the Jam2 promoter is subject to several altered regulatory events 
compared to WT D3 ES cells.  Our results implicate the involvement of 3 of 4 distinct 
conserved regions present within the promoter region in the regulation of Jam2 in WT D3 
and Ecad-/- ES cells.  The expression of Jam2 in WT D3 ES cells appears to result from 
binding of positive regulatory factors within the first 459bp of promoter in which CR1 is 
located, and the absence of Jam2 expression in Ecad-/- ES cells is likely to be caused by 
binding of negative regulatory factors (or absence of positive regulatory factors) within 
the -2023 to -4629 region of the promoter, the location of CR3 and CR4, with additional 
regulatory events occurring in Ecad-/- ES cells within -460 to -1062 (CR2), and -1063 to 
-2022 regions (non-conserved region). 
 
To identify the region of the Jam2 promoter responsible for Jam2 transcript expression in 
WT D3 ES cells, different lengths of the Jam2 promoter placed upstream of the luciferase 
gene in pGL3-Basic plasmid were transfected into WT D3 ES cells and promoter activity 
was determined.  Our results indicate that expression of Jam2 in WT D3 ES cells is 
regulated within the first 260 base pairs of the un-translated region and the first 459 base 
pairs of the promoter (+260 to -459, 0.5k plasmid).  Results of ECR Browser and 
literature searches indicate a consensus sequence for binding of the transcription factor 
Sp1 within CR1 (Figure 4.5a).  Interestingly, this is consistent with the finding of Wang 
et al (2009) who found that in the mouse sertoli cell line MSC-1, Jam2 expression is 
increased upon binding of Sp proteins to Sp binding motifs within a similar region of the 
promoter (-135 to +364, described as -499/-1 by Wang et al) (Wang and Lui, 2009).  
Promoter activity is unaltered following transfection of the next 1563bp of promoter (1k 
and 2k plasmids) in WT D3 ES cells, suggesting that binding of additional factors within 
these regions is either non-existent or does not affect overall transcript expression levels 
(Figure 4.5b-c).  This result differs from those of Wang et al (2009) who found that 
inclusion of -636bp to -1571bp of Jam2 promoter in MSC-1 cells reduced promoter 
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activity by almost half (Wang and Lui, 2009).  A slight decrease in promoter activity was 
detected in WT D3 ES cells following transfection of the 5k plasmid, although promoter 
activity remained significantly higher than control plasmid activity.  Therefore, it is 
possible that negative regulatory elements may be present in the Jam2 promoter between 
2023bp and 4629bp that affect Jam2 expression.  ECR browser and literature searches 
indicate a Zeb1 binding site (Figure 4.5d (i)) and CACCC box (Figure 4.5d (ii)) within 
CR4 of the Jam2 promoter region, either of which could be exerting a negative effect on 
Jam2 promoter activity.  The potential regulatory effects of these two elements are 
discussed in further detail below with regard to Jam2 promoter activity in Ecad-/- ES 
cells. 
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Figure 4.5  Predicted mechanisms of Jam2 promoter regulation in WT D3 ES cells. Depiction of 
predicted transcription factor binding in WT D3 ES cells to (a) 0.5k plasmid, Sp1 binds to CR-1 
to positively regulate Jam2 expression, (b) 1k plasmid, no additional regulation is observed (c) 2k 
plasmid, no additional regulation is observed, and (d) (i) 5k plasmid, binding of regulatory factor 
CBE to CACCC box in CR-4 facilitates binding of unknown negative regulatory factor within 
promoter e.g. within CR-2, or (ii) Zeb1 binding within CR-4 negatively regulates Jam2 
expression. Relative promoter activity as determined by the luciferase assay in Figure 3a is 
shown. Abbreviations: CBE, CACCC box binding element; ?, unknown factor binding within 
CR2. 
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The same approach was taken to identify regions of the Jam2 promoter that may be 
responsible for the repression of Jam2 expression in Ecad-/- ES cells.  Transfection of the 
different promoter lengths into Ecad-/- ES cells gave both informative and surprising 
results; the region of promoter responsible for the repression of Jam2 transcript 
expression was identified as being within -2023 to -4629, but -460 to -1062, and -1062 to 
-2022 regions were found to be subject to additional regulation in Ecad-/- ES cells 
compared to in WT D3.  The +260 to -459 section of promoter (0.5k plasmid) is 
sufficient to induce promoter activity in both WT D3 and Ecad-/- ES cells (fold-change 
approximately +1.6). However, inclusion of -460 to -1062 (1k plasmid) led to a further 
significant increase in luciferase activity in Ecad-/- but not WT D3 ES cells.  Activity is 
lowered significantly when the -1063 to -2022 region of the Jam2 promoter in included 
(2k plasmid) but remains significantly higher than control plasmid activity.  Promoter 
activity is reduced to background levels in the +260 to -4629 Jam2 promoter region in 
Ecad-/- ES cells, a much greater reduction than seen in WT D3. 
 
The similarity in promoter activity of the 0.5k plasmid in WT D3 and Ecad-/- ES cells 
suggests that the same regulatory mechanism may be present in both cell lines, indicated 
as being Sp1 by ECR browser analysis (WT D3, Figure 4.5a; Ecad-/- Figure 4.6a) 
(Walker et al., 1990).  The variation in promoter activity seen in Ecad-/- ES cells when 
comparing 1k and 2k plasmid activity is markedly different to the constant level of 
activity seen in WT D3 cells for these plasmids.  The altered activities of the 1k and 2k 
plasmids occurs exclusively in the Ecad-/- ES cells and therefore this difference is likely 
to be a direct result of the absence of E-cadherin from these cells.  Analysis of CR2 of the 
Jam2 promoter reveals 2 consensus sequences previously identified as transcription factor 
binding domains; CAGCTG, a known E-box motif (Aranburu et al., 2001; Yan et al., 
2006), and CACGC, the core recognition motif of the DRE for the Ahr/Arnt complex 
(Bermúdez de León et al., 2006; Oesch-Bartlomowicz et al., 2004; Wang et al., 1999).  E-
boxes are known to be bound by transcription factors possessing the basic helix-loop-
helix (bHLH) structural motif, such as E12/E47, AP-4 and c-Myc, and are found in the 
promoter of many genes, including E-cadherin (Perez-Moreno et al., 2001).  This breadth 
of functional variety in these transcription factors unfortunately prevents the proposal of a 
hypothesis regarding the regulatory effects of E-boxes in the Jam2 promoter at this stage 
(Figure 4.6b). The Ahr/Arnt complex is also a bHLH-possessing transcription factor, 
which is involved in cellular responses to toxicity by binding to DRE regions of target 
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genes, such as cytochrome P1-450 (Androutsopoulos et al., 2009).  Interestingly, 
Ahr/Arnt has been shown to regulate the expression of genes in conjunction with Sp1, 
providing a possible explanation for the increase in promoter activity observed between 
the 0.5k to 1k plasmid (Figure 4.6b) (Wang et al., 1999).   
 
The decrease in promoter activity seen using the 2k plasmid compared to 1k plasmid in 
Ecad-/- ES cells demonstrates the limited capacity of the ECR browser for predicting 
regulatory regions within genomes, as no conserved transcription factor binding sites are 
noted within this region.  However, an alternative explanation is that the 2k plasmid may 
regulate transcription via physical repression by inhibiting binding of positive regulatory 
factors to CR1 and/or CR2.  The similarity in promoter activity displayed by 0.5k and 2k 
plasmids suggests that physical disruption within CR2 is most likely to be the case 
(Figure 4.6c). 
 
The repression of Jam2 transcript expression in Ecad-/- ES  cells (and slight decrease in 
promoter activity in WT D3 cells) can be located between -2023 and -4629bp in the Jam2 
promoter.  ECR browser and literature searches identify 2 potential regulatory elements 
within this region of the promoter; a CACCC box which has been shown to bind Sp1 and 
CACD transcription factors (Broggini et al., 1989; Hartzog and Myers, 1993; Horie and 
Takeishi, 1997), and a Zeb1 binding site ((Sekido et al., 1997), referred to as DeltaEF1). 
Interestingly the binding of factors to CACCC boxes has been found to regulate the 
activity of regulatory elements within promoters (Hartzog and Myers, 1993).  This 
suggests a possible role for the CACCC box in negatively regulating factors downstream 
within the Jam2 promoter (WT D3 Figure 4.5d (i); Ecad-/- , Figure 4.6d (i)), and 
therefore it is the absence of this region from the 0.5k, 1k and 2k promoter-luciferase 
plasmid constructs that may explain the positive promoter activity of the smaller 
promoter lengths (0.5k, 1k, and 2k plasmids) seen in Ecad-/- ES cells.  An alternative 
explanation for the reduction in promoter activity of the 5k plasmid is provided by the 
second potential regulatory element identified in this region of the Jam2 promoter, Zeb1 
(WT D3 Figure 4.5d (ii) , Ecad-/-, Figure 4.6d (ii)).  Zeb1 is a zinc-finger transcription 
factor known to directly repress the expression of several genes, including E-cadherin 
(Vandewalle et al., 2009), and its expression has been found to be associated with cells 
passing through an EMT event (Gregory et al., 2008).  Furthermore, Zeb1 expression has 
been found to be involved in the Tgf-β signalling pathway, thus providing a possible link 
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between the down-regulation of Jam2 expression and the reliance on Activin/Nodal 
signalling for maintenance of pluripotency demonstrated by Ecad-/- ES cells (Postigo, 
2003). 
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Figure 4.6 Predicted mechanisms of Jam2 promoter regulation in Ecad-/- ES cells.  Depiction of 
predicted transcription factor binding in Ecad-/- ES cells to (a) 0.5k plasmid, Sp-1 binds to CR-1 
to positively regulate Jam2 expression, (b) 1k plasmid, additional binding of either Ahr/Arnt 
(Ahr) or unknown regulatory element (?) in CR-2 increases Jam2 expression, (c) 2k plasmid, 
physical inhibition of Ahr/Arnt or unknown regulatory factor to CR-2 by -1063 to -2022 region of 
Jam2 promoter resulting in reduction in promoter activity, and (d) (i) 5k plasmid, binding of an 
unknown regulatory factor CBE to CACCC box in CR-4 facilitates binding of unknown negative 
regulatory factor (??) within promoter e.g. within CR-2, or (ii) Zeb1 binding within CR-4 
negatively regulates Jam2 expression.  Relative promoter activity as determined by the luciferase 
assay in Figure 3b is shown. Abbreviations: CBE, CACCC box binding element; ?, unknown 
positive factor binding within CR2; ??, unknown negative factor binding within CR2.  
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The function of Jam2 in stem cells is currently unknown and we hoped that the unveiling 
of the factors involved in Jam2 regulation in ES cells would help clarify its role.  
Unfortunately, our findings provide no clear indication as to the function of Jam2 in ES 
cells as Sp1 is a particularly ubiquitous transcription factor, which may be functioning as 
part of the minimal promoter of Jam2.  However, our results indicate that the regulation 
of Jam2 in mouse ES cells (both WT and Ecad-/-) is different to that of MSC-1 mouse 
sertoli cells regarding the -460 to -1062 region of the Jam2 promoter, as our results show 
unchanged or increased promoter activity in WT D3 and Ecad-/- ES cells respectively, 
whereas a decrease in promoter activity was reported in the MSC-1 cell line (Wang and 
Lui, 2009). 
 
The results of this study confirm that the absence of E-cadherin from mouse ES cells 
results in alterations in the regulation and expression of downstream targets, such as Jam2.  
Our findings imply both the involvement of transcription factors known to be involved in 
E-cadherin-linked processes, Zeb1 and E-boxes, and factors with no previously reported 
link to E-cadherin, CACCC box and Ahr/Arnt.  Further investigations into both these 
groups would be of great value, as they would have the potential to greatly expand our 
understanding of the signalling and regulatory events that take place following loss of E-
cadherin from ES cells.  
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5.1 Abstract 
Jam2 is a cell-surface protein expressed in a variety of cell types including ES cells. In 
mouse ES cells, Jam2 transcript expression is positively regulated by E-cadherin, a cell-
surface adhesion protein essential for maintaining epithelial integrity. Loss of E-cadherin 
protein is associated with EMT-events in embryo development, tumour cell metastasis 
and spontaneous differentiation of ES cells. In this study we assessed the ability of Jam2-
/- mouse ES cells to undergo an EMT event during spontaneous differentiation. Whilst 
undifferentiated Jam2-/- ES cells exhibit increased transcript expression of the E-cadherin 
repressors Slug, Snail and Sip1, cell surface E-cadherin expression was unaffected. 
Furthermore, the EMT event in differentiating Jam2-/- ES cells was indistinguishable to 
that of the parental cell line E14, with both cell lines exhibiting an E- to N-cadherin 
switch, increased gelatinase activity and motility. In addition, spontaneous differentiation 
of Jam2-/- ES cells resulted in expression of marker transcripts associated with the three 
primary germ layers. We conclude that whilst Jam2 may function in ES cells to 
negatively regulate Slug, Snail and Sip1 transcript expression it is unlikely to play a role 
in EMT events or lineage determination of differentiating ES cells.  
 
 
5.2 Introduction 
EMT is an essential process for mesoderm and neural crest formation during embryo 
development.  Cells of the epiblast undergoing EMT lose their epithelial morphology 
acquiring fibroblast-like properties including increased motility, decreased adhesion, 
alterations in cell polarity, and a less structured cell morphology providing the cells with 
the ability to migrate through the primitive streak as it forms (Viebahn, 1995).  These 
changes correspond with down-regulation of E-cadherin and the up-regulation of matrix 
degrading proteases and the transcription factors Snail, Slug, E12/E47, Sip1 and Twist 
(Bolos et al., 2003; Cano et al., 2000; Chen and Behringer, 1995; Perez-Moreno et al., 
2001; Vandewalle et al., 2005).  E-cadherin down-regulation is a defining step during 
EMT and is associated with up-regulation of less adhesive cadherins, such as N-cadherin.  
Loss of E-cadherin is also associated with tumour cell metastasis, in what has been 
suggested to be an EMT-like event, where cancer cells lose their epithelial morphology 
and become less structured, more motile and invasive (Thiery, 2002). 
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E-cadherin is a cell-surface glycoprotein involved in calcium-dependant cell adhesion 
(Overduin et al., 1995). It is essential during embryo development as Ecad-/- embryos fail 
to form a trophectodermal epithelium and die at implantation (Larue et al., 1994).  
Recently published data has shown that Ecad-/- ES cells display Lif-independent self-
renewal, instead utilising Activin and Nodal signalling pathways for maintenance of 
pluripotency (Soncin et al., 2009).  Microarray analysis of Ecad-/- ES cells has revealed 
significant alteration in the expression of over 2000 genes, including 235-fold down-
regulation of Jam2 transcripts (Soncin, manuscript in preparation).  Recent work within 
our lab has demonstrated that E-cadherin positively regulates Jam2 transcript expression 
in mouse ES cells (Ritson, unpublished).  Jam2 is a cell-surface protein belonging to the 
Ig superfamily which also includes Jam1, Jam3, Esam and Car (Ebnet et al., 2004).  Jam2 
expression is found in undifferentiated embryonic, neural and haematopoietic stem cells, 
although its function in these cells is unknown (Sakaguchi et al., 2006).  Jam2 expression 
has also been detected at the intercellular boundaries of endothelial cells, in and around 
tumours and sites of inflammation, the blood-testis barrier between sertoli cells, and in 
the gliomas and dendritic cells of adult tissues (Cunningham et al., 2000; Gliki et al., 
2004; Liang et al., 2002; Palmeri et al., 2000; Tenan et al., 2009; Wang and Lui, 2009; 
Zimmerli et al., 2009). To date the only demonstrated function for Jam2 in differentiated 
cell types is in neutrophil extravasation, where the use of a Jam2 blocking antibody 
reduced monocyte numbers in the extravascular compartment at sites of inflammation 
(Bradfield et al., 2007; Ludwig et al., 2009). 
 
ES cells are pluripotent cells capable of indefinite self-renewal (Smith, 2001).  Recently 
published data has shown that mouse and human ES cells undergoing spontaneous 
differentiation exhibit an EMT-like event, displaying many hallmarks of EMT such as an 
E- to N-cadherin switch, up-regulation of EMT-associated transcription factors and 
matrix metalloproteases (Eastham et al., 2007; Spencer et al., 2007). In the present study 
we have investigated the role of Jam2 during EMT using a Jam2-/- mouse ES cell line.  
We demonstrate that Jam2-/- ES cells undergo an EMT-event that is similar to WT ES 
cells, suggesting that absence of this protein in ES cells does not alter the EMT process.  
In addition we show that although E-cadherin repressor transcripts are present in 
undifferentiated Jam2-/- ES cells, that E-cadherin expression is unaffected.  Furthermore, 
we show that despite the expression of Jam2 in several cells and tissues originating from 
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the mesoderm, the absence of Jam2 does not affect the expression of mesoderm marker 
transcripts during spontaneous differentiation of mouse ES cells. 
 
5.3 Materials and Methods 
Mouse ES Cell Culture 
E14tg2a (E14, Jam2-/- parental cell line) and Jam2-/- (a kind donation from A. Okuda, 
Japan) mouse ES cell lines were cultured in gelatin-treated 6-well plates (Greiner Bio-
One, Gloucestershire, UK) with Knock-out DMEM supplemented with 10% v/v FBS, 
2mM L-glutamine, 50μM 2-mercaptoethanol (all from Invitrogen, Paisley, UK), 1:100 
non-essential amino acids (PAA, Somerset, UK), and 1000 U/ml Lif (ESGRO, Millipore, 
Livingston, UK) at 37oC/5% CO2.  Cells were passaged every 2 days prior to confluence 
by washing twice with 2ml PBS (PAA, Somerset, UK) and incubating with 1.5ml trypsin 
(PAA, Somerset, UK).  Gelatin-treated plates were prepared by adding 0.1% w/v gelatin 
(Sigma-Aldrich, Dorset, UK) per well for a minimum of 24 hours.  The gelatin was 
removed and the wells allowed to air dry prior to use.  To differentiate the cells, FBS was 
replaced with 10% v/v KSR (Invitrogen, Paisley, UK) and cells were grown in the 
absence of Lif, a method of differentiation previously shown to induce EMT-like events 
in mouse ES cells (Spencer et al., 2007).  The media was replaced every 2 days.  The 
differentiation assay was performed three times and the results presented represent all 
three repeats. 
 
Fluorescent Flow Cytometry Analysis 
Cells were harvested from the 6-well plates using cell dissociation buffer (PAA, 
Somerset, UK), transferred to a 1.5ml eppendorf, washed once with 900μl PBS and 
incubated with primary antibody (or control) diluted 1:100 (unless otherwise stated) in 
FACS buffer (0.2% BSA w/v, 0.1% sodium azide w/v in PBS) for 30 min on ice.  
Primary antibodies were as follows: rat anti-mouse E-cadherin (DECMA-1, 1:500 
dilution, Sigma-Aldrich Dorset, UK); anti-mouse SSEA1 (Santa Cruz, California, USA); 
rat anti-mouse Jam2 (RnD Systems, Oxfordshire, UK); and rabbit anti-mouse N-cadherin 
(Santa Cruz, California, USA). Isotype control antibodies were used at the same 
concentration as primary antibodies and were as follows:  goat IgG (Abcam, Cambridge, 
UK), rabbit IgG (Santa Cruz, California, USA), rat IgG (RnD Systems, Oxfordshire, UK), 
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and mouse IgM (Santa Cruz, California, USA). Cells were washed in 900μl PBS and 
incubated with the appropriate PE- or FITC-conjugated secondary antibody (all Santa 
Cruz, California, USA, 1:200) for 30 min on ice.  Cells were washed as described above, 
resuspended in 300μl 1% w/v PFA and cell fluorescence analysed using a FACScalibur 
(BD Biosciences, Oxford, UK).  Viable cells were gated using forward and side scatter 
and all data represents cells from this population.  All plots are representative of three 
independent analyses. 
 
RT-PCR Analysis 
Total RNA was extracted from cells using TRI reagent (Sigma-Aldrich, Dorset, UK), 
treated with DNase (Promega, Southampton, UK) and phenol/chloroform extracted (as 
described previously by (Ward et al., 2003)).  cDNA was synthesised using 1μg RNA in 
20μl nuclease free water (Applied Biosystems, Warrington, UK), 5μl 100mM DTT, 
1.25μg oligoDT, 40u RNAsin, 5μl RT enzyme buffer, 10u AMV reverse transcriptase 
and 5μl 250μM dNTP (all Promega, Southampton, UK) at 42oC for 1 hour.  For the PCR, 
1μl cDNA, 1μl 50pmol/μl forward and reverse primers (Invitrogen, Paisley, UK) and 8μl 
Reddymix (Abgene, Epsom, UK) were combined and run at 94oC for 5 min, then 35 
cycles of 94oC for 30 sec, 60oC for 40 sec and 72oC for 45 sec, followed by 72oC for 7 
min, using a 2720 Thermal Cycler (Applied Biosystems, California, USA).  Samples 
were visualised on 2% w/v agarose gel (Melford, Suffolk, UK) containing 8% SafeView 
Nucleic Acid Stain (NBS Biologicals, Huntingdon, UK) using a Uvi Pro Platinum Gel 
Doc (UVItec, Cambridge, UK).  All experiments were repeated in triplicate and results 
presented are representative of all.  Details of all primer sequences, annealing 
temperatures and product sizes are shown in Table 5.1. 
 
Zymogram Analysis 
WT E14 and Jam2-/- ES cells were cultured in KSR media without Lif for 4, 6 and 8 
days.  25μl of culture medium was removed from the cells, mixed with 25μl Zymogram 
Sample Buffer and separated on a precast 10% gelatin gel at 125 V for 90 minutes.  The 
gel was incubated with Zymogram Renaturation buffer for 1 hour at room temperature, 
then developed overnight in Zymogram Development Buffer.  The gel was stained for 1 
hour using Coomassie R-250, and briefly washed with destaining solution 
(Methanol:Acetic acid:Water, 50:10:40).  Images were captured using a Fluorchem 5500 
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light cabinet (Alpha Innotech, California, USA).    The experiment was performed three 
times and the results shown are representative of all.  All reagents were from Bio-Rad, 
Hertfordshire, UK. 
 
 
Table 5.1  List of primer sequences used in this study. 
 
Name Forward Reverse Size oC 
E-cadherin GAGGTCTACACCTTCCCGGT CGAAAAGAAGGCTGTCCTTG 108 60 
N-cadherin CCCAAGTCCAACATTTCCATCC AAAGCCTCCAGCAAGCACG 781 60 
Jam2 CCTGGACTATCATAAGGCAAAT CATCTTAAACCAGATGTACTCCG 457 60 
β-tubulin TCACTGTGCCTGAACTTACC GGAACATAGCCGTAAACTGC 317 60 
Snail CAGCTGGCCAGGCTCTCGGT GCGAGGGCCTCCGGAGCA 381 60 
Slug CACTCCACTCTCCTTTACC CAGACTCCTCATGTTTATGC 597 60 
Sip1 CGTTCAAACACAAACACC CCAGTCTCTTCCTCATCC 454 60 
E12/E47 GAGGAGTGGCCTCACAAGTGG GTGCGTGGGACCTTCAGGT 232 60 
Twist AATTCACAAGAATCAGGGCGTGGG TCTATCAGAATGCAGAGGTGTGGG 117 60 
Mmp-2 TGGGTGGAAATTCAGAAGGTGC ATCTACTTGCTGGACATCAGGGGG  695 60 
Mmp-9 TGCGACCACATCGAACTTCG CCAGAGAAGAAGAAAACCCTCTTGG 687 60 
Timp1 CTTGCATCTCTGGCATCTGG  AAGTAGACAGTGTTCAGGC 654 60 
Timp2 GAGATCAAGCAGATAAAGATG  GACCCAGTCCATCCAGAGGC 321 60 
Nanog AGGGTCTGCTACTGAGATGCTCTG CAACCACTGGTTTTTCTGCCACCG 364 60 
Oct-3/4 AGAAGGAGCTAGAACAGTTTGC CGGTTACAGAACCATACTCG 415 60 
Fgf5 GGCAGAAGTAGCGCGACGTT TCCGGTTGCTCGGACTGCTT 515 55 
Eno2 CCAAGTCACCCAGAACACCT AAACACCCCAACACACCAAT 236 60 
Musashi ATGGTGGAATGCAAGAAAGC TAGGTGTAACCAGGGGCAAG 191 60 
β3-tubulin TGAGGCCTCCTCTCACAAGT CGCACGACATCTAGGACTGA 207 60 
Sox2 CACAACTCGGAGATCAGCAA CTCCGGGAAGCGTGTACTTA 541 60 
Afp GAAGAATTGCAGAAACACATCG AGCCAAAAGGCTCACACC 699 55 
Gata6 GCCAACTGTCACACCA TGTTACCGGAGCAAGCTTTT 190 60 
Transthyretin GGTATTTGTGTCTGAAGCTGG GGTTGCTGACGACAGCCGTGG 392 60 
Goosecoid GAAGCCCTGGAGAACCTCTT CCGAGTCCAAATCGCTTTTA 247 60 
Brachyury CATTACACACCACTGACG GATATAGGACCCTACCTAGC 472 60 
Myh6 CTGCTGGAGAGGTTATTCCTCG GGAAGAGTGAGCGGCGCATCAAGG 312 60 
Runx1 CCAGCAAGCTGAGGAGCGGCG CGGATTTGTAAAGACGGTGA 347 55 
CD133 GAAAAGTTGCTCTGCGAACC TCTCAAGCTGAAAAGCAGCA 196 60 
Myl2 TGTGGGTCACCTGAGGCTGTGGTTCAG GAAGGCTGACTATGTGTCCGGGAGATGC 298 60 
Myh7 TGCAAAGGCTCCAGGTCTGAGGGC GCCAACACCAACCTGTCCAAGTTC 491 60 
 
 
Cell Motility Assay 
Transwells (5μm pore size using a 24-well plate, Corning Life Sciences, Amsterdam) 
were immersed in 0.1% w/v gelatin overnight and rinsed in PBS.  Transwells were 
blocked in FBS-containing medium for 30 minutes and washed in PBS.  1x105 ES cells 
were added to each transwell in 100μl KSR media, which was then placed in a well 
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containing 500μl KSR media and left overnight at 37oC/5% CO2.  The transwell was 
removed and the well of the plate was washed twice with PBS before staining with 
crystal violet.  The number of cells on the bottom of the plate were counted.  The assay 
was perfomed three times and p values were calculated using unpaired T-test. 
 
5.4 Results 
 
Jam2-/- ES Cell Differentiation is associated with an E- to N-cadherin switch 
comparable to WT E14 cells. 
It has recently been shown that mouse and human ES cells undergoing spontaneous 
differentiation display several characteristics associated with cells passing through an 
EMT event, including an E- to N-cadherin switch.  To determine whether Jam2 
expression in mouse ES cells is required for this switch to take place WT E14 and Jam2-
/- ES cells were cultured for 12 days without Lif in serum-replacement media to induce 
spontaneous differentiation.  Cell surface protein expression of E-cadherin and N-
cadherin was assessed by fluorescent flow cytometry and E-cadherin, N-cadherin and 
Jam2 transcript expression was assessed by RT-PCR every 3 days.   
 
Undifferentiated WT E14 ES cells express E-cadherin and Jam2 at the cell surface, 
whereas N-cadherin expression is almost absent (Day 0, Figure 5.1a (i)).  As cells 
undergo spontaneous differentiation cell-surface E-cadherin expression decreases, and is 
almost entirely absent by day 12 (E-cad, Figure 5.1a (i)).  Cell-surface N-cadherin 
expression increases as the cells differentiate, reaching maximum expression at day 6, 
then steadily decreasing to background levels by day 12 (N-cad, Figure 5.1a (i)).  Jam2 
protein expression is rapidly lost from the cell surface as cells undergo differentiation, 
however a slight increase in cell-surface expression is seen at day 9 most likely reflecting 
the Jam2-expressing cell types resulting from the lineage specification of the 
differentiating cells (Jam2, Figure 5.1a (i)).  Dual staining for E-cadherin and N-cadherin 
at day 6 by fluorescent flow cytometry confirms the near exclusive expression of these 
proteins at the cell surface and verifies that an E- to N-cadherin switch has occurred 
(Figure 5.1a (ii)).  RT-PCR analysis revealed that E-cadherin transcript levels remain 
relatively constant as the cells differentiate despite alterations in cell surface protein 
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observed by fluorescent flow cytometry analysis (E-cad, Figure 5.1a (iii)).  N-cadherin 
transcript expression mirrors that of the cell-surface protein, with transcripts present at 
low levels at day 0 and increase markedly following differentiation, reaching a peak at 
day 6, then expression appears to decline at days 9 and 12 (N-cad, Figure 5.1a (iii)).  
Jam2 transcript expression also appears to correlate with the expression of Jam2 at the 
cell surface, with expression highest at day 0, decreasing at day 3, then increasing slightly 
at day 6 and 9 (Jam2, Figure 5.1a (iii)).   
 
Jam2-/- ES cells were cultured in parallel under the same conditions as WT E14 ES cells, 
and were assessed for the ability to undergo an E- to N-cadherin switch.  Analysis of cell-
surface E-cadherin expression by fluorescent flow cytometry shows that as the Jam2-/- 
ES cells differentiate, E-cadherin expression decreases at a similar rate to that observed in 
WT E14 cells, reaching background levels at day 12 (E-cad, Figure 5.1b (i)).  Assessment 
of cell-surface N-cadherin expression by fluorescent flow cytometry revealed near 
absence of this protein at day 0 and a subsequent increase in expression as the cells 
differentiated, reaching maximum expression at day 9, before decreasing slightly by day 
12 (N-cad, Figure 5.1b (i)).  This contrasts slightly with WT E14 ES cells where cell-
surface N-cadherin expression was almost absent by day 12 in these cells (6.7% and 
59.5%, WT E14 and Jam2-/- respectively).  Dual staining of Jam2-/- ES cells for E- and 
N-cadherin at day 6 by fluorescent flow cytometry confirmed an E- to N-cadherin switch, 
as cells were mostly E- or N-cadherin positive (Figure 5.1b (ii)).  RT-PCR analysis 
confirmed the absence of Jam2 transcripts from Jam2-/- ES cells (Jam2, Figure 5.1b (iii)).  
E-cadherin transcript expression remained at similar levels throughout the time period, as 
was observed in WT E14 cells (E-cad, Figure 5.1b (iii)).  N-cadherin transcript 
expression closely mirrors cell-surface protein expression, with transcript expression 
increased upon differentiation of the Jam2-/- ES cells and remaining elevated across the 
remaining time points (N-cad, Figure 5.1b (iii)). 
 
These results indicate that the absence of Jam2 from mouse ES cells does not affect 
spatio-temporal expression of E- or N-cadherin transcripts and proteins following 
spontaneous differentiation.  
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Figure 5.1  Jam2-/- ES cell differentiation is associated with an E- to N-cadherin switch 
comparable to WT E14 cells. (a) WT E14 ES cells were cultured in synthetic replacement media 
in the absence of Lif for 12 days to induce spontaneous differentiation. (i) Cell surface E-
cadherin, N-cadherin and Jam2 were assessed at day 0, 3, 6, 9 and 12 by fluorescent flow 
cytometry. Percentage value represents positive cell population.  E-cadherin/N-cadherin/Jam2, 
green profile; control, purple profile.  (ii) Fluorescent flow cytometry dual staining for E-cadherin 
(PE) and N-cadherin (FITC) on WT E14 ES cells at day 6 of differentiation.  Percentage of cells 
within each quadrant is shown.  (iii) RT-PCR analysis of E-cadherin (E-cad), N-cadherin (N-cad), 
Jam2, and β-tubulin (β-tub, control) transcript expression at day 0, 3, 6, 9 and 12.  (b) Jam2-/- ES 
cells were cultured under the same conditions as described in (a) to induce spontaneous 
differentiation.  (i) Cell surface E-cadherin and N-cadherin were assessed at day 0, 3, 6, 9 and 12 
by fluorescent flow cytometry.  Percentage value represents positive cell population.  E-
cadherin/N-cadherin, green profile; control, purple profile.  (ii) Fluorescent flow cytometry dual 
staining for E-cadherin (PE) and N-cadherin (FITC) on Jam2-/- ES cells at day 6 of 
differentiation.  Percentage of cells within each quadrant shown.  (iii) RT-PCR analysis of E-
cadherin (E-cad), N-cadherin (N-cad), Jam2, and β-tubulin (β-tub, control) transcript expression 
at day 0, 3, 6, 9 and 12. 
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Absence of Jam2 from mouse ES cells undergoing spontaneous differentiation does 
not affect cellular motility or the up-regulation of E-cadherin repressor transcripts 
and EMT-associated molecules. 
In addition to an E- to N-cadherin switch,  ES cells undergoing an EMT event typically 
up-regulate expression of the E-cadherin repressor transcription factors Snail, Slug, and 
Sip1.  To determine whether absence of Jam2 from mouse ES cells exerts any effect on 
the expression of these molecules, transcript expression of Snail, Slug, Sip1, as well as 
E12/E47 and Twist, were assessed by RT-PCR at 3-day intervals in spontaneously 
differentiating WT E14 and Jam2-/- ES cells.  In undifferentiated WT E14 ES cells Snail, 
Slug and Sip1 transcripts were not detected, whereas E12/E47 and Twist transcripts were 
detected (WT E14 day 0, Figure 5.2a).  By day 3 of differentiation transcripts for Snail, 
Slug and Sip1 were detected. Snail transcript expression continued to increase over days 
6, 9 and 12, Slug transcript expression peaked at day 6 and levels remained relatively 
constant at days 9 and 12, whereas Sip1 transcripts remained elevated over days 3, 6 and 
9, and decreased slightly by day 12 (Snail, Slug and Sip1, Figure 5.2a).  E12/E47 and 
Twist transcript expression remained relatively unaltered at all time points assessed 
(E12/E47 and Twist, Figure 5.2a).  In Jam2-/- ES cells transcripts for all molecules were 
detected at day 0, with expression of Snail, Slug and Sip1 increasing following induction 
of differentiation, whereas E12/E47 and Twist transcript expression remained relatively 
unaltered (Jam2-/-, Figure 5.2a).   
 
To determine if the absence of Jam2 from mouse ES cells affects the up-regulation of 
gelatinases during EMT, spontaneously differentiating WT E14 and Jam2-/- ES cells 
were assessed for Tissue inhibitor of metalloproteinase (Timp) and Mmp transcripts and 
proteolytic activity.  RT-PCR revealed no alteration in the pattern of Mmp-2, Mmp-9, 
Timp-1 or Timp-2 transcript expression at any of the time points (day 0, 3, 6, 9 and 12) in 
Jam2-/- ES cells compared to WT E14 (Figure 5.2b (i)).  Furthermore, gelatin-zymogram 
analysis revealed that Jam2-/- ES cells display similar protease activity to WT E14 ES 
cells, as Mmp-2 activity was detected in the media from both cell lines (Figure 5.2b (ii)). 
Cellular motility was assessed in differentiating WT E14 and Jam2-/- ES cells at day 4, 6 
and 8 following induction of differentiation.  Cellular motility of both WT E14 and Jam2-
/- ES cells increased as the cells differentiated (Figure 5.2c) in keeping with the up-
regulation of cell-surface N-cadherin seen at similar time points (Figure 5.1a (i), Ncad).  
No significant difference in motility was seen between WT E14 and Jam2-/- ES cells at 
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any of the time points (p>0.05) indicating that absence of Jam2 from ES cells does not 
affect the increase in cell motility seen as cells differentiate. 
 
These results further suggest that the absence of Jam2 in ES cells does not affect the 
EMT event following spontaneous differentiation of ES cells, although one function of 
Jam2 in ES cells may be to negatively regulate the E-cadherin repressors Snail, Slug and 
Sip1. 
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Figure 5.2  Absence of Jam2 in mouse ES cells does not affect the up-regulation of E-cadherin 
repressors or EMT-associated molecules during spontaneous differentiation. (a) RT-PCR analysis 
of E-cadherin repressors Snail, Slug, Sip1, E12/E47, Twist, and β-tubulin (β-tub, control) 
transcript expression in WT E14 and Jam2-/- ES cells at day 0, 3, 6, 9, and 12 following induction 
of differentiation.  (b) (i) RT-PCR analysis of Mmp-2, Mmp-9, Timp-1, Timp-2 and β-tubulin (β-
tub, control) transcript expression in spontaneously differentiating WT E14 and Jam2-/- ES cells.  
(ii) Gelatin zymogram analysis for Mmp activity in spontaneously differentiating WT E14 and 
Jam2-/- ES cells at days 4, 6, and 8.  (c) Cellular motility of WT E14 and Jam2-/- ES cells at day 
4, 6, and 8 following induction of differentiation was assessed using 5μm pore size transwell 
plates.  Data represents percentage of 1x105 cells plated that migrated through the pores after 24 
hours, error bars show +/-1SD.  p>0.05 for all time points. 
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Pluripotency and differentiation marker expression is comparable in WT E14 and 
Jam2-/- ES cells undergoing spontaneous differentiation. 
As ES cells differentiate into cells of the 3 primary germ layers, endoderm, mesoderm, 
and ectoderm, pluripotency marker expression is down-regulated and up-regulation of 
lineage specific markers is observed (Smith, 2001).  To determine whether Jam2 is 
required for the ability of ES cells to differentiate into cells representative of the 3 germ 
layers, spontaneously differentiating WT E14 and Jam2-/- ES cells were assessed for 
pluripotency and lineage marker expression over 12 days.  Analysis of cell-surface 
expression of the pluripotency marker SSEA-1 at day 0, 6 and 12 by fluorescent flow 
cytometry revealed that undifferentiated WT E14 and Jam2-/- ES cells express SSEA-1 
and that expression is markedly decreased in both cell lines following differentiation 
(Figure 5.3a).  RT-PCR analysis revealed no difference in Oct-3/4 or Nanog transcript 
expression between undifferentiated or differentiating WT E14 and Jam2-/- ES cells 
(Figure 5.3b).  The presence of Oct-3/4 and Nanog transcripts in the KSR-Lif cell 
population may be explained by the use of KSR-Lif rather than other methods of 
inducing ES cell differentiation, such as FBS-Lif or EB formation.  KSR-Lif may be 
selecting for Oct-3/4 and Nanog positive cells as KSR is also routinely used in 
conjunction with Lif to maintain ES cell pluripotency.  However, the growth of ES cells 
in KSR-Lif provides a method of ES cell differentiation that induces the cells to pass 
through an EMT-like event and therefore allows for the study of E-cadherin down-
regulation in relation to this cellular event. 
Ectoderm, endoderm, and mesoderm transcript expression was assessed by RT-PCR 
using a panel of markers for each lineage: ectoderm- Ffg5 (primitive ectoderm), Musashi, 
β3-tubulin, Eno2 and Sox2; endoderm-Afp, Gata6, Ttr, and Goosecoid; mesoderm-
Brachyury, Myh6, Runx1, CD133, Myl2, and Myh7 (Ectoderm, Figure 5.4a; Endoderm, 
Figure 5.4b, Mesoderm, Figure 5.4c).  Our results show that absence of Jam2 in mouse 
ES cells does not significantly alter the spatio-temporal expression of transcripts of any 
of the lineage markers assessed. 
 
 
 
 
 
 
Chapter 5  The Role of Jam2 During EMT in Mouse ES Cells 142
 
 
SSEA1 Probe
E14
Jam2-/-
Day 0              Day 6            Day 12                     
Nanog
Oct-3/4
β-tub
(a)
(b)
WT E14 JAM2-/-
Day   0     3      6     9     12     0      3     6      9    12
66.7% 54.5% 33.7%
74.6% 39.7% 31.9%
 
 
 
 
 
 
 
 
 
 
Figure 5.3  Pluripotency marker expression is comparable in WT E14 and Jam2-/- ES cells 
undergoing spontaneous differentiation.  (a)  Cell surface analysis of SSEA-1 expression by 
fluorescent flow cytometry on WT E14 and Jam2-/- ES cells at day 0, 6 and 12 following 
induction of spontaneous differentiation.  Percentage value represents positive cell population.  
SSEA-1, green profile; control, purple profile.  (b) RT-PCR analysis of pluripotency markers 
Oct-3/4 and Nanog, and β-tubulin (β-tub, control) in WT E14 and Jam2-/- ES cells at day 0, 3, 6, 
9 and 12 following induction of spontaneous differentiation.   
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Figure 5.4  Differentiation marker expression is comparable in WT E14 and Jam2-/- ES cells 
undergoing spontaneous differentiation. RT-PCR analysis of (a) ectoderm, (b) endoderm, and (c) 
mesoderm marker transcript expression in spontaneously differentiating WT E14 and Jam2-/- ES 
cells at day 0, 3, 6, 9, and 12.  Abbreviations: Fgf5, fibroblast growth factor 5; Msh, Musashi; 
β3tub, β3-tubulin; Eno2, neural-specific enolase 2; Afp, α-fetoprotein; Ttr, transthyretin; Gsc, 
Goosecoid; Bchy, brachyury; Myh6, myosin heavy chain 6; Myl2, myosin regulatory light chain 
2; Myh7, myosin heavy chain 7; β-tub, β-tubulin (control). 
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5.5 Discussion 
EMT events are crucial for embryonic development and are also associated with 
metastasis of tumour cells.  The study of the cellular events that take place during EMT is 
therefore of value to both developmental biology and cancer research.  Characteristic 
events that take place during EMT include an E- to N-cadherin switch, the up-regulation 
of the E-cadherin repressor transcription factors Snail, Slug, Sip1, E12/E47 and Twist, 
and the up-regulation of pro-migratory proteases (Mmps).  E-cadherin is a cell adhesion 
protein that also plays an important role in cell-signalling and in the expression of other 
cell surface proteins, including Jam2 (Soncin et al., 2009)(Ritson, unpublished).  Given 
the recent discovery that E-cadherin expression positively regulates Jam2 transcripts 
(Chapter 3) and protein, and the high expression of Jam2 in undifferentiated WT ES cells, 
the aim of this study was to determine whether absence of Jam2 expression in mouse ES 
cells would impair the ability of WT ES cells to undergo EMT. Our results show that the 
down-regulation of E-cadherin during EMT is unaffected by absence of Jam2, and that 
the reciprocal up-regulation and cell-surface localisation of N-cadherin is also unaffected.  
In addition, we show that the transcriptional up-regulation of EMT-associated 
transcription factors, Mmp activity and cellular motility remains unaltered in the absence 
of Jam2.  Whilst transcript expression of Snail, Slug and Sip1 were detected in 
undifferentiated Jam2-/- ES cells, suggesting that this protein may negatively regulate 
these transcripts, expression of E-cadherin in these cells demonstrates that these repressor 
molecules are unlikely to be functional in these cells.  Furthermore, we confirm that 
absence of Jam2 from mouse ES cells does not alter the transcriptional up-regulation of 
markers of the 3 primary germ layers. 
 
Recent data has shown that E-cadherin positively regulates the expression of Jam2 in 
undifferentiated mouse ES cells.  To date this relationship appears to be unidirectional as 
loss of Jam2 from mouse ES cells does not affect the expression or localisation of E-
cadherin (Ritson, unpublished).  Our results further confirm these findings since the 
absence of Jam2 in ES cells also has no effect on the down-regulation of E-cadherin 
during the E- to N-cadherin switch that occurs during ES cell differentiation.  The 
concomitant up-regulation of N-cadherin observed during the E- to N-cadherin switch 
plays an important role during EMT as N-cadherin confers increased motility and 
invasiveness to cells (Hazan et al., 2004; Nieman et al., 1999).  Our results indicate that 
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absence of Jam2 from mouse ES cells does not affect either the transcriptional up-
regulation of N-cadherin or its localisation to the cell-surface during EMT. 
 
Jam2 expression is detected in a variety of cell types and tissues in addition to ES cells, 
including heart tissue, myoblasts, osteoblasts, sperm epithelium, dendritic cells and 
brown adipose tissue (Aurrand-Lions et al., 2001b; Gliki et al., 2004; Zimmerli et al., 
2009)(http://biogps.gnf.org).  Given that several of these cells and tissues are derived 
from mesoderm it is interesting to note that the absence of Jam2 does not appear to alter 
the expression of any of the mesoderm markers during the period of spontaneous 
differentiation studied in this work.  However, our results do confirm those of Sakaguchi 
et al (2006) who detected both cardiac- and skeletal muscle-specific genes when Jam2-/- 
ES cells were differentiated via embryoid body culture (Sakaguchi et al., 2006).  In 
addition, our results also confirm their conclusion that Jam2 is dispensable for 
maintaining ES cell identity, as cell-surface expression of the pluripotency marker SSEA-
1 is reduced in differentiating Jam2-/- ES cells at a rate comparable to that of 
differentiating WT E14 ES cells.  
 
In conclusion, our results suggest that Jam2 is not required for the successful induction of 
EMT during mouse ES cell spontaneous differentiation and further confirm that absence 
of Jam2 is unlikely to affect the development of mesoderm-derived cell lineages. 
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6. Discussion 
 
In this study I have shown that E-cadherin positively regulates the expression of Jam2, 
confirming microarray data that revealed a 235-fold decrease in Jam2 expression in Ecad-
/- compared to WT ES cells (Soncin, unpublished).  This provides further evidence of the 
diversity of function that E-cadherin exerts in ES cell biology, adding to the increasing 
list of molecules that E-cadherin expression affects, including the heparan sulphate 
proteoglycan Perlecan, the pro-migratory protein 5T4, and the tumour-suppressor protein 
TβRII (Soncin, unpublished)(Andl et al., 2006; Spencer et al., 2007).  We show that, 
despite a requirement of the terminal 71 amino acids of the E-cadherin cytoplasmic 
domain for this regulation, the involvement of β-catenin is unlikely, as β-cat-/- ES cells 
do not express Jam2 indicating that the presence of β-catenin is not required for the 
repression of Jam2.  Furthermore treatment of WT ES cells with the Gsk-3β inhibitor 
BIO did not affect Jam2 transcript expression.  The requirement of the terminal 71 amino 
acids of E-cadherin for the positive regulation of Jam2 also suggests the potential 
involvement of one or more of the other molecules associated with this region.  Firstly, 
α-catenin is bound through β-catenin to the cytoplasmic domain of E-cadherin and, 
interestingly, embryos expressing mutated α-catenin protein mimic the Ecad-/- embryo 
phenotype, failing to develop trophectoderm, and ES cells derived from these embryos do 
not form cell-cell adhesions (Torres et al., 1997).  Furthermore, the binding of α-catenin 
to E-cadherin through β-catenin provides E-cadherin with a connection to the actin 
cytoskeleton which has been shown to be essential for E-cadherin based cell adhesions 
(Nagafuchi and Takeichi, 1988).  It has also been shown that homophilic dimerisation of 
E-cadherin results in the recruitment of signalling molecules such as Egfr to the cadherin-
catenin complex (Pece et al., 1999; Perrais et al., 2007).  Therefore, the incorrect 
conformation of the cadherin-catenin-cytoskeleton complex in cells either expressing 
truncated E-cadherin or entirely absent of E-cadherin expression, could increase the 
availability of these molecules for involvement in downstream signalling pathways, 
resulting in the repression of target genes such as Jam2.  Clarification of either of these 
hypotheses could be provided by analysis of Jam2 expression in ES cells lacking α-
catenin, and use of inhibitors targeting associated signalling molecules.  
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The ability of Ecad-/- ES cells to remain pluripotent in the absence of Lif, instead 
utilising Activin/Nodal signalling, is a significant discovery as it shows how critical E-
cadherin is in regulating signalling and growth factor requirements in these cells (Soncin 
et al., 2009).  Identification of the mechanism behind this alteration would be of great 
benefit to, firstly, advance our understanding of the nature of ES cell pluripotency and, 
secondly, to further determine the importance of E-cadherin function in ES cells.  In 
addition, the increased proliferation and motility displayed by Ecad-/- cells is similar to 
the behaviour of tumour cells following the down-regulation of E-cadherin (Yang et al., 
2006).  Therefore, determining the mechanisms underlying these alterations would 
further our understanding of the nature of tumour progression and potentially identify 
novel drug targets for therapy.  Our results show that although Jam2 transcripts are down-
regulated 235-fold in Ecad-/- ES cells the absence of Jam2 in Ecad-/- ES cells is not 
responsible for the altered growth factor response, increased motility, increased 
proliferation, nor the lack of cell-cell adhesions observed in these cells.  However, the 
mechanisms behind these alterations remain the focus of the research undertaken in the 
Ward group. 
 
Currently, the only confirmed role for Jam2 is in the adhesion, rolling, and retention of 
leukocytes within endothelial tissues following extravasation from the circulation 
(Bradfield et al., 2007; Ludwig et al., 2009).  Despite the expression of Jam2 in ES cells 
and other tissues of the body, at present the importance of this expression remains 
unknown.  Our results corroborate those of Sakaguchi et al (2006) who found that Jam2 
is not required for the maintenance of the pluripotent state of mouse ES cells (Sakaguchi 
et al., 2006).  Further to this, we show that Jam2 does not regulate E-cadherin expression 
or localisation in mouse ES cells, and that the behaviours exerted by Ecad-/- ES cells can 
not be attributed to the absence of Jam2 from the cells.  The unaltered motility of Jam2-/- 
compared to WT ES cells was surprising given the role of Jam2 in leukocyte-endothelial 
cell adhesions and transmigration.  It may be, however, that out our method for analysing 
motility was unable to detect any differences between specific cell lineages relevant to 
this behaviour.  Our study of the regulation of Jam2 suggested that Sp1 may be 
responsible for the positive regulation of Jam2 in WT ES cells.  Therefore the expression 
of Jam2 in ES cells may be constitutive until actively repressed, in keeping with the 
discovery that up to 60% of genes are expressed in ES cells, whereas only 10-20% of 
genes are expressed in somatic cells (Eckfeldt et al., 2005).  The combination of high 
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Jam2 expression detected in undifferentiated NS, HS and ES cells, and the immediate 
down-regulation of cell-surface Jam2 seen following differentiation of WT ES cells 
shown in this study, suggests that cell-surface Jam2 may be used as a potential marker of 
ES cell pluripotency (Ivanova et al., 2002; Sakaguchi et al., 2006). 
 
Down-regulation of E-cadherin in epithelial cells results in the acquisition of an invasive 
and motile mesenchymal phenotype (Birchmeier and Behrens, 1994).  Whereas events 
that precede this down-regulation are well-documented, the downstream events are less 
well understood.  The altered regulation of Jam2 promoter activity seen in Ecad-/-ES 
cells compared to WT ES cells provides a novel insight into the alterations in cellular 
signalling that take place following loss of E-cadherin in ES cells, which may also be 
relevant in other cell lines.  Our results implicate several regulatory elements which may 
act in Ecad-/- ES cells but not WT and therefore may be active as a result of down-
regulation of E-cadherin; E-boxes, Ahr/Arnt, Zeb1, and CACCC box.  The next step in 
this investigation is to confirm the involvement of these factors, firstly through use of site 
directed mutagenesis studies, followed by RNAi knockout experiments.  It would be of 
particular interest to examine the potential involvement of the Ahr/Arnt complex as this 
has been shown to be regulated by Estrogen, and Esrrb has been shown by microarray to 
be down-regulated 578-fold in Ecad-/- ES cells compared to WT (Chamberlain and 
Sanders, 1999)(Soncin, unpublished).  The same microarray data reveals a 63-fold down-
regulation in Klf4 transcripts in Ecad-/- compared to WT ES cells, and interestingly Klf4 
has been shown to regulate gene activity by binding to CACCC boxes (Sheilds and Yang, 
1998). 
 
The study of EMT is important to both embryo development and cancer research fields.  
The down-regulation of E-cadherin and gain of invasive and migratory phenotypes seen 
during EMT is the subject of intensive study as E-cadherin expression inversely 
correlates with tumour aggressiveness and patient survival (Tamura et al., 1996).  We 
show that the absence of Jam2 from mouse ES cells does not alter the ability of the cells 
to undergo EMT when induced to spontaneously differentiate, and we hypothesise 
therefore that it is unlikely to be of importance during the EMTs of development or 
metastatic tumour progression.  Alternatively, however, the parameters investigated 
within this study may not represent the potential importance of Jam2 during EMT or, 
alternatively, the EMT model used may be more representative of one specific EMT (e.g. 
 
Chapter 6  General Discussion 150
gastrulation) rather than another (e.g. neural crest formation) and, therefore, the 
importance of Jam2 in this EMT may not have been recognised.  Our results do show, 
however, that differentiating Jam2-/- ES cells appear to retain cell-surface N-cadherin 
expression for longer than differentiating WT ES cells. One possible explanation is that 
once the cells have undergone EMT they begin to go through the reverse process of MET, 
and that absence of Jam2 from cells delays or affects this process.  However, this would 
require further, more in-depth investigation as this technique of ES cell culture has only 
been assessed for modelling reproduction of EMT, not MET.  Unpublished microarray 
data within our lab shows that Jam2 expression is down-regulated 3.9-fold in 
undifferentiated N-cadherin null ES cells compared to WT, so it may be that there exists 
a relationship between Jam2 and other cadherins in addition to E-cadherin.  Alternatively, 
given the predominantly endothelial location of Jam2 expression in adult tissues, it may 
be that absence of Jam2 would affect the ability of cells to undergo an EndMT rather than 
EMT, the study of which would require an alternative method of assessment, as the study 
of EndMT is not provided by the method of assessment used in this study.  
 
In summary, we have discovered that E-cadherin positively regulates Jam2 transcript 
expression, although Jam2 is not essential for WT mouse ES cell self-renewal or 
differentiation nor does loss of Jam2 in Ecad-/- ES cells appear to be relevant to the 
phenotype of these cells.  The consequent investigation into the regulation of Jam2 by E-
cadherin has led to the most insightful part of this work: the alterations in signalling that 
take place following loss of E-cadherin from cells.  E-cadherin is a major player in 
embryo development and cancer metastasis, consequently the more we learn about the 
regulatory functions of E-cadherin the more we uncover potential novel drug targets for 
the treatment, or ideally prevention, of tumour metastasis. 
 
Further Work 
Some of the work presented in this thesis will require additional investigation to enable 
publication in a high impact journal. Due to time constraints, it has not been possible to 
complete this additional work. In the next year I wish to carry out the following 
experiments to enable publication of my thesis results in a high impact journal:  
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1. mRNA and protein expression levels will be assessed for the transcription factors 
Ahr/Arnt and Zeb1 which my studies have shown may be involved in repressing Jam2 
transcript expression in Ecad-/- ES cells (see Chapter 4).  Confirmation of the presence or 
absence of these factors in WT D3 and Ecad-/- ES cells will provide an initial indication 
as to whether these factors could be regulating Jam2 gene expression in these cell lines. 
 
2. Targeted mutagenesis of the transcription factor binding sites of the Jam2 promoter 
identified in Chapter 4 will be assessed. The effect of mutating single base pairs within 
the predicted binding sites of Zeb1, Ahr/Arnt, Sp1 and the CACCC box (all identified by 
ECR browser analysis) will be assessed using promoter-luciferase constructs similar to 
those described in Chapter 4.  This analysis will provide confirmation of the involvement, 
or lack of involvement of, these regions in the regulation of Jam2 gene expression in WT 
and E-cadherin-/- mouse ES cells. 
 
3. Where a transcription factor is identified as a potential regulator of Jam2 transcript 
expression in WT D3 and/or Ecad-/- ES cells, RNA interference will be employed to 
knockdown expression of the transcripts/protein and Jam2 expression assessed in these 
cells to confirm the observation. In addition, band-shift or chromatin 
immunoprecipitation analysis will be performed to confirm the presence/absence of the 
transcription factors on genomic DNA and/or on mutated DNA sequences treated either 
with purified transcription factors or nuclear lysates from WT D3 and Ecad-/- ES cells.  
This analysis should provide final confirmation of the involvement of these transcription 
factors in the regulation of Jam2 in mouse ES cells. 
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RNAi 1 GGATCCCGTTACTGTGACTTCTTGACGGTTTGATATCCGACCGTCAAGAAGTCACAGTAATTTTTTCCAAAAGCTT
BamH1                    Antisense Loop                       Sense           term sig HindIII
RNAi 2 GGATCCCGTTTCCTTCTTTATCCTGGCATTTGATATCCGATGCCAGGATAAAGAAGGAAATTTTTTCCAAAAGCTT
RNAi 3 GGATCCCGTAGTGACTTTAGATGCAGGACTTGATATCCGGTCCTGCATCTAAAGTCACTATTTTTTCCAAAAGCTT 
(a)
(b)
 
 
 
 
 
 
 
Supplementary data 1.  pRNATin-H1.2/Hygro Plasmid map and Jam2 RNAi sequences.   
(a)  Plasmid map depicting location of features on pRNATin-H1.2/Hygro plasmid; inducible 
H1.2 promoter, MCS, CMV promoter, green fluorescent protein marker (cGFP), SV40 promoter, 
Hygromycin resistance gene, origin of replication (pUC ori), Ampicillin resistance gene, and T7 
primer site.  (b) Jam2 hairpin loop RNAi sequences 
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(a)
(b)
 
 
 
 
 
 
 
Supplementary Data 2.  pIRES Puro3 Plasmid Map and multiple cloning site sequence.  
(a) Plasmid map depicting location of features on pIRES Puro3 plasmid; CMV promoter 
(PCMV), MCS, internal ribosome entry site (IRES), Puromycin resistance gene (Puror), the 
polyadenylation signal from SV40, origin of replication (ColE1 ori), and Ampicillin 
resistance gene.  (b) MCS sequence showing restriction enzyme sites. 
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CCTCTGCTTCCACCTCTCAGGGACCTCCTCTGCTCCGCCGCCGGGCGAAGTGCTGGGAGAC
CCAGCCGCCTGTCGCGCTCCTGCAGGGGGACCCTCAGCTAGGCAGCCAGCTGGCGCCCGC
GTAGATGGCGAGGAGCCCCCAAGGCCTCCTGATGCTGCTGCTGCTACACTACTTGATCGTC
GCCCTGGACTATCATAAGGCAAATGGGTTTTCTGCATCAAAAGACCACCGTCAAGAAGTCA
CAGTAATAGAGTTCCAAGAGGCTATTTTGGCTTGTAAAACCCCAAAGAAGACTACCTCCTC
CAGACTGGAGTGGAAGAAGGTGGGACAGGGGGTCTCCTTGGTCTACTACCAACAGGCTCT
CCAAGGTGACTTTAAAGACCGTGCTGAGATGATAGATTTCAATATACGAATCAAAAATGTTA
CAAGAAGTGATGCTGGAGAGTATCGCTGTGAAGTCAGCGCTCCGACTGAGCAAGGCCAGA
ACCTGCAGGAAGATAAAGTCATGCTAGAAGTACTAGTGGCTCCTGCTGTTCCTGCCTGTGA
AGTGCCCACTTCTGTTATGACTGGAAGTGTGGTGGAGCTACGATGCCAGGATAAAGAAGGA
AACCCAGCTCCGGAGTACATCTGGTTTAAAGATGGCACAAGTTTGCTAGGGAATCCAAAAG
GCGGCACACACAACAACAGCTCGTACACAATGAACACGAAGTCTGGAATTCTGCAATTCAA
CATGATTTCCAAGATGGACAGTGGAGAGTATTACTGCGAAGCCCGGAACTCTGTCGGACAC
CGCAGGTGCCCTGGGAAGCGAATGCAAGTAGATGTTCTCAACATAAGCGGCATCATAGCA
ACGGTTGTGGTGGTGGCCTTCGTGATTTCTGTATGTGGCCTTGGCACATGCTATGCTCAGAG
GAAAGGCTACTTTTCAAAAGAAACTTCCTTCCAGAAGGGCAGTCCTGCATCTAAAGTCACT
ACGATGAGCGAAAATGATTTCAAGCACACAAAATCCTTTATAATTTAAAAGAATTCCAGTTTT
GAGCTGCACCAAAACCAGTTGTCACATGTTATTAAAATATTGTAAAACTCTGTGTCTTACACTT
GCAAAGTGATGAAGAAATATGAAAGTGGGAGTTCATCAGAAGTTTTATGATCTCTAACTCACAA
GAAATATTTTAAGCAAAATGTTCTTGCCATCACTAAATTACAACCTGGCATCTTGTGTCTGA
 
 
 
 
 
 
 
Supplementary Data 3.  Jam2 cDNA sequence. Jam2 cDNA sequence encoded by 3-2, 
3-4 and 3-5 plasmids.  Forward and reverse primer sites (underlined), start and stop 
codons (red), untranslated region (grey) and coding sequence (black) are shown.   
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MCS
 
 
 
 
 
 
 
Supplementary Data 4.  pGL3-Basic plasmid map.  Map of pGL3-Basic plasmid 
depicting origin of replication (f1 ori), MCS, luciferase gene (luc+), SV40 poly A signal, 
and Ampicillin resistance gene (Ampr). 
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GATGGGCAGGCATTCAAAAATATGCGCCCATGAGGGCCATTCTTATTCAAACCACCACACATTGTCACTGACTGGAAGACCTTTTACTT
GGCCCCAACTCCTAAAAGTCCACAGCCCCTCCCAGGATCACCCCCTCTCTGGACCAAACGTCTTTGTGAGGACTTTTGGGAGGAAGCAA
GGTCATCTCATGTACTGGGGGTGGAATGCTGAGCCAAGGGACACTCATGTCTGAGGTCTGAGGAGGTGACATGCCATAGGGAAGCTGGG
TAATGAGGGACTTTCAAAGAGACCTTGACTCTTATCCATAGAAGGTTAAGCTTTATCTGTGAGATAGTTGAGAATTCTCGTGGTACTGG
AAACAGGAGATTTGTTTTCTGCTCTCTGAAAATTACAGCGTGGGCACACTTCCCAGCACCTTCTCCACACCCATGAGGAAAAATAACCC
TTGCAACACAGAGACACCAACTCTGAGACACTGTTGAGAAGTCACTCGGTTTAGACTCAGCCCTTTCCTTCGTCGCTTGTTTTAAGAAA
TACGCCTCCACACCTCTTCAAGGCTATTTGAATTCAGAATTAGAGTGGGTGGAAGGGAGAGAAATGGTGTTGAGTCCCAAAATACCAAG
TCTCCATTTGTGTTTACCTGAAAAATCCTGTTTATAAACTTAAAGCGAAAGTGAGTCTGGGCGTTTTGGGGATGGGAGCAGAGATCAAA
GGGGCGGGGCTTCAGTGGGCTACGGGTGTTTATTTCTGTAACTAGTTTCAGTAACACTATACATAATGCTCCCACTTTTTCCTTTCCTT
CGGGCCTCTCTCACCCTCACCTACAGCTAATTGGAAGCATAATCTTGCTTATCAGGTTTGTGAAAAAGCAACAGACTTCGCGGTCCATT
CCTACTTTCTGTCTGCCGTCCAGTTCCTCGGTTTACACCTTTGTCCTTTTCATGGACGATAACAATGGCTTTAGGCTTGCCTGAGGCAC
TGTTTCTCTCATCTCCAACCTACCCTGTCTGTGATAACAGAAACATTTTATGCTTGCGTAATTCTAGATCGCACCTCCTTTTCCACCAA
AGTGTCTATTGGAAACAACAAGTGTGGCAAGTAGGACCGAAGAATTGAATTTTAAAATTAAATTAAATTCAAACTTACATAGTCATCTG
ATTCTAGAGCCTACTATACTGGATAACAGAGTTCTAAAATACGGTGCTTATGCTGGTCATTGTAGAGAGGCAGGGGGATTGAAAGTTTG
AGGCAGGAGACGGTTCTGGAAGACAAAGGAAGCTGTGAAAGTCAATGAGATCAAACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
GTGTGTGTGTGTGTGTGTTGGGGGGCACATAAGTAGCTACAGTAAGAAGTGAGATGAGAGCCAGCTTGGTGGTGGCGGGGGGGGGGGGG
GGGGGGGGCGCATGTCTTGAATCCCAGCAGTTAGGCTGCAGAGGCAGGCAAATCTCTGAAGCTCTGGGTTCAAAGCCAGCTTGGTCTAC
AGAGTGAAGTCCAGGACAGCCAGGGCTACAATAGTGATACCTTGTCTGAAAAACAAAATAAGGAAGGGAAGGAGGAGGGAGAGGAGGGT
GGATGGAGAGGGGAGAGAGGGAAAGGAAACCCCAGAGAAAGAACACAGGAAAGATAAATCTAAACTGTAAGGAATGAGTTAGGAGCAAA
CCTGCCGTCCCAGGTGGCCTTGTTAATAGCACCTGAGCTATGTGGTATGACGCTGCTTTAGTTAACCTGTATCTTCTCCTCCCCTGCCA
CATTGCTTTCAAAGGACTCATTTCCTGCAGCATGACGTCCAGAGTCAGTAGTACCGTGCTGAATAGCATTCTTACGTAACCCAGTCTCT
CGCTTTTCCCCTGCTATGTCCTCTGTCCAATTCCGTTTATATTCTAGGGCTGGAGAGTCTTGGTTCTCCTAAGCAAACCCCAGTTTTAG
ATCTCCCAGCTATCACCACTACTATTTGTCCTACCTGAAATGTCCACCCTTTACTTCTTTCCTTTCCAATAGTCCATATTTGAAGACCT
AAGAAATACAGCCCTGACCTCATGCCCATCAGGGAGACCATCCCCTTTTCCTTGACTTTGGGTGAGCCACGGGGCACCTCTCAGCCCAG
TTTTCCTCATCTGTAAAGTGGGAATGCTAACATTTCCTCCTTTGGGGAAGATTAAGTATTGCTACTTTTAAACTCTACCATTACGAAAG
CATAAAATAAAGCCAGCTGTTGTGGCCCCCATCCCAACAGTTATCATGTGATGTTAGAAATATTTACAAATGGAACTGTCTCACTCCTG
GAGACTGTGAGTTTATTAAGAGCAAAGCTTGGTCTTACTCAGTGCTCTCCCTGGAGATACACTGTAGCCATTGGACAGATGCCTTGGCC
AGCTTGTTAATGAATGAGTCAATGACTAAATAGAATGTCACAGAATAAGCTCTCTGTCTTTTTTTTTTTCATGATTTTTTTTTTAAGGA
AGAGCAAAAAAGACAGAGTTATAGCAAAGATGAGGGAGAAGGACTATAACAACTTCGTCTTGTAAAAATGTATTAAAATTTTGGGTCCG
CTGTGGTGGTACAAGGAAACAGAGGGAAGCAGATCTCTATGAGTTCGAGGTCAGCCTGGTCTACAGAGTGAGTTCCAGGACAGCCAGAG
CTATATATAGAGAGAGCTTGTCTCAAATAACCAACAGCAACTATGATGGTTGACATTACATTTAAAGTTTATATTTACTATGCTTGAGA
GACCAAAAAAAGAAAAAAAATGCCTCTAACATGCAAGGCCTTAGCTTGTACAGGCTCTACCCTACAAGCCCACTTCTCCCAGACATTAA
AGATTAATCTTAAAGAGACTGGTCGTATAAAATTTGCTGTTCTAGCAAGTAGTAGGTCAACTTCAATTTCTGCCTTCGTAATCAAACTT
GATTACTCTGCTCAAAAAATATGACTAGGACCAATACAAAACATATATGTTAAATTAGACGCTGCCTATAGGTATAATCGTGTGGGGTT
TGCCTTTGTATGCCTTAGGCTGCTTTGTCTAGAGGCTGTGTCTTGGGATCACTCTCAGATGCTGTTTTGGCAAACAAATAAACAAAAAC
AAAAAACACCCTCTTTCTATTAAAATTTATTTATGGTCATGGTGAATCTCTGAGTGACCCCAGACCCATAAAACACCAACAACAAAATG
ACAGATTAATCTAAGAAAACAGATTAAACAGTCTCTAAAGAGGCACATGCGTCTCTCACTCTCAACATCAGAACCACTGAAGCAAACAA
TGCCAAGGCAATGGATATTTCCCCAAGGCATCTCATCCGAGAGAAGGGGGAGGCGCCATCTAGAGGGGCCACTCACAATTCCCGTGGTT
CTAAGAACCTGTCTTACCACCCTATAGGACGAGACTGAAGACCAGACAATGGCTTAGATGTGGGCTGCATGGATGTGTGGATCCTTGGC
TCTGTATTTTATCTCACTTCAGGGCCCCAAAGACAGACTTGGGGTTCACTGGAACTCTACAATGTGGCTATATCGAATCAATCAATCAA
TCAATCAATATCTCTCCCTTTCTCTTCTCAGTTTTCACGACTAATTTGACTCTTTTAATTGGATTGTCAAGGACAATTGACTTAACCTG
TCTCTGAGCACAGGCCTTAAGTCTTTTTTTTTTTTTTTTTTTTTTTTTGCCTTAAGTCTTAAGTTAGATGACACCCTTACTCCCTTACT
GTTTGTGAGTTTGGGCTACCAGCTCCATTTTTGCCTTTTTTTTTTTTTTTTTTTTTAACTTTGCTTTTCTTGCCCTCAGGGGTCTTCTG
TCCCCTCCCCTTCCCCATGAGGGCCAAAGCTTTCATCACTGTTGCCCAGGCAACAGTGGGGATGCCTCATTCCTCACAGCTCTGCATAT
CTAAGTATATCTTAAGCCTTTGTCCGCAAGGCTGGCTCAATTCTTTGTAAGTGGTCCACCACTAAATCAGCCATCCTCTACACATAATT
ATTTATTATTTAGCTTTATTTAAAACGATTTTAAAAAATGTCTTCACCTGACAACGGCCTTTACACAGACGGGTCAATTTTCTTGAATG
CCCCAGCCATCAGTTCTGGAGAGGAAATGTGAAAATCGCCTTTGCAAGTGCACGCTTCCGAAGTGCGGGTCAATTTTAAAGCACGCACT
GGAGCATTCATAATGGATTTCCCTTTTAAAAGCACATGAGACCAAAAATAAACCTGACAAAAGGGCAGCTGTAGAGTTTTAACATGTGG
AAAACTCCACAGGCGGCAGTTACATAACGGGGAAGAAACAAGATAAATATTTCACACCGTTAGATGAACTTCCAGATGACAACTAAGAA
GCCAAGAGCCCAGAACACACCTTAACTCTCTAAGGGGTTGGGGGGACGGGGAGGACGGACTTGAAGCCAGAAGAGGCTAAGCCTGATGA
TAAAATCTGGGACCTGACTTGCAACTTGAGTGATGCCTTTGTCCCCCGCCCCCTCCGCCCCTCCCCACCCCCCCTTTCTAGAGGCAGGG
GCTGAGCTCATGCCCCTATACTTTAAGAGCGCTTCGCCAGCGGTTTTGTCCGCTAGATAGAAATTTTCCAAAAAATATCTCCCACGCTA
GGCAAAACACTGAAAAGGAAGTTTTTTTGCGCCAAGAGGAGAGACATGGCGAGACAGACCGAGCCACTACCGCTCCCAACACACACACA
CCCTGCCCATCCCACCCGGCTGCGCTCCTCCTGCCCCCAGCTCCTCGCCCTGGGGACAGCTGGCAGCCTAGCGCGGGACTAGACACAAA
GCGGATCAGTCTGGGGGCGGGGGGCCGACCTGCAGGGTTCTCCCTCAAGAGGCTAGTCCTCTGCCGCCACTCGCTTAGGACCCTGCGGA
CACCGCGTCCCGCGTCCACGCCCTCCCCTCAACCCTCTTCCACCCTTCAAAAGAAGGACTGTCCCAGACACCACGTCCTAGGGCCAGAA
GACCTGCCCCCACGACAGTCGCTGGAGACACCCCAGACCGGAGAGACTGACATCGGGACAGGACCCGCCCCTCTGCTTCCACCTCTCAG
GGACCTCCTCTGCTCCGCCGCCGGGCGAAGTGCTGGGAGACCCAGCCGCCTGTCGCGCTCCTGCAGGGGGACCCTCAGCTAGGCAGCCA
GCTGGCGCCCGCGTAGATG 
 
 
 
 
 
Supplementary Data 5.  Sequence of Jam2 promoter region.   The first 4814 base pairs upstream 
of the Jam2 gene, 332 of the untranslated region (yellow highlight) and the ATG start codon are 
shown.  Blue highlighted text shows positions of forward (within promoter) and reverse (within 
UTR) primers used for generation of 0.5, 1, 2 and 5k plasmid constructs. 
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